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Abstract 
          This thesis describes the synthesis of a library of chalcones and several 
flavanones and 1,5-benzothiazepines derived from chalcones and some biological 
studies of these compounds against neuraminidase (NA). 
 
The environmentally benign one-pot method using PMA/SiO2 in ethanol has 
successfully been applied toward the preparation of flavanone analogues from 2′-
hydroxychalcones, 2′-aminochalcones and 2′-mercaptochalcones in reasonable yields. 
Reactions were screened in a variety of parameters, including solvents, temperatures, 
reaction time and amount of catalyst used.  The nature of the solvent played a key role 
in the reaction where the reaction performed well in a polar protic solvent such as 
ethanol and only moderately in a polar aprotic solvent like acetonitrile. The reactions 
also seemed to be temperature dependent resulting a significant improvement in the 
yeild. All the reactions occurred smoothly in 1 mol% PMA-SiO2 in ethanol. The 
reaction times varied from 8.5-22 hrs depending upon the type of chalcone. 
 
Mono and dicationic ionic liquids (ILs) were employed as reusable catalysts for the 
synthesis of synthesize 1,5- benzothiazepines from chalcones and orthoaminothiophenol 
(o-ATP) in reasonable quantities. The counter ion was observed to influence the 
reaction time as well as yield of the reaction by effecting in the acidity of ILs. Better 
yields of 1,5- benzothiazepines were obtained in more acidic ILs. 
 
Amongst all 1,5-benzothiazepines synthesized, 4-(4-methoxyphenyl)-2-(naphthalen-2-
yl)2,3dihydrobenzo[b][1,4]thiazepine,MA12, was transformed to 3-(4-methoxyphenyl)-
2-(naphthalen-2-ylmethyl)-2H-benzo[b][1,4]thiazine, 6MR during column purification. 
iii 
 
The conversion of seven-membered ring, thiazepine to six-membered ring, thiazine is 
proposed to occure through a naphthyl shift or hydrogen shift. 
 
The synthesized compounds (chalcones, flavanones and 1,5-benzothiaepines) were then 
investigated for their potency as NA inhibitors. Chalcones are shown to have some kind 
of activity as NA inhibitors. Quantitative structure-activity relationships for the 
chalcone compounds with the aid of 2D and 3D-QSAR models have been also studied. 
Flavanones and 1,5-benzothiazepines with promising Cdocker energy (compared to 
DANA with Cdocker interaction energy equal to -46.11 kcal/mol), were expected to be 
active against neuraminidase. However, the bioassay results were not corroborate with 
the modeling results. This observation presumably is due to the flavanones binding at 
the allosteric sites rather than the active site, the larger size of the seven-membered ring, 
lack of flexibility and solubility of 1,5-benzothiazepines.  
 
 
 
 
 
 
 
 
 
342 words 
 
iv 
 
Abstrak 
 
Tesis ini menerangkan yang tentang sintesis beberapa chalcone dan flavanones 
serta 1,5-benzothiazepins dari chalcone dan kajian keaktifan biologi sebatian tersebut 
terhadap neuraminidase (NA). 
 
Satu periuk kaedah mudah serta mesra alam menggunakan PMA/SiO2 dalam etanol 
telah berjaya digunakan ke arah penyediaan analog flavanone daripada 2′-
hydroxychalcones, 2′-aminochalcones dan 2′-mercaptochalcones dalam hasil yang 
munasabah. Tindak balas ini dilakukan dalam pelbagai parameter, termasuk pelarut, 
suhu, masa tindak balas dan mangkin yang digunakan. Sifat pelarut memainkan peranan 
penting dalam tindak balas di mana tindak balas menunjukkan prestasi yang baik dalam 
pelarut protic terkutub seperti etanol dan hanya sederhana di dalam aprotic terkutub 
pelarut seperti asetonitril. Tindak balas ini juga bergantung secara langsung kepada 
suhu di mana hasil turut meningkat dengan peningkatan suhu. Semua tindak balas 
berlaku dengan lancar pada 1 mol % PMA/ SiO2 dalam etanol. Masa tindak balas 
berbeza dari 8.5-22 jam untuk penukaran pelbagai chalcone. 
 
Cekar ionic (ILs) mono dan dikation bertindak sebagai mangkin yang boleh diguna 
semula untuk mensintesis 1,5-benzothiazepines dari chalcone dan 
orthoaminothiophenol (o-ATP) dalam kuatiti yang munasabah. Ion kaunter telah 
mempengaruhi masa tindak balas dan hasil tindak balas dengan mempengaruhi keasidan 
ILs. Hasil 1,5-benzothiaepines yang telah diperolehi dalam ILs yang lebih berasid. 
v 
 
 Diantora 1,5-benzothiazepies disintesis, 4-(4-methoxyphenyl)-2-(naphthalen-2-yl)-2,3-
dihydrobenzo[b][1,4]thiazepine, MA12, telah bertukar kepada 3-(4-methoxyphenyl)-2-
(naphthalen-2-ylmethyl)-2H-benzo[b][1,4]thiazine, 6MR semasa proses pelunenon 
kromatografi. Penukaran gelang tujuh thiazepine ke gelang enam thiazine dijangkakan 
berlaku melalui peralihan naftil atau anjakan hidrogen. 
 
Sebatian yang telah disintesis (chalcone, flavanone dan 1,5-benzothiazepines) telah 
dikaji potensinya bagai bahan perencat NA. Yang mana chalcones telah menunjukkan 
keaktifan terhadap NA. Hubungkait kuantitatif struktur- keaktifan untuk chalcone 
dengan bantuan model 2D dan 3D-QSAR telah juga dikaji. Flavanones dan 1,5-
benzothiazepines dengan tenaga Cdocker yang baik (berbanding dengan DANA yang 
mampunyai tenaga interaksi Cdocker -46.11 kcal / mol), dijangka aktif terhadap 
neuramidase. Akan tetapi, keputusan bioasei tidak menyokong keputusan pemodelan. 
Ini mungkin disebabkan oleh flavanones yang terikat di laman allosterik berbanding 
tapak aktif dan saiz gelang tujuh yang besar serta, kekurangan fleksibiliti dan 
keterlarutan 1,5-benzothiazepines dalam pelarut yang digunakan. 
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CHAPTER 1 
  
GENERAL 
INTRODUCTION 
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1.1 Introduction to Chalcones: 
 
Chalcones are polyphenolic organic compounds belonging to a class of natural 
products called flavonoids.  They are found in many different plant tissues like 
Lauraceae (Shimomura et al.1988), Compositae and Leguminosae (Xu et al. 2011) 
families. They are also known as pigments of the yellow to orange- colored flowers of 
many plant species such as Coreopsis and other Asteraceae taxa (Andersen et al. 2006). 
This group of natural products is abundant in vegetables and fruits. For example, 
significant amounts of chalcones like butein, phloretin, chalconargenin, arbutin and 
phloridzin occur in tomato, apples, pears, bearberry and strawberry (Nelson et al. 1993; 
Hijova et al. 2006) 
 
Structurally, chalcones comprises two benzene rings, A and B, linked through an α, β-
unsaturated carbonyl group (Figure 1.1).  
 
                                                    
 
Figure 1.1 General structure of chalcone 
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The IUPAC name for the chalcone is 1, 3-diphenyl-2-propen-1-one. However, 
this nomenclature was thought to be too complicated for routine use. Therefore, semi-
systematic names and trivial names are more commonly used (Andersen et al. 2006). 
As an example, 1-(2, 4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one is 
known as 2′, 4′, 4-trihydroxychalcone (semi systematic name) or (trivial name) 
isoliquiritigenin (Figure 1.2) 
 
 
 
                     
 
                            
Figure 1.2 1-(2, 4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one 
 
The biosynthetic pathway of chalconaringenin and isoliquiritigenin is outlined in 
Scheme 1.1. These chalcones are formed. through. condensation. reactions. of three 
molecules. of malonyl. coenzyme A (malonyl-CoA) .with p-coumaroyl-CoA in the 
presence of .chalcone synthase enzyme (Schroder et al. 1999). Malonyl-CoA (acetate 
pathway) and  p-coumaroyl-CoA (shikimate pathway) are believed to be the origin of 
the ring A and B, respectively (Schroder et al. 1997). 
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Scheme 1.1 Overview of the biosynthesis of (I) chalcones and (II) 
 
As shown in Scheme 1.2, the chalcones are often synthesized through an aldol 
condensation reaction between an acetophenone and a benzaldehyde in the presence of 
5 
 
aqueous bases (A) or under acidic condition (B). Claisen-Schmidt condensation reaction 
is the most well-known method for the synthesis of chalcones (Patil et al.  2009). 
A. Base catalyzed reaction:  
 
 
 
 
 
 
B. Acid catalyzed reaction: 
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Scheme 1.2 General methods for the synthesis of chalcones 
 
Chalcones are considered valuable pharmaceutical targets since they have been reported 
to possess a wide rang of biological activity such as anti-oxidant (Miller et al.1996), 
anti-inflammatory (Rojas et al. 2002), anti-microbial activities (Prasad et al. 2007). 
Structures of some reported bioactive chalcones is shown in Figure 1.3. 
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Figure 1.3 Structures of some biologically active chalcones 
 
 
Interest in the chemistry of chalcone and chalcone derivatives intensified when 
it was discovered that they are promising precursors to other classes of flavonoids.  As 
an example, in plants, open chain polyphenolic chalcones are transformed to flavanones 
and dihydrochalcones (Figure 1.4). The conversion of chalcones to flavanones in nature 
is often through a stereospecific reaction which is catalyzed by the enzyme chalcone 
isomerase. The co-occurrence of chalcones and flavanones as natural products could be 
explained by their close structural and biogenetic relationship (Andersen et al. 2006). 
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Figure 1.4 Conversion of chalcones to (2S)-flavanones and dihydrochalcones 
 
 
 
Morever, as summarized in Scheme 1.3, this versatile class of organic 
compounds is considered as key building block for the synthesis of other biologically 
active compounds, like oxazoles, pyrazoles, pyrimidines (Bapna et al. 2008; Patil et 
al.2009), benzodiazepines (Du et al.2006) and benzothiazepines (Cherkupally et al. 
2008). In this study, we focused on the synthesis of a library of chalcones. In addition, 
some of the chalcones synthesized have been used as a backbone to the synthesis of 
flavanones and 1, 5-benzothiazepines. 
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Scheme 1.3 Versatility of chalcones 
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1.2 Scope and objectives of this thesis: 
 
Chalcones are considered as one of the most versatile naturally occurring 
organic compounds owing to their unique structure which enable them to act as a 
central core structure for constructing a variety of known bioactive heterocyclic five, six 
and seven-membered rings. 
 
They have been shown to be promising moieties for drug discovery research over the 
past two decades. Although they are found to be widely distributed in plants, these 
sources are limited due to increasing population and the costly extraction and isolation 
process.  Thus, synthesis can be considered as an alternative approach to provide these 
compounds with structural diversity and in larger quantities for further development. In 
this project, we aim to develop green, efficient and more effective synthetic routes to 
the bioactive compounds, comprising chalcones, flavanones and 1, 5-benzothiazepines. 
These three groups of compounds have been evaluated for the possible neuraminidase 
inhibitors by exploring computationaland bioassay techniques. 
 
The present study has been conducted with the following objectives:  
 
1. To develop an efficient one-pot synthesis of flavanone and its derivatives from 
hydroxyl, aza and thiochalcones. 
2. To develop an efficient one-pot synthesis of 1, 5-benzothiazepines and its 
derivatives from chalcones 
     3.    To assess activities of the synthesized compounds for inhibition of H1N1 virus.  
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This dissertation is consist of two main parts. Part I contain Chapters 2, 3, 4 and 
5 give an overview of flavonoids and some of their biological properties. Chapter 2 is 
devoted to the discussion of the potential health benefits of flavonoids. Chapter 3 is a 
review of the most relevant synthetic routes for the synthesis of flavanone and its aza- 
and thio- analogues. The development of an efficient and green protocol for the 
synthesis of flavanones has been reported in Chapter 4. Chapter 5 deals with the 
synthesis of flavonoids analogues and their potential inhibition activity on H1N1 virus. 
   
Part II contain Chapter 6, 7, 8 and 9 and deals with 1, 5-benzothiazepines and their bio 
importance. 
Chapter 6 describes the biological properties of this class of heterocyclic rings. Chapter 
7 is recap of some effective synthetic routes for the synthesis of 1, 5-benzothiazepines. 
The development of an efficient synthetic methodology reports in Chapter 8.  Chapter 9 
deals with the synthesis of 1, 5-benzothiazepines and their biological activity against 
H1N1 virus. 
 The products were characterized on the basis of spectroscopy data. 
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CHAPTER 2 
 
FLAVONOIDS AND 
THEIR BIOLOGICAL 
IMPORTANCE 
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There have been considerable reports which suggested that vegetable and fruits 
consumption has a significant role in maintaining health and preventing chronic 
diseases such as heart disease and cancer (Joshipura et al.1999; Levi et al 1999 & 2000; 
Chen et al. 2002). This protective effect has been attributed to presence of the 
significant amounts of various types of flavonoids in such plant-based foods. For 
example, Peterson et al. have identified eight types of flavanones; namely, didymin, 
eriocitrin, hesperidin, naringin, narirutin, neoeriocitrin, neohesperidin, poncirin in citrus 
fruits such as grapefruit, lemons, and limes in a total amount of 17-27% (Peterson et al. 
2006). 
 
Flavonoids are class of polyphenolic natural products comprising two benzene rings (A 
and B) linked with a heterocyclic pyran ring C (Figure 2.1) (Harborne, 1994).  
 
 
 
 
Figure 2.1 Basic flavonoid structures 
 
Although more than 4000 unique species of flavonoids have been identified (Middleton 
et al. 2000), due to the ample range of bio- beneficial effects and the wide distribution, 
studies on the chemistry of flavonoid still remains attractive for many phytochemists 
and synthetic organic chemists.
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Based on molecular structures, flavonoids can be divided into subclasses, i.e.  
chalcones, flavanones, flavones, isoflavones, , biflavones,  flavonols, flavanonols, 
flavan-3-ols, anthocyanidins, aurones, coumarins, and catechins (Harborne, 1994; 
Pietta, 2000). In this project, focus is placed on the synthesis of chalcones and 
flavanones since the idea of extending nitrogen and sulfur substituted chalcones to the 
corresponding azaflavanone and thioflavanone is very attractive and it could provide 
useful information on the effect of these heteroatoms on their biological activities 
(Figure 2.2).  
 
 
 
 
 
 
 
 
Figure 2.2 General structure of 2′-hydroxyl-,mercapto- and aminochalcones and 
corresponding flavanones 
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Flavonoids have been reported to possess a broad spectrum of biological 
activities such as anti-oxidant, anti-inflammatory, anti-cancer (Nijveldt et al. 2001; 
Pietta, 2000; Ballesteros et al. 1995; Heim et al.2002), anti-hypertensive (Wu et 
al.1992), anti-malarial (Li et al.1995), anti-bacterial (Schutz et al. 1995) anti-tumor 
(Xia et al.1998), anti-HIV(Ishikawa et al.1999) and radio protective agents ( 
Blickenstaff et al. 1995). Some flavonoids have the ability to act as selective estrogen 
receptor modulators (Chen et al. 2004). Of the flavonoids, chalcones are one of the 
most versatile.  These polyphenolic compounds contain two aromatic rings linked by an 
α, β-unsaturated carbonyl group. They are known to be precursors of isoflavonoids and 
other flavonoids such as flavanones. In addition, chalcones are considered to be the 
central core for other biologically active compounds like oxazoles, pyrazoles, 
pyrimidines (Patil et al. 2009) and azepines (Cherkupally et al. 2008). Besides its 
structural importance, chalcones are attractive species on their own due to their reported 
pharmaceutical properties such as anti-oxidant (Miller et al.1996), anti-inflammatory 
(Rojas et al. 2002), anti-microbial activities (Prasad et al. 2007). 
 
 Flavanones are one of the important subtypes of flavonoids, widely distributed in the 
plant kingdom. They found abundantly in plants of the family leguminosae, compositae 
and moraceae (Harborne, 1994; Harborne et al. 2001). Due to their unique rudimentary 
structure as starting material for many other bioactive compounds (Kumar et al.2008) 
there have been a growing interest for the synthesis and structure activity relationship 
studies on flavanones. 
 
 Azaflavanone derivatives had been reported to have good leads for non-steroidal anti-
inflammatory drugs; NSAIDs (Philipp et al.1980); while the thioflavanone derivatives 
have been used as precursors for biologically active compounds such as 
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benzothiazepine and thiochroman–4-one1, 1-dioxides (Holshouser et al. 1981). 
Nevertheless, limited number of studies had been carried out on the synthesis and SAR 
for nitrogen and sulfur containing flavanones especially in terms of their anti-viral 
activities. Therefore, in this study, we focused on synthesis and anti-viral inhibition 
properties of these compounds. 
 
 
 
2.1 Neuraminidase inhibition effect:  
 
The Orthomyxoviridaes are a family of RNA viruses, which includes  five 
genera: Influenza virus A, Influenza virus B, Influenza virus C, Isa virus and Thogoto 
virus.  Influenza virus A, B and C can cause influenza in birds, humans and some other 
mammals and amongst them, type A viruses are the most virulent human pathogens. 
Influenza A is further classified to subtypes like H1N1, H2N2, H3N2, H5N1, H7N7, 
H1N2, H9N2, H7N2, H7N3 and H10N7. H and N stand from hemagglutinin (H) and 
neuraminidase (N) which are proteins on the surface of the influenza virus strain 
(Figure 2.3). Hemagglutinin is responsible for the binding of the virus to the host cells 
and causes agglutination of red blood cells. Neuraminidase is an enzyme which is in 
charge of the initiation of the influenza infection by promoting the release of the virus 
from the host cell. 
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                                              Figure 2.3 Structure of the influenza virion 
 
Although there are different types of H and N proteins, the ones that normally 
cause influenza during flu seasons are H1N1 (swine and bird flu) and H3N2 (Hong 
Kong flu). The most common cause of human flu in 2009 (Pandemic H1N1/ 09 virus) 
was the swine origin subtype H1N1 virus which infected more than 1.6 million people 
with 19,633 death cases worldwide (Figure 2.4).The 2009 flu outbreak in Malaysia 
started in August 2009 with imported cases from affected countries like United States 
America and Australia followed by local transmission in June 2009 with 12,210 total 
number of infected cases and 92 death cases (Xinhua, 2009; Bernama, 2010). Although, 
yearly, influenza have been reported to caused numerous of mortality and morbidity and 
hospitalizations (Monto et al. 1997, Glezen et al .1982), but the worldwide outbreak of 
the new strain of the virus thet emerged in 2009 cause a global panic.  
 
 
                                                            
                                                               
                                                               
   
Figure 2.4
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(H1N1), A/Jinan/15/90 (H3N2), and B/Jiangshu/10/2003 were used as the source of 
neuraminidase (Liu et al.2008). Isolated flavonoids from Rhodiola rosea and 
Glycyrrhiza uralensis roots also have been shown to have non-competitive inhibitory 
activity against neuraminidase (Jeong et al. 2009; Ryu et al. 2010).However, most of 
researches were conducted on naturally occurring flavonids and amongst all subtypes of 
flavooids, chalcones have not been extensively studied for their potency as NA 
inhibitors. Our recent interest in flavonoids, specially chalcones and flavanones has 
been inspired by the potential health benefits arising from the possible anti H1N1 
activity of this class of compounds.  
 
2.2 Anti-viral effects 
 
A number of studies have been conducted on the anti-viral effect of flavonoids. 
Calophyllum coumainins and Baicalin have been reported to have anti-HIV-1 activity 
(Ishikawa et al.1999; Kitamura et al. 1998). Similarly, isolated flavonoids from 
Geranium carolinianum L have been shown to have reasonable anti-viral activity 
against hepatitis B virus (Li et al. 2008). Flavonoids like Glaranine and 7-O-
methylglabranine were also reported to inhibit dengue viral growth (Sanchez et al. 
2000). Tan et al. recently reported that panduratin A and its derivatives to exhibit good 
competitive inhibitory activities towards dengue 2 virus NS3 serine protease (Tan et al. 
2006). In another study, Rajkumar and co-workers reported isolated flavonoids from 
Poncirus trifoliate such as Poncirin, rhoifolin, naringin and marmesin to be fairly 
effective mosquito repellent (Rajkumar et al. 2008).   
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2.3 Anti-oxidative effects 
 
Oxygen metabolism is the most common reason for the production of reactive 
oxygen and free radicals in the human body which can cause cellular membrane 
damage, cell death and tissue damage. The presence of free radicals in the body 
eventually can result in many diseases and complications such as liver disease, cancer, 
asthma, and diabetes. Antioxidant agents have the ability to inhibit or delay the 
formation of free radical oxygen species by controlling the oxidation process of an 
oxidisable source. Flavonoids especially polyhydroxylated flavonols and catechins, can 
help the body counteract the effect of  these free radical oxygen through various 
mechanisms like scavenging of the free radicals, quenching of the singlet oxygen by 
hydrogen donation and  chelation of metal ions involved in free radical production 
(Patil et al. 2009, Miller et al.1996). 
 
2.4 Anti-inflammatory effects 
 
Inflammatory responses are often caused by the release of excess amount of 
different mediators by activated macrophages. For example, nitric oxide can cause 
edema, facilitate leukocyte movement in vessels and produce cytokine (Patil et al. 
2009). Flavonoids like fluorinated chalcones are reported to prevent the nitric oxide 
generation from the nitric oxide synthase (Rojas et al. 2002). Release of arachidonic acid 
by other pro-inflammatory agents like cyclo-oxygenase (COX) and 5-lipoxygenase can 
be prevented by Quercetin (Boots et al. 2008; Loke et al. 2008; Valerio et al. 2009).  
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2.5 Anti-cancer effects 
 
Flavonoids such as chromone and xanthone derivatives have been reported to be 
potent inhibitors for aromatase enzyme. Aromatase is the key enzyme involved in 
hormone-based breast cancer (Recanatini et al. 2001). Abyssinone II and its derivatives, 
a group of natural flavanones, were evaluated as aromatase inhibitors and have shown 
satisfactory inhibitory activity (Maiti et al. 2007). Substituted quinolones have shown 
cytotoxic and anti tubulin effects to various human tumor cell lines like lung carcinoma 
(A-549), breast cancer (MCF-7), renal cancer (CAKI-1), and melanoma cancer 
(SKMEL-2) in vitro (Xia et al. 1998). Thiochromones and thiochroman-4-ones were 
screened on CF1 male mice and successfully inhibit tumor growth (Holshouser et 
al.1981). In addition, it has been reported that flavonoids have antitumor activity to the 
human kidney carcinoma cells TK-10 in vitro (Cabrera et al. 2007). 
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The synthesis of flavanones often involve an intramolecular conjugate addition 
of 2′-hydroxychalcone, 2′-aminochalcones and 2′-mercaptochalcones to the 
corresponding cyclic system in the presence of an acid or a base catalysts. The required 
chalcones normally synthesized via Claisen-Schmidt condensation of 2′-
hydroxyacetophenone, 2′-aminoacetophenone and2′-mercaptoacetophenone with 
various benzaldehydes (Marais, 2005; Narender and Papi Reddy 2007). As outlined in 
Scheme 3.1, the retrosynthetic analysis consists of two primary disconnections, which 
can provide a facile and versatile synthetic route to produce a variety of products for the 
synthesis of flavanones without a lengthy protection-deprotection strategy. 
 
                                  
              
                                                                                
  Scheme 3.1.Retrosynthesis strategy of flavanone synthesis   
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Acid catalyzed reactions can be performed using orthophosphoric acid, acetic 
acid (Cheng et al.1963) and silica gel (Sangwan et al.1984), while base catalysis has 
been carried out with strong alkali (Kaene etal.1970) and other bases such as L-proline 
(Chandrasekhar et al. 2005; Chandrasekhar et al. 2007) . Other cyclization methods 
involve different reaction conditions such as light (Stermitz et al.1975) heat (Harris et 
al.1967), electrolysis (Sanicanin et al.1986) and Ni/Zn/K halide catalysis (Ali et al. 
1984). 
 
3.1 Acetic acid catalyzed flavanone synthesis 
 
Acetic acid is one of the most common solvents / acid catalysts in organic 
synthesis due to its commercial availability and reasonable price. It is reported to be a 
promising catalyst for the transformation of   2′-hydroxychalcones to the corresponding 
flavanones. As shown in Scheme 3.2, cyclization to produce flavanone was carried out 
by refluxing the 2′-hydroxychalcone (1equivalent) in 25ml of glacial AcOH for 72h. 
The reaction mixture was poured into water and extracted with organic solvents. The 
organic layer was dried and purified by column chromatography to yield the 
corresponding flavanone in moderate to good quantity (Cabrera et al.2007). 
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Scheme 3.2. Synthesis of flavanones using AcOH 
 
 
3.2  L-proline catalyzed flavanone synthesis 
 
An efficient method reported by Chandrasekhar et al, involved a reaction of 
variety of aryl aldehydes with substituted 2′-hydroxyacetophenones in the presence of 
30mol% L-proline in DMF (Scheme 3.3). In a typical experiment, 2′-
hydroxyacetophenone and benzaldehyde were heated together with 30mol% L-proline 
in DMF (0.02M) for about eighteen hours. Ether extraction followed by water wash 
gave the crude which was purified by column chromatography to furnish flavanone and 
chalcone in a ratio of 7:3. (Chandrasekhar et al. 2005). 
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Scheme3.3. S.Chandrasekhar synthetic route of flavanone 
 
A similar method has been employed by Chandrasekhar by replacing 2′-
aminoacetophenone with 2′-hydroxyacetophenone in the synthesis of azaflavanones 
(Chandrasekhar et al. 2007). In this approach 2′-aminoacetophenone and benzaldehydes 
were stirred with 30mol% of L-proline in methanol (5ml). The reaction proceeded 
smoothly at room temperature for 48h. As shown in proposed mechanism by 
Chanasekhar et al, unlike other previous approaches, benzaldehyde and 2′-
aminoacetophenone underwent a Schiff-base reaction followed by addition of nitrogen 
from L-proline to the carbonyl group and cyclization reaction to form the desired 
azaflavanones.(Scheme 3.4) 
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Scheme3.4 Proposed mechanism for the synthesis of Azaflavanone using L-poline 
 
 
3.3 Microwave accelerated solvent-free synthesis of flavanones 
 
In this method, the synthesis of flavanone was carried out by using organic acid 
(TFA) and a mineral support (silica gel) in the microwave. The main objective of this 
method is to minimize the usage of conventional solvent for the flavanone synthesis. 
0.2ml TFA and 1g silica gel was added to the mixture of 0.1mmol chalcone in 5ml dry 
DCM. The solvent was then evaporated under vacuum, and the resulting powder was 
irradiated by microwave. The crude was extracted with ethyl acetate and washed with 
water and purified by column chromatography (Sagrera et al .2003). The reaction is 
summarized in Scheme 3.5 
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Scheme 3.5. Microwave Accelerated Solvent-Free Synthesis of Flavanone 
 
 
3.4   Jea In Lee synthetic method 
 
 Unlike most of the synthetic routes which proceed through intramolecular 
cyclocondensation of 2′-hydroxychalcones to the corresponding flavanones; Lee and 
co-workers introduced a method where the reactions proceeded without involving in 2'-
methoxy or 2'-hydroxychalcones. 2′-Methoxy benzoic acid was treated with 2 
equivalents methyllithium in THF to produce 2'-methoxyacetophenone which 
subsequently treated with 1 equivalent LDA in THF at -20oC to yield the corresponding 
lithium enolate. Addition of benzaldehyde to this reaction mixture followed by 
acidification (pH=4) and extraction produced 1-(2'-methoxyphenyl)-1-oxo-propan-3-(4'-
chlorophenyl)-3-ol as a key intermediate. The desired flavanones were obtained by 
heating of this intermediate with 2 equivalents 48% hydrogen bromide in glacial acetic 
acid. The reaction is summarized in Scheme 3.6 (Lee et al. 2004). 
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Scheme 3.6. Synthesis of flavanones using 2′-Methoxy benzoic acid. 
 
In another approach, Lee and co-workers repeated the procedure by treating 2′-
hydroxybenzoic acids  with 3 equivalents methyllithium in THF to yield the   
corresponding  2′-hydroxyacetophenones which was then reacted with benzaldehydes in 
the presence of 2 equivalents LDA in THF at -78oC for about 1hr. The mixture was 
quenched with saturated NH4Cl solution to give 1-(2'-Hydroxyphenyl)-1-oxo-propan-3-
phenyl-3-ols (4, Scheme 3.7). The residue subsequently underwent cyclodehydration 
reaction following slow addition of Ph3P/diethylazodicarboxylate (DEAD) in 
dichloromethane at 0oC to yield the desired flavanone ( 5) and 2′-hydroxychalcone ( 6) 
in a ratio of 13:1  (Lee et al. 2007). 
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Scheme 3.7. Synthesis of flavanones using 2′-hydroxy benzoic acid. 
 
Similar methodology by Lee and co-workers was employed for the synthesis of 
thioflavanone by methylation of thiosalicylic acid (Scheme 3.8). The resulting 
mercaptoacetophenone was treated with LDA in THF at -150C. To the reaction mixture, 
a solution of benzaldehydes in THF was added. After 2hrs of stirring, the mixture was 
quenched with 0.5 N-HCl and extracted with methylene chloride followed by aqueous 
sodium bicarbonate workup and column chromatography purification gave 
thioflavanones as the product (Lee et al.2008). 
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Scheme3.8. Synthesis of thioflavanones from thiosalicylic acid 
 
 
 3.5     Synthesis of azaflavanones from substituted aniline 
 
As summarized in Scheme 3.9, in this method, a mixture of substituted aniline, 
ethyl benzyl acetate and p-toluenesulfonic acid were refluxed in toluene to give the 
intermediate 1 which subsequently cyclized under thermal condition to yield the 
azaflavanones in reasonable yield (Park et al.2004).  
        
 
Scheme 3.9 Synthesis of azaflavanone using p-toluenesulfonic acid 
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3.6    Eco-friendly polyethylene glycol promoted flavanone synthesis 
 
 
Kumar and co-workers employed an eco-friendly method to synthesize 
flavanones and azaflavanones by reacting 1.4 mmol 2′-hydroxychalcones or 2′-
aminochalcones in 0.5 ml solution of polyethylene glycol (PEG-400) at optimized 
temperature (130oC) for appropriated time (Scheme 3.10). The reaction mixture was 
extracted with diethyl ether and washed with brine. Removal of solvent and column 
chromatographic purification yielded the corresponding flavanones and azaflavanones 
in reasonable yields (Kumar et al.2008). 
     
 
 
 
Scheme 3.10.  Synthesis of flavanones and azaflavanones in PEG-400 
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3.7   Synthesis of azaflavanone using Silica gel supported TaBr5 
 
This method is based upon heat-facilitated intramolecular Michael addition of 
amino group in 2′-aminochalcones to an α, β-unsaturated ketone using silica supported 
tantalumpentabromide as catalyst (Scheme 3.11). Even though the reactants were heated 
relatively high temperatures (140-1500C) in the absence of solvent; the configuration of 
both the TaBr5 catalyst and the 2′-aminochalcones is secured due to the attachment of 
substrate and catalyst to the silica gel matrix. In this method, a solution of 1mmol 2′-
aminochalcones in 1-1.5ml DCM was added toTaBr5 (5–10 mol %). 200mg Oven dried 
silica gel added to the mixture, DCM was then evaporated and the mixture was heated 
up to140-150oC with stirring. After completion of the reaction, the mixture was 
extracted with diethyl ether and purified by column chromatography. The same reaction 
condition for the synthesis of flavanone from 2′-hydroxychalcones has been carried out 
but the isomerization reaction of 2′-hydroxychalcones to corresponding flavanone was 
not as efficient as of 2′-aminochalcones to azaflavanones (Ahmed et al. 2006) 
 
 
           
Scheme 3.11.Azaflavanone synthesis using silica gel supported   tantalumpentabromide 
 
      
 
 
34 
 
3.8     Synthesis of thioflavanone and flavanones from oxathiolone chalcones 
 
Thioflavanones have been synthesized from specific oxathiolone chalcones. In 
the first step, chalcones bearing oxathiolone ring were synthesized through a reaction of  
the corresponding acetophenone and benzaldehyde (1:1.5 mmol) in acetic acid 
(1.3mmol) and catalytic amount of concentrated sulfuric acid (Konieczny et al.2007). 
Due to the base sensitivity of oxathiolone ring, base catalyzed Claisen-Schmidt reaction 
is not applicable to the synthesis of these types of chalcones. Indeed, the chalcones then 
underwent cyclization reaction by refluxing the corresponding chalcones in basified 
methanol followed by acidification of the reaction mixture with hydrochloric acid 
(Schem 3.12, A) 
For the  synthesis of flavanones from oxathiolone- chalcones to occur, presence of a 
methoxy group at 5th position of oxathiolone- chalcones is necessary  (Scheme 3.12, B). 
Treatment of the chalcone with BF3.SMe2 in DCM followed by quenching with water 
resulted in the hydroxychalcones which upon stirring  in acetic acid containing catalytic 
amount of sulfuric acid to give oxathioloflavanone  (Konieczny et al. 2009).  
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Scheme 3.12.  Synthesis of thioflavanone and flavanones from oxathiolone chalcones 
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3.9     Flavanone synthesis catalyzed by anhydrous potassium carbonate 
 
 
 
Mondal and co-workers refluxed a mixture 1mmole of 2'-hydroxychalcones and 
anhydrous potassium carbonate (1.5gr) in dry acetone for 3-5hrs to give flavanones. The 
same reaction was repeated in a microwave by adding 1.5 gram anhydrous potassium 
carbonate to a solution of 2'-hydroxychalcones (1mmol) in DCM (Scheme 3.13). 
Removal of the solvent followed by irradiation of the resulting solid in microwave for 3 
minute at 131oC gave flavanone in good yield (Mondal et al. 2011). 
 
 
 
 
                                                                          
 
               
 
Scheme 3.13.  Synthesis  of flavanones using anhydrous potassium carbonate 
 
However, many of the reported methods suffer from disadvantages such as low yields, 
long reaction times, strong acidic medium leading to environmental pollution, high cost 
of the catalyst and lack of recovery and reusability of the catalysts. In addition, most of 
the reported synthetic methodologies are not applicable to synthesis of all subtypes of 
flavanones. Hence, there is still a need to develop mild, high-yielding protocols for the 
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cyclization of substituted chalcones to flavanones via environmentally friendly 
methods. Nowadays, heterogeneous catalysts are preferred over homogeneous processes 
due to their regenerability and reusability, ease of handling and simplicity of work up. 
Considering the bio-importance of flavanones, exploring a green alternative in 
flavanone synthesis motivated us to carry out a study on heterogeneous condition 
alternatives. 
 
 Heteropoly acids (HPAs) are a group of solid acids with bifunctional catalytic ability in 
homogeneous and heterogeneous conditions (Kozhevnikov et al.1998). They have been 
used as efficient catalyst in various organic reactions such as the Fries rearrangement of 
phenyl acetate (Kozhevnikova et al.2002), Friedel-Crafts acylation of phenols (Kaur et 
al.2002), oxidation of alcohols (Firouzabadi et al. 2003), Nazarov rearrangement 
(Murugan et al. 2010). Phosphomolybdic acid belongs to the family of heteropoly acids 
(HPAs) and has gained importance as a catalyst since it is inexpensive, environmentally 
friendly and stable at high temperature (Kumar et al.2005; Kozhevnikov et al.1998). It 
has  been used as catalyst in many chemical transformations such as: regioselective 
opening of aziridines with nucleophiles (Kumar et al. 2004), chemoselective hydrolysis 
of acetonides (Yadav et al.2005), Ferrier rearrangement (Yadav et al.2006), selective 
deprotection of tert-butyldimethylsilylether (Kumar et al. 2005),  and aziridination of 
olefins with chloramine–T (Kumar et al. 2004). The structure of phosphomolybdic acid 
is shown in 
 
Figure 3.1 Structure of phosphomolybdic acid. 
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Flavanones are generally synthesized through the cyclization reaction of 2′-
substituted chalcones which can itself be prepared via Claisen-Schmidt condensation.In 
this project, a library of chalcones has been synthesized following the reported methods 
(Marais, 2005; Narender 2007). The chalcones were prepared by reacting 2′-
acetophenone, 2′-aminoacetophenone and 2′-mercaptoacetophene with various 
benzaldehydes. The 2′-hydroxyl- and 2′-azachalcones were purified by column 
chromatography and characterized by spectroscopic methods. In case of 2′-
thiochalcones, attempts to isolate the pure products were unsuccessful. Presumably, 
thiochalcones undergo oxidative coupling easily to form the corresponding disulfides 
(Zolfigol et al.2007). However, the formation of the desired chalcone is evident in the 
1H NMR spectra of the crude reaction mixture. Hence, the crude mixture of the 
mercaptochalcones was used directly for the cyclization reaction to produce 
thioflavanones. 
 
Acetic acid is one of the most convenient catalyst used in the synthesis of flavanone 
from 2′-hydroxchalcone (Scheme 4.1). The synthesis of flavanone began by addition of 
one equivalent of 2′-hydroxchalcone to glacial acetic acid (25ml per mmol of 2′-
hydroxchalcone) and refluxed for 72 hrs. The reaction mixture was then poured into 
water and extracted with organic solvents (Cabrera et al.2007). 
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Scheme 4.1 Conventional method for synthesis of flavanones 
 
In the synthesis of flavanones from 2′-hydroxchalcone, acetic acid was employed as the 
solvent and catalyst. However, for the synthesis of azaflavanone, the reaction was 
carried out in the mixture of phosphoric acid and acetic acid (1:1) (Wang et al. 2006). 
Refluxing 1 equivalent of 2′-aminochalcone in acetic acid alone for about 96 hrs gave 
only 20% yield of azaflavanone. The synthesis of thioflavanone from 2′-
mercaptochalcone in acetic acid has never been reported. Unfortunately, our attempts to 
synthesise thioflavanones in acetic acid were also unsuccessful (Scheme 4.2). 
Previously, Taylor and Dean reported the synthesis of thioflavanone from protected 
thiochalcone in which the deprotection and cyclization of thiochalcone to the 
corresponding thioflavanone was carried out in formic acid (Taylor et al.1988). This 
procedure has been found to be inefficient for 5-methoxythioflavanones since the 
methoxy group can be partially cleaved in presence of formic acid to yield a mixture of 
flavanones and thioflavanones (Scheme 4.3). 
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Scheme 4.2 Reaction of 2′-mercaptochalcones and 2′-aminochalcones in acetic acid 
 
 
Scheme 4.3 Taylor and Dean method for thioflavanone synthesis 
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 As mentioned in chapter 3, phosphomolybdic acid supported on silica gel 
(PMA/SiO2) has been used as a catalyst in many chemical transformations such as: 
regioselective opening of aziridines with nucleophiles (Kumar et al. 2004), 
chemoselective hydrolysis of acetonides (Yadav et al.2005), Ferrier rearrangement 
(Yadav et al.2006), selective deprotection of tert-butyldimethylsilylther (Kumar et al. 
2005),  and aziridination of olefins with chloramine–T (Kumar et al. 2004).  Intrigued 
by above catalytic properties, we decided to examine PMA/SiO2 as catalyst for 
flavanone synthesis. 
 
PMA/SiO2 was prepared by stirring 0.1 equivalents H3PMo12O40 in MeOH and 0.9 
equivalents of silica gel (100-200 mesh) at room temperature for about six hours. 
Methanol was then removed under reduced pressure, to yield the PMA/SiO2 as a yellow 
solid (Kumar et al. 2004). 
 
Reactions for preparation of flavanones from chalcones were screened in a variety of 
parameters, including solvents, temperatures, reaction time and amount of catalyst used  
(Table 4.1). Since the presence of hydroxyl (-OH) group at C-2′ position is a 
requirement for intramolecular conjugated addition in the synthesis of flavanones; 2′-
hydroxychalcone was selected as a model substrate to study the reaction efficiency. As 
shown in Table 4.1, the nature of the solvent played a key role in the reaction. The 
cyclization reaction of 2′- hydroxychalcone catalytic amount of PMA-SiO2 indicated 
that the reaction performed well in ethanol and only moderately in acetonitrile (Entries 
4 and 10, Table 4.1). The difference in the reactivity of the catalyst in acetonitrile and 
ethanol could be explained by the difference in the nature of the solvents. Acetonitrile is 
a polar aprotic solvent while ethanol is a polar protic solvent. Being a protic solvent, 
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ethanol is capable of hydrogen bonding. This capability presumably, enhances the 
activity of the catalyst. On the other hand, since conversion of chalcone to flavanone is 
a hydrogen-transfer type reaction as shown in Scheme 4.4, the presence of protic 
solvents like alcoholic solvents may promote the reaction due to the hydrogen bond-
donating ability of this class of solvents (Andrew et al. 1985).  
  
 
 
 
 
Scheme 4.4. Illustration of solvation of intermediate T.1 by protic solvent 
 
 
 The reactions seemed to be temperature dependent as yields were significantly 
improved when reactions were performed under reflux compared to room temperature 
(Entries 3 and 4, Table 4.1).  
 
 
The optimal quantity of the catalyst was found to be at 1 mol%. Excess amount of 
catalyst did not increase the yields. Under the best conditions tested, a solution of 
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substituted chalcones in ethanol was stirred with 1 mol% of PMA-SiO2 under reflux to 
give 97% yield of flavanone (Entry 4, Table 4.1). This reaction was completed in about 
8.5 hours.   
 
Table 4.1. Screening of the reaction conditions 
 
 
Entry Solvent Temperature PMA/SiO2 
(mol %) 
aYield of 
product ( %) 
Reaction 
time(hr) 
1 Ethanol rt - - 48 
2 Ethanol 880C - - 48 
3 Ethanol rt 1mol% 40% 48 
4 Ethanol 880C 1mol% 97% 8.5 
5 Ethanol 880C 5mol% 98% 8.5 
6 Ethanol 880C 10mol% 98% 8.5 
7 Acetonitile rt - - 48 
8 Acetonitile 880C - - 48 
9 Acetonitile rt 1mol% 15% 48 
10 Acetonitile 850C 1mol% 32% 24 
11 Acetonitile 850C 5mol% 35% 24 
12 Acetonitile 850C 10mol% 42% 24 
  
a
Isolated yield calculated from 2′-hydroxychalcone. 
 
 
Control experiments (Entries 1, 2, 7 and 8, Table 4.1) involved performing the reactions 
in solvent without addition of catalyst. In all cases, no product was obtained, either at 
room temperature or under reflux. 
 
To study the efficiency of the catalyst, the best reaction condition for the synthesis of 
flavanone from 2′- hydroxychalcone (entry 4, Table 4.1) was employed for the 
synthesis of azaflavanone and thioflavanone from 2′-aminochalcone and 2′-
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mercaptochalcone, respectively. In general, the reactions of 2′-hydroxychalcones were 
observed to be faster than 2′-mercaptochalcones and 2′-aminochalcones. The reaction 
times varied from 8.5-9 hrs for the conversion of  2′-hydroxychalcones, 9.5 
 
hrs for 2′-
mercaptochalcones and 17-22 hrs for 2′-aminochalcones to produce the desired 
flavanone in excellent yield (80-97%),  thioflavanone (86-90% ) and azaflavanone (52-
68%) in moderate to good yields, respectively (Scheme 4.5). 
 
                             
 
 
Scheme 4.5    Comparison of reaction times and yields for different type of chalcones 
 
To explore the effect of the concentration on the yield of the different types of 
flavanones, the intramolecular cyclization reaction of 2′-hydroxychalcones, 2′-
mercaptochalcones and 2′-aminochalcones were screened in four different 
concentrations (Table 4.2). The yields of flavanone analogues were observed to be 
influenced by the concentration of the chalcone. The optimal concentration for the 
transformation of chalcones to flavanones (intramolecular cyclization) was found to be 
0.2M for all types of flavanones. As shown in Table 4.2, at 0.2 molar concentrations, 
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97% flavanone, 86% thioflavaone and 52% azaflavanone were obtained from 
corresponding chalcones (Entry 2, Table4.2).  
 
 
                          Table 4.2 Product distribution in various concentrations 
         
 aIsolated yield calculated from 2′-hydroxycchalcon (estimated from 1HNMR spectroscopy of crude mixture) 
 
b
 Isolated yield calculated from 2′-thiochalcone (estimated from 1HNMR spectroscopy of crude mixture) 
  cIsolated yield calculated from 2′-aminocchalcone      
                            
 
 
 
 
 
However, increasing the concentration of the chalcone (> 0.2M) seemed to 
promote more intermolecular chalcone-chalcone reactions. Due to the high 
concentration of reactants the probablity of intermolecular collision is higher which 
result in an increase in Michael adduct being form in all cases.  As an example, in the 
case of 2′-hydroxychalcone, an increase in concentration from 0.2 M to 1.0 M resulted 
in an enhancement of Michael adduct yield by ten times. Likewise, by increasing the 
concentration of 2′-thiochalcone from 0.2M to 1.0 M, the intermolecular reaction of was 
promoted from 7% to 15%. However, this concentration effect resulting in 
intermolecular reaction was observed to be more pronounced in the case of 
Entry Concentration 
(Molar) 
aYield of 
flavanone  
Yield of 
Michael 
adduct  
bYield of 
thioflavanone   
Yield of 
Michael 
adduct  
cYield of 
azaflavanone  
Yield of 
Michael 
adduct  
1 0.1 92% 2% 75% 5% 30% 5% 
2 0.2 97% 2% 86% 7% 52% 10% 
3 0.4 85% 7% 55% 10% 40% 32% 
4 1 55% 20% 35% 15% 15% 70% 
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azaflavanones. As seen in Entry 4 (Table 4.2), refluxing 1M 2′-aminochalcones gave 
the Michael adduct as a major product with 70% yield (Scheme 4.6).  
 
 
 
  
 
   
Scheme 4.6 Effect of the concentration in yield of the reaction of 2′-aminochalcone in 
PMA-SiO2 
 
 
Presumably, this is due to the hydrogen bond stabilization of the Michael addition 
product. As shown in part A, Scheme 4.7, in the case of 2′-aminochalcone, the Michael 
adduct could be stabilized by three (A1) or two (A2) hydrogen bonds while in the case 
of 2′-hydroxychalcone and 2′-thiochalcone, B, the Micheal addition products were only 
stabilized by one hydrogen bond. This may possibly affect the yields of intermolecular 
reaction products in case of 2′-aminochalcone as compare to 2′-hydroxyl and 2′-
thiochalcone. 
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Scheme 4.7 Stabilization of conformations of intermolecular Micheal addition products 
of 2′-aminochalcone (A), 2′-hydroxychalcone and 2′-thiochalcone (B) 
 
In order to compare the stability of A1 and A2, both structures were subjected to 
quantum calculation. Initial structure of the A1 and A2 were built and optimized with 
density functional theory (DFT) with double–numeric quality basis set (DN basis set) 
using Material Studio 4.4. As it shown in Figure 4.1, structure A1 with three hydrogen 
bonds is relatively more stable than A2 which has two hydrogen bonds. Although this 
energy gap is not very large (0.00119 Hartree = 0.74 kcal/mol), this result could still 
explain the preference of structure A1. 
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               A1 = -1418.2345022 Ha                                      A2= -1418.2356818 Ha                                           
 
Figure 4.1 Illustration of H-bonding in A1 and A2 
 
All the reactions occurred smoothly in 1 mol% PMA-SiO2 in ethanol. The reaction of 
chalcones without 2′- hydroxyl, 2′- amino and 2′- mercapto substituent did not produce 
the corresponding flavanone. This seemed to indicate that presence of heteroatom 
substituent at C-2′ on the chalcone is required for intramolecular cyclization to occur. 
2′-Hydroxychalcones reacted faster than 2′-mercaptochalcones and 2′-aminochalcones 
to give the corresponding flavanones in excellent to moderate yield. The low reactivity 
of mercapto chalcones may be attributed to the fact that thiols are easily oxidized to 
form disulfides (Zolfigol et al.2007). However, the reaction time for mercaptochalcones 
is not significantly longer than hydroxychalcones; lower yields of product were 
obtained with the mercaptochalcones even after stirring for a longer time. 
 
Following the completion of the reaction, the catalyst was recovered with a simple 
workup and filtration for further reuse.  As shown in Table 4.3, the recovered catalyst 
did not show appreciable loss in its activity since more than 89% yield of the flavanone 
was obtained even when the catalyst was reused for the third time (Table 4.3).          
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Table 4.3. The cyclization of 2-hydroxychalcone catalyzed by PMA-SiO2 and catalyst 
recycle  
                         
 
Substrate 
 
Product 
 
Condition 
 
aYield 
O
OH
 
 
1 mol% PMA-SiO2, 
reflux, 8.5 h 
97% 
 
1st recycle, reflux,  
8.5 h 
 
95% 
 
2nd  recycle, reflux, 
8.5h  
 
89% 
 
aIsolated yield calculated from 2′-hydroxychalcone 
 
 
The plausible mechanism for the intramolecular cyclization of bicyclic 2′-
hydroxychalcones, 2′-mercaptochalcones and 2′-aminochalcones into tricyclic 
flavanones in PMA-SiO2 is shown in Scheme 4.8. The reaction was possibly initiated 
by addition of PMA to the carbonyl oxygen followed by intramolecular conjugation 
addition to form a tricyclic enol which preferably tautomerized to the corresponding 
ketone.  
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Scheme 4.8 Proposed mechanism for the synthesis of flavanones in PMA-SiO2 
 
In summary, an efficient synthetic route was developed by using PMA-SiO2 a reusable 
catalyst for the cyclization of various chalcones to flavanones as a part of this study. 
The simple protocol, low cost of the catalyst, reusability and environmental 
considerations make this method useful and attractive (Sakirolah & Yaeghoobi, et al., 
2011). Subsequently, this method was used for the preparation of various flavanone 
derivatives that are used for biological activity testing. For example, as shown in the 
Scheme 4.9, flavanone MF13 has been synthesized from chalcone MC42 using this 
method (see chapter 5). 
   
 
 
Scheme 4.9 Conversion of chalcone MC42 to flavanone MF13 using 1mol% PMA / 
SiO2 
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ANALOGUES WITH 
POTENTIAL 
NEURAMINIDASE 
INHIBITION EFFECT 
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In the last decade, a number of investigations have been accomplished on 
flavonoids for their potential neuraminidase inhibitory effect. However, most of 
researches were conducted on naturally occurring flavonoids. Amongst all subtypes of 
flavonoids, chalcones have not been extensively studied for their potency as NA 
inhibitors. In addition, structure-activity relationships for the chalcones have not been 
well studied. 
 
Investigation by Ryu and co workers on the inhibition effect of extracted flavonoids 
from Sophora flavescensa and Glycyrrhiza uralensis showed  isolated flavonoids to be 
fairly potent with IC50 value of 20 µM or below in all cases. The results of Lineweaver-
Burk and Dixon plots suggested a non-competitive mode of inhibition. For these 
flavonoids, the exact binding site of neuraminidase protein and the actual mechanism of 
the action of these isolated flavonoids on the new receptor are still unclear. The aim of 
the present investigation was to explore the structural requirements for the interactions 
of flavonoids with the neuraminidase protein in order to deduce the potential directions 
for synthetic lead-optimisation studies. Preliminary structural-activity relationship 
information obtained showed isolated flavonoids (chalcones and flavanones) to have 
good to excellent activity against neuraminidase (Table 5.1; Ryu et al. 2008; Ryu et al. 
2010).  Hence, methoxy substitution was observed to decrease the inhibition potency. 
Glycosides also led to decreases in bioactivity, but hydroxyl group seemed to increase 
the activity (Ryu et al. 2010).  
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Table 5.1.  IC50 and Ki values for reference flavonoids isolated from Glycyrrhiza 
uralensis on neuraminidase activity 
 
Compound IC50 (µM)a Inhibition type (Ki  µM) 
 
 
 
 
 
9.0 ± 0.7 
 
 
 
Noncompetitive 
(9.9 ± 0.7 ) 
 
 
 
 
22.4 ±  2.2 
 
 
 
Noncompetitive 
(20.1 ± 2.5 )            
 
 
 
 
 
124.0 ± 2.3 
 
 
 
 Noncompetitive 
(94. ± 10.1)                
 
 
 
 
 
12.9 ± 1.2 
 
 
Noncompetitive 
(15.2 ± 0.2 ) 
 
 
 
 
 
46.8 ± 3.3 
 
 
  
Noncompetitive 
(33.1 ±10.7)        
 
 
 
 
 
 
82.3 ± 0.1 
 
 
 
Noncompetitive 
(123.7 ±0.7) 
                   aAll compounds were examined in a set of experiments repeated three times; IC50 value of compounds represent the 
                   concentration that caused 50% enzyme activity loss; Oseltamivir was used as a positive control(IC50 value+1.59 nM)  
                   (obtaining from Ryu et al., 2010).   
 
 
 
Based on the preliminary SAR information, a library of flavonoids was prepared by 
incorporating various substituent like OH, OMe, methylenedioxy, methyl, halogen, 
naphthalene, NO2, SH, NH2 and dimethylamine into the flavonoid structure. The 
general strategy to further explore this template is depicted in Figure 5.1.  A library of 
flavonoid analogues (Table 5.2 and 5.3) was prepared in the hope to gain useful 
1 
2 
3 
4 
5 
6 
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information on the substitution of different functional groups and its molecular 
interactions with the neuraminidase enzyme. We focused on electron donating and 
electron withdrawing groups as well as hetero atoms (eg. O, N, and S) on the flavonoid 
backbone to study the influence of these substituent on the neuraminidase inhibition 
activity. Preliminary molecular modeling results suggested that the carbonyl, hydroxyl- 
and methoxy- substituent in the flavonids could participate in hydrogen bonding while 
benzene and naphthalene rings could form pi interaction with the enzyme, allowing 
better protein- ligand interaction. In addition, 2D and 3D QSAR models indicate that, 
the electrostatic effect may enhance bioactivity of the chalcones while the steric 
influence of the substituent would diminish their potency as NA inhibitors. The 3D 
QSAR model also showed the importance of the position of the hydroxyl group in A 
ring which can influence on the hydrogen-bond donating and accepting capacities as 
well as the hydrophobicity which presumably would enhance the biological activity 
(Yeaghoobi & Frimayanti, et al., 2012; Unpublished result). 
 
 
 
Figure 5.1 General strategies to prepare flavonoids analogues 
   
The substituted chalcones MC1-MC50 (Table 5.2) with different functionalities 
were prepared via a Claisen-Schmidt condensation reaction between appropriate 
acetophenones and benzaldehydes (Marais et al. 2005). All compounds synthesized 
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were purified by chromatographic method and characterized using spectroscopic 
techniques except for MC47-MC50 which could not be isolated in their pure form due 
to the instability of mercaptochalcones during purification where thiols were   oxidized 
to form disulfides (Zolfigol et al.2007; Konieczny et al. 1999).  
 
Flavanones MF1-MF17 (Table 5.3) were prepared via an intramolecular cyclization 
reactation from the corresponding chalcones using catalytic amount of PMA/SiO2 in 
ethanol under reflux. The resulting flavonones were then purified and characterized 
using spectroscopic techniques.  
 
Chalcones MC1-MC46 and flavanones MF1-MF17 were then tested for their H1N1 
neuraminidase inhibitory potency by the well known in vitro MUNANA assay (M. 
Potier et al. 1979).  DANA (2-deoxy-2,3-didehydro-N-acetylneuraminic acid), a known 
neuraminidase inhibitor was used as standard inhibitor (Figure 5.2) 
 
Figure 5.2. Structure of DANA 
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Table 5.2.  Yields and melting points of chalcones synthesised 
 
 
 
 
 
Entry Structure Yield
a
 (%) 
mp(0C) 
found 
mp(0C) 
reported 
MC1 
 
78 55-56 56-57 
MC2  
 
82 149-150 153-154 
MC3  
          
65 152-154 156-158 
MC4 
           
45 159-160 163-165 
MC5 
 
91 89-90 86-87 
MC6  
 
53 158-159 160-161 
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‘Table 5.2, continued’ 
Entry Structure Yielda 
(%) 
mp(0C) 
found 
mp(0C) 
reported 
MC7 
              
65 148-149 150-153 
MC8 
               
53 135-137 138-139 
MC9 
               
87 91-92 93-94 
MC10 
           
OOH
OCH3
OCH3
 
92 115-117 112-113 
MC11 
 
85 158-159 152 
MC12 
 
82 135-137 138 
 
‘Table 5.2, continued’ 
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Entry Structure Yielda 
(%) 
mp(0C) 
found 
mp(0C) 
reported 
MC13 
 
85 115-117 117-118 
MC14 
 
56 149-152 153-156 
MC15 
 78 135-137 135-137 
MC16 
 
72 138-140 - 
MC17 
 75 110-112 112-114 
MC18 
        
65 152-154 - 
 
‘Table 5.2, continued’ 
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Entry Structure Yielda 
(%) 
mp(0C) 
found 
mp(0C) 
reported 
MC19 
 
75 -b -b 
MC20 
 
54 152-153 - 
MC21 
 
 
65 158-159 - 
MC22 
 
67 182-185 191 
MC23 
 
55 125-126 118-120 
 
‘Table 5.2, continued’ 
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Entry Structure Yielda 
(%) 
mp(0C) 
found 
mp(0C) 
reported 
MC24 
 
85 112-114 - 
  MC25 
 
75 119-122 123-125 
MC26 
 
75 112-114 - 
MC27  
 
82 123-125 - 
MC28 
 
45 101-103 104-106 
 
‘Table 5.2, continued’ 
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  Entry Structure Yield
a
 
(%) 
mp(0C) 
found 
mp(0C) 
reported 
MC29 
 
52 92-94 - 
MC30  83 107-10 - 
MC31  65 51-52 44-45 
MC32 
 
65 135-136 129-131 
MC33 
 75 155-156 148-151 
 
‘Table 5.2, continued’ 
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Entry Structure Yielda 
(%) 
mp(0C) 
found 
mp(0C) 
reported 
MC34  
 
52 132-133 - 
MC35  
 
45 145-148 151-152 
MC36   47 144-146 148-150 
MC37  
 
54 142-144 - 
MC38  
 
65 66-68 70-71 
 
‘Table 5.2, continued’ 
64 
 
 
 
  
Entry Structure Yielda 
(%) 
mp(0C) 
found 
mp(0C) 
reported 
MC39  
 
63 156-157 150 
MC40  
 
58 143-145 - 
MC41  
              
72 152-153 - 
MC42  
 
87 148-149 - 
MC43  
 
52 172-173 180-182 
MC44  
 
72 104-106 108 
 
‘Table 5.2, continued’ 
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Entry Structure Yielda 
(%) 
mp(0C) 
found 
mp(0C) 
reported 
MC45  
 75 162-163 158 
MC46  
 
68 184-186 180 
MC47  
       
42 -c -c 
MC48  
 
35 -c -c 
MC49  
  
47 -c -c 
MC50  
 
32 -c -c 
All products were identified by NMR spectroscopy 
a Isolated yield;   b Chalcones are in liquid form 
c the melting point could not be obtained since the crude mixture subjected to the cyclization 
‘Table 5.2, continued’ 
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Figure 5.3. X-ray crystal structure of (E)-1-(2-aminophenyl)-3-(naphthalen-2-yl) prop-
2-en-1-one with thermal ellipsoids at 50% probability. Atoms are labeled anonymously. 
Crystallographic data can be referred from appendix C. 
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Table 5.3 Yields and melting points of flavanones synthesised 
Entry Structure Yielda 
(%) 
mp(0C) 
found 
mp(0C) 
reported 
MF1 
 
97 95-97 97 
MF2 
 
94 153-155 155-158 
MF3 
 
93 152-153 154 
MF4 
 
88 136-138 132-133 
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Entry Structure Yielda 
(%) 
mp(0C) 
found 
mp(0C) 
reported 
MF5 
 
94 127-128 127-128 
MF6 
          
89 86-87 82-83 
MF7 
       
96 185-187 185-187 
MF8 
          
92 188-189 - 
MF9 
      
52 145-147 149-150 
  
‘Table 5.3, continued’ 
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Entry Structure Yielda 
(%) 
mp(0C) 
found 
mp(0C) 
reprted 
MF10 
             
68 193-195 200-202 
MF11 
            
72 171-172 168 
MF12 
            
55 149-151 147 
MF13 
            
75 233-235 - 
MF14 
       
86 52-55 56-57 
  
‘Table 5.3, continued’ 
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Entry Structure Yielda 
(%) 
mp(0C) 
found 
mp(0C) 
reported 
MF15 
        
88 122-123 126-127 
MF16 
 
             
84 97-99 93-94 
MF17 
 
90 112-115 116-117 
                    a Isolated yield.  All products were identified by 1H and 13C-NMR 
 
 
                                        
 
 
 
 
 
 
 
 
 
‘Table 5.3, continued’ 
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Flavonoids as potential Neuraminidase inhibitors: 
 
Chalcones MC1-MC46 have been docked to the neuraminidase of A/ Breving 
Mission/ 1/1918 H1N1 strain in complex with zanamivir (PDB ID = 3B7E, obtained 
from protein data bank, http://www.pdb.org). To evaluate our synthesized compounds 
for their potential H1N1 activity, the chalcones prepared have been tested against 
neuraminidase. In addition, docking studies between the chalcones and the active site of 
NA were carried out using Cdocker (Discovery Studio 2.5, Accelrys). The Cdocker 
energy reflects the interaction energy for the ligand-protein complex and the lower 
energy means the interaction is more stable. The result of bioassay (percentage of 
inhibition in 1000 µm) and Cdocker energy is summarized in Table 5.4. The calculated 
Cdocker energy for MC2, MC4, MC6, MC7, MC8, MC16, MC18, MC29, MC34, 
MC36, MC37, MC39, MC43 and MC46 showed relatively low Cdocker interaction 
energy (DANA is standard with -46.11 kcal/mol). This seemed to corroborate with the 
experimental data which showed moderate to excellent activities of these compounds 
against neuraminidase (ranging between 42.9 to 94.7%). In addition, MC1, MC5 and 
MC15 which showed relatively higher Cdocker interaction energy did not show good 
H1N1 inhibition activities. However, in some cases, the Cdocker energy calculation was 
not in agreement with the bioassay. As an example, in case of MC3, MC9-14, MC19-
28, MC30-33, MC38, MC40, MC41 and MC45 the Cdocker interaction energy was 
found to be low (ranging between -43.25 to -31.19 kcal/mol), but their bioassay results 
did not show these chalcones to be active against neuraminidase.  
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Table 5.4 Chalcone activity against Neuraminidase 
Entry (-) Cdocker interaction 
energya,b (kcal/mol) 
Inhibition  in 1000µm 
(%)c 
MC1 28.25 6.9 
MC2 31.80 70.1 
MC3 35.69 39.6 
MC4 29.74 92.1 
MC5 28.08 12.9 
MC6 36.94 88.6 
MC7 33.04 46.7 
MC8 36.94 94.7 
MC9 35.35 20.1 
MC10 38.65 20.2 
MC11 43.25 12.9 
MC12 35.41 19.5 
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Entry (-) Cdocker interaction 
energya,b (kcal/mol) 
Inhibition  in 1000µm 
(%)c 
MC13 32.54 17.0 
 
MC14 35.37 15.2 
MC15 29.25 16.4 
MC16 43.05 93.4 
MC17 45.41 25.14 
MC18 41.32 58.2 
MC19 38.39 30.5 
MC20 37.21 12.9 
MC21 40.40 20.1 
MC22 38.58 21.9 
MC23 39.28 11.5 
MC24 38.12 15.4 
‘Table 5.4, continued’ 
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Entry (-) Cdocker interaction 
energya,b (kcal/mol) 
Inhibition  in 1000µm 
(%)c 
MC25 35.31 19.1 
MC26 35.31 20.9 
MC27 46.85 37.5 
MC28 39.12 16.2 
MC29 41.97 43.7 
MC30 32.22 31.2 
MC31 31.38                   22.4 
MC32 38.12 12.1 
MC33 33.82 19.5 
MC34 33.22 65.3 
MC35 29.85 42.5 
MC36 32.40 55.7 
 
 
 
‘Table 5.4, continued’ 
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a
 Calculation performed by Frimayanti et al. using  Cdocker (Discovery Studio 2.5, Accelrys) ; 
         
b
 Enzym: 3b7E (Neuraminidase of  A/ Breving Mission/ 1/1918 H1N1 strain in complex with zanamivir; 
      
 c
 Bioassay performed by Ikram et al. using DANA as standard with -46.11 kcal/molCdocker interaction energy             
 
 
 
 
 
 
 
 
 
Entry (-) Cdocker interaction 
energya,b (kcal/mol) 
Inhibition  in 1000µm 
(%)c 
MC37 33.47 42.9 
MC38 31.74 34.9 
MC39 31.60 63.6 
MC40 35.85 26.4 
MC41 35.78 19.1 
MC42 31.19                   6.8 
MC43 30.32 75.4 
MC44 27.82 41.2 
MC45 33.26 36.6 
MC46 35.29 54 
 
 
  
‘Table 5.4, continued’ 
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Flavanones MF1-MF17 have been also docked to the neuraminidase of A/ 
Breving Mission/ 1/1918 H1N1 strain in complex with zanamivir (PDB ID = 3B7E, 
obtained from protein data bank, http://www.pdb.org). To validate the computational 
observations for the potential of these flavanones have been tested against 
neuraminidase. The result of bioassay (percentage of inhibition in 250µm) and Cdocker 
energy is summarized in Tables 5.5. The bioassay results did not show good activity 
although, the calculated Cdocker interaction energy for MF3, MF4, MF5 and MF10 was 
found to be relatively low (ranged from -30.82 to -31.45 kcal/mol). This observation 
may be due to the binding of flavanones as ligand to the allosteric site rather than the 
active sites (Ryu et al. 2008). Bioassay results of chacone and flavanone analogues are 
shown in Table 5.6 and Table 5.7 respectively.   
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Table 5.5 Flavanone activity against Neuraminidase 
 
                  a Calculation performed by Frimayanti et al.using  Cdocker (Discovery Studio 2.5, Accelrys) ; 
                  b Enzym: 3b7E (Neuraminidase of  A/ Breving Mission/ 1/1918 H1N1 strain in complex with zanamivir;. 
             c
 bioassay erformed by Ikram et al. using DANA as standard with -46.11 kcal/molCdocker interaction energy 
 
 
 
Entry (-) Cdocker interaction 
energya,b (kcal/mol) 
Inhibition  in 250µm 
(%)c 
MF1 26.22 8.2 
MF2 27.04 11 
MF3 31.45 12 
MF4 30.86 14.7 
MF5 30.82 10.7 
MF6 27.16 8.0 
MF7 25.89 1.8 
MF8 28.48 6.4 
MF9 28.93 7.3 
MF10 31.20 5.3 
MF11 26.63 5.1 
MF12 27.22 3.0 
MF13 27.74 7.7 
MF14  18.34 4.7 
MF15 25.60 13.5 
MF16 26.76 12.6 
MF17 26.32 5.4 
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CHAPTER 6 
  
1,5-BENZOTHIAZEPINES 
AND THEIR POTENTIAL 
HEALTH BENEFITS 
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Thiazepines and diazepines are seven- membered heterocyclic rings with two 
hetero atoms. Benzothiazepine and benzodiazepine moieties are two subgroups of this 
family of heterocycles in which the thiazepine or diazepine rings are fused to a benzene 
ring.  
 
1,5-Benzodiazepines are an important class of organic compounds. They are effective 
analgesic, anti-convulsant and sedative medicines   (Page et al. 2002) because not only 
they are completely absorbed but also as they are lipophilic, they can penetrate the brain 
easily (Fernández et al. 2006). Thus, this class of heterocyclic compounds continues to 
attract many chemists and pharmacologists since 1955 when the first benzodiazepine 
“Chlordiazepoxide” (Librium) was discovered by Leo Sternbach and subsequently 
synthesized by Hoffmann_ Laroche in 1960. Commercial “diazepam” was marketed in 
1963 for the first time (Shorter et al. 2005).  Based on molecular structures, 
benzothiazepines can be divided to some other subclasses, i.e.  1,4- benzothiazepines, 
4,1- benzothiazepines and 1,5- benzothiazepines (Levai et al.1999). 1,5-
Benzothiazepines  broadly used as anti-feedant (Reddy et al. 1993), tranquilizer (Kugita 
et al. 1971), anti-depressant (Geyer et al. 1970), CNS stimulant(Kawashima et al.1985), 
calcium channel blocker ( Kugita et al. 1971), anti-microbial agent (Dandia et al. 1998). 
Moreover, 1,5-benzothiazepines have been combined with other well-known 
pharmaceutically active compounds such as benzofuran derivatives to form a single 
molecule with improved pharmaceutical properties (Cherkupally et al. 2008). The 
general structure of 1,5-benzodiazepine and 1,5-benzothiazepine is shown in Figure 6.1. 
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Figure 6.1 General structure of 1,5- benzodiazepines and 1,5- benzothiazepines 
 
1,5-benzodiazepines are well established in pharmacological and medicinal chemistry.  
However, limited number of studies had been carried out on the synthesis and SAR for 
1,5-benzothiazepines, especially in terms of anti-viral activities. 
 
6.1 Anti-viral effect: 
 
 The anti-viral effects of   benzodiazepines and benzothiazepines have mainly 
been focused on HIV and hepatitis viruses. Nicol and co-workers showed that 
dibenzothiazepinethione derivatives to have anti-viral activities against Varicella-Zoster 
virus, hepatitis B and HIV-1 (Nicol et al. 1992). In another study, Delpa and co-workers 
showed 1,4- benzothizapines and 1,4-benzodiazepines with a peptide side-chain to have 
inhibitory effect on hepatitis B, and D viruses by affecting the binding of the hepatitis 
virus to annexin V (Delpa et al.2000). A group of thiazolothiazepines have also been 
reported to be promising candidates for the HIV treatment by targeting the integrase 
enzyme (Neamati et al. 2000). Tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-
one and -thione (TIBO), are also known for their activity on HIV-1 virus (Pauwels  et 
al. 1990).         
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A number of tricyclic derivatives of 1,4-benzothiazine and 1,5-benzothiazepine 
were also reported to have  anti- HIV properties in vitro (Grandolini et al.1999). In 
addition, 2H-pyrrolo [3,4-b] [1,5] benzothiazepine derivatives were also reported to be 
potent candidates for HIV-1 (Di Santo et al. 2005).  
 
 Our recent interest in 1,5-benzothiazepines has been inspired by the anti-viral 
properties of this class of compounds. Thus, in this study we explored on neuraminidase 
inhibitory activity of this class of heterocycles. 
 
6.2 Platelet aggregation inhibitory effect: 
 
Platelet aggregation is a process in which platelets in the blood will clump 
together. This process can eventually lead to the formation of clot in the blood vessels 
and cause cerebral vascular complications. Few 1,5-benzothiazepine derivatives bearing 
N-amino groups (Figure 6.2) have been reported to have potent platelet aggregation 
caused by platelet activating effectors, collagen, epinephrine and arachidonic acid 
(Bariwal et al. 2008). 
 
 
 
Figure 6.2 Structure of 1,5- bezothiazepines with potential anti-platelet aggregation 
properties 
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6.3 Anti-cancer effect: 
 
The anti-cancer properties of benzothiazepine derivatives have been shown in 
number of studies. For example, 1,4- benzothizepine and its analogues synthesized by 
Garofalol and co-workers were shown to have potent anti-tumors activities against 
murine L1210 and human lymphoblastic CCRF_CEM leukemia cell growth (Garofalo 
et al.1993). 
Evaluation of some synthesized pyrrolo[1,5]benzoxa(thia)zepine analogues  against 
tumor cell showed these compounds to be promising potent apoptotic agents (Mc Gee et 
al. 2005). 1,4-Benzodiazepine-2,5-diones was also reported to exhibit anti-tumor 
activity by disrupting   Hdm2:p53 interaction (Marugan et al. 2006).  
 
6.4 Anti-bacterial and anti-fungal effect: 
 
A number of benzothiazepines have been investigated for their anti-bacterial and 
anti-fungal activities. A group of synthesized methylene-bis-benzofuranyl-[1,5]-
benzothiazepines were found to have in vitro anti-bacterial activities, nearly as active as 
those well known anti-bacterial medicines such as streptomycin and penicillin. 
Substitution at the 4th position of this class of benzothiazepines was observed to play a 
key rule in enhancing the potent bioactivity. Moreover, these compounds exhibited 
moderate to good anti-fungal activities (Cherkupally et al. 2008). 2,4-Diaryl-2,3-
dihydro-1,5-benzothiazepines and their 1, 1- dioxide derivatives were also found to 
have anti-bacterial and anti-fungal properties (Jadhav et al.1983; Barot et al. 2001). 
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6.5 CNS activity effect: 
 
1,5- Benzothiazepine derivatives such as thiazesim and quentiapine have been 
clinically approved to be effective candidates for CNS (Central Nervous System) 
disorders.  Pyrrolo- derivatives of benzothiazepines have been shown to have excellent 
sedative action comparable with diazepam (Nacci et al. 1984). Imidazolo- derivatives 
were also reported to be fairly active on CNS inhibition with notable anti-inflammatory 
activities (Ambrogi et al.1995, Grandolini et al.1995). Furthermore, oxadiazolo- 
derivatives has been tested against seizures and have exhibited comparable activity to 
clobazam (De Sarro et al.1995).  
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CHAPTER 7 
  
SYNTHETIC ROUTES TO 
THE BIOACTIVE 1,5-
BENZOTHIAZEPINES 
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The synthesis of 1,5-benzothiazepine and its other analogue, 1,5-
benzodiazepines often involve an intermolecular cyclo-condensation of o-
aminothiophenol (o-ATP) and o-phenylenediamine (o-PDA) with ketones (Ried et 
al.1959), α-β-unsaturated carbonyl systems like chalcones or β-haloketones (Ried et 
al.1957). Chalcones are normally synthesized via Claisen-Schmidt condensation of 
acethophenones with various benzaldehydes (Marais, 2005; Narender and Papi Reddy 
2007). As outlined in Scheme7.1, retrosynthetic analysis consists of three primary 
disconnections, which can provide a facile synthetic route for the synthesis of 1,5- 
benzothiazepines and 1,5- benzodiazepines without a lengthy protection-deprotection 
steps. 
 
H
O
R'
R
R
O
Claisen-Schmidt
condensation
N X
R'
X
NH2
O
O
NH2
XH
R'
cyclo- condensation
1, 4 Micheal addition
R'
R
R
X= NH,S
R, R' = various substituents
 
               Scheme7.1.Retrosynthesis strategy for the synthesis of 1,5- benzothiazepines 
and  1,5-benzodiazepines 
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7.1 Acetic acid catalyzed azepine synthesis 
 
Acetic acid has been reported as a mild media for the synthesis of 1,5-
benzodiazepines (Reddy et al.2000) and 1,5-benzothiazepines (Cherkupally et al.2008). 
For the synthesis of 1,5-benzodiazepines, an equimolar of 1,1′-(4,6-dihydroxy-1,3-
phenylene)diethanone, 1, and bromoacetophenone was refluxed in an acetone solution 
of potassium carbonate (6 hrs). After completion of the reaction, acetone was removed 
and the residue was poured over ice. The solid was filtered out, washed with hot 
alkaline solution, and neutralized with diluted HCl. Recrystalization produced 
compound 2, which was treated with the appropriate benzaldehyde through Claisen-
Schmidt condensation to give the chalcone 3. Refluxing chalcone 3 and o-PDA in 
ethanol containing a few drops of glycial acetic acid resulted in the 1,5-benzodiazepines 
4. This method is summarized in Scheme 7.2 (Reddy et al.2000). Later, Cherkupally 
and co-workers reported a similar synthetic route for the synthesis of 1,5-
benzothiazepine derivatives where trioxane and salicylaldehyde1' were reacted in a 
mixture of acetic acid and concentrated sulfuric acid to produce the aldehyde 2' which 
underwent Claisen-Schmidt condensation in presence of different methyl ketones to 
produce methylen-bis- chalcone 3'. Reaction of chalcone 3' with o-ATP yielded 1,5- 
benzothiazepines 4'. To improve potential bioactivity, compound 4' was treated with 
bromoacetophenone in presence of potassium carbonate followed by alkaline solution 
of ethanol to give 5'. The reaction is summarized in Scheme 7.3 (Cherkupally et 
al.2008).   
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Scheme 7.2 Synthesis of 1,5-benzodiazepines in acetic acid 
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Scheme 7.3 Synthesis of 1,5-benzothiazepines in acetic acid 
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7.2   Gallium triflate   catalyzed azepine synthesis 
 
Gallium triflate, Ga(OTf)3, has been used as a catalyst for azepine synthesis. It 
was observed to perform well in acetonitrile. This catalyst has been reported to be 
efficient for the synthesis of 2,2,4-trisubstituted 1,5-benzodiazepines through the 
reaction of 2 equivalent aromatic or aliphatic ketones with 1 equivalent o-PDA (Scheme 
7.4, A). Moreover, Ga(OTf)3 has been reported to catalyze the synthesis of 2,4-
disubstituted 1,5-benzodiazepines and 1,5-benzothiazepines from 1 equivalent chalcone 
with o-PDA and o-ATP respectively (Scheme 7.4, B). In a typical experiment, 1 mmol 
of chalcones, 0.1 mmol Ga(OTf)3  and o-PDA (1 mmol) or o-ATP (1.2 mmol) were  
refluxed in MeCN for 4-6 hrs to produce the desired 1,5-benzodiazepines and 1,5-
benzothiazepines respectively (Pan et al. 2008). 
 
 
 
 
 
Scheme 7.4 Synthesis of 2,2,4-trisubstituted 1,5-benzodiazepines; A and 2,4-
disubstituted 1,5-benzodiazepines; B in Ga(OTf)3 
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7.3      LiAlH4   catalyzed azepine synthesis 
 
The synthesis of oxygen- bridged 1,5- benzothiazepine derivatives, 2 has been 
carried out by reacting o-ATP with phenolic β-ketones in DMSO under reflux condition 
( Scheme 7.6). The 2-phenyl-4-(2′-(-hydroxyphenyl)-4,5-dihydro-1,5-benzothiazepine 
derivatives (3, Scheme 7.5) can be produced from benzofuro-annelated 2-phenyl 1,5- 
benzothiazepine (2, Scheme 7.5), through reduction and furan ring opening. Lithium 
aluminum hydride (LAH) can catalyze this reaction at room temperature. This method 
enabled us to synthesize a wide range of 1,5-benzothiazepines bearing a hydroxyl group 
at ortho position by mean of synthetic protocol (Ahmad et al.2000). 
 
 
 Scheme 7.5 Synthesis of 2-Phenyl-4-(2′-(-hydroxyphenyl)-4,5-dihydro-1,5-
benzothiazepines using LAH 
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7.4     Solid phase azepine synthesis 
 
Solid phase synthesis has been reported as an alternative method to the solution-
phase synthesis which can enable the synthetic chemist to prepare an acceptable amount 
of 1,5- benzothiazepines from functionalized chalcones by minimizing the possibility of 
side reactions of substitutions in benzaldehyde during chalcone synthesis. Firstly, a 
solution of substituted benzaldehyde in DMF needs to be treated with the Wang 
bromide resins in the presence of CsCO3 and sodium iodide. The supported chalcone, 2, 
has been synthesized by the addition of acetophenone to the alkylated compound, 1 in 
presence of a methanolic solution of MeONa. To synthesize 1,5-benzothiazepine, 3, a 
mixture of supported chalcone and o-ATP have been heated in THF and treated with 
acetic acid followed by the cleavage of the Wang bromide in TFA / DCM (Scheme 7.6, 
A).  As summarized in Scheme 7.6, B, similar procedure can be carried out by 
protecting functionalized acetophenones (Micheli et al. 2001). 
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Scheme 7.6 Solid phase synthesis of 1,5-benzothiazepines using supported 
benzaldehyde , A, and supported acetophenone, B. 
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7.5   Ionic Liquid promoted 1,5-benzodiazepine synthesis 
 
1, 3-n-dibutylimidazoliumbromide ([bbim] Br) is a room temperature ionic 
liquid which has been used to promote the synthesis of 1,5-benzodiazepines by reacting 
1 equivalent o-PDA with 2 equivalents cyclic or acyclic ketones. This reaction is 
summarized in Scheme 7.7 (Jarikote et al. 2003). 
 
 
Scheme 7.7 ([bbim] Br promoted synthesis of 1,5-benzodiazepines 
 
 
In a similar work, Du used 1-butylpyridinium hydrogen sulphate ([BPy] HSO4) for the 
synthesis of 1,5-benzodiazepines from chalcones and o-PDA. In this method, a mixture 
of 1 equivalent chalcone, 1.5 equivalent o-PDA and catalytic amount of [BPy] HSO4 
were refluxed in ethyl acetate. After completion of the reaction, the reaction mixture 
was added to MeOH, filtered and the crude was purified by column chromatography to 
give the desired benzodiazepine in 69% yield (Du et al. 2006). The reaction is 
summarized in Scheme 7.8. 
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Scheme 7.8 [BPy] HSO4 promoted synthesis of 1,5-benzodiazepines 
 
 
Recently, Yadav and co-workers reported the synthesis of 1,5-benzodiazepine 
ribofuranosides by using various imidazolium salt ionic liquids such as 1, 3-di-n-
butylimidazolium bromide, [BBIM] Br; 1-butyl-3-methylimidazolium bromide, 
[BMIM]Br; 1-butyl-3-methylimidazolium tetrafluroborate, [BMIM]BF4; 1-butyl-3-
methylimidazolium hezaflurophosphate, [BMIM]PF6 and 1-methoxyethyl-3-
methylimidazolium mesylate, [MOEMIM]Ms (Yadav et al. 2010). To start with, 2 
equivalent of ketone and 1 equivalent of o-PDA were stirred with ILs for 3-5hrs. After 
completion of reaction, the reaction mixture was extracted with ethyl acetate/ water and 
purified. The resulting 1,5-benzodiazepines was stirred with 1.1 equivalent bromosugar 
in ILs and the reaction mixture, extracted with DCM/water to produce1,5-
benzodiazepines nucleoside (Scheme 7.9). 
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Scheme 7.9 Plausible mechanism for the synthesis of 1,5-benzodiazepine 
ribofuranosides in ILs 
 
 
Due to the wide range of biological, industrial and synthetic applications of 1,5- 
benzodiazepines and 1,5-benzothiazepines, the development for a milder and more 
efficient method for their synthesis continues to challenge synthetic organic chemists. 
On the other hand, ILs, especially imidazolium salt ILs are known for their 
effectiveness as a catalyst/ promoter in various organic reactions like the Claisen 
rearrangement (Han et al.2005), Friedel-Crafts reaction (Surette et al. 1996), alkylation 
reaction (Koch et al.1976), Diels-Alder reaction (Lee et al.1999), asymmetric 
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hydrogenation (Monteiro et al.1997) and  Heck coupling (Vallin et al.2002, Deshmukh 
et al. 2001).  Although, the syntheses of 1,5-benzodiazepines based on the reaction of 
acyclic and cyclic ketones with o-PDA in ILs are well documented (Attri et al.2010; 
Jain et al. 2010; Xie et al.2009; Jadidi et al. 2009; Du et al.2006; Xu et al. 2005), to the 
best of our knowledge, the synthesis of 1,5-benzothiazepine catalysied in ILs has never 
been reported. Therefore, as a part of this research, we decided to examine the effect of 
ILs for the synthesis of 1,5- benzothiazepines based on the reaction of various chalcones 
with o-ATP.  
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CHAPTER 8 
  
AN EFFICIENT 
SYNTHESIS OF 1,5-
BENZOTHIAZEPINES 
IN IONIC LIQUIDS 
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  The synthesis of 1,5-benzothiazepines and its other analogue 1,5- 
benzodiazepines generally contain three main steps (Scheme 8.1). The precursor 
chalcone is prepared via Claisen-Schmidt reaction of various benzaldehydes and 
acetophenones (Marais, 2005; Narender et al. 2007). In the second step, the chalcone 
will react with orthophenylendiamine (o-PDA) or orthoaminothiophenol (o-ATP) 
through Michael addition followed by cyclo-condensation to give the desired 1,5- 
benzodiazepines and 1,5- benzothiazepines, respectively. 
 
 
Scheme 8.1 Synthesis of 1,5- benzodiazepines and 1,5- benzothiazepines 
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As mentioned in chapter 7,  Reddy et al. and Cherkupally et al. reported the 
reaction of chalcones with o-PDA and o-ATP were expected to generate the 1,5- 
benzodiazepines and 1,5- benzothiazepines. However,  in our hands, the reaction of 2′-
hydroxchalcones with o-PDA and o-ATP in ethanol with catalytic amount of acetic acid 
led to the formation of flavanone, 1, instead of the desired 1,5- benzodiazepines and 
1,5- benzothiazepines, 2 (Scheme 8.2). 
 
 
Scheme 8.2 Reaction of 2′-hydroxchalcones with o-PDA and o-ATP in EtOH / AcOH 
 
 
This is confirmed by the spectroscopy profile of the products where for example, in the 
case of product 1, when R = H, the 1HNMR spectrum shows the presence of three 
aliphatic protons as three sets of dd at δ 5.41, 3.02 and 2.82 ppm.  In addition, the 
presence of a carbonyl at
 
δ 191.99 ppm in the13CNMR spectra has confirmed the 
product to be 1 (see Appendix A, spectral data for flavanones). 
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Ionic liquids (ILs), particularly imidazolium salts ionic liquids, have been 
classified as efficient to conventional organic solvents (D'Anna et al. 2009).  They are 
reported to be environmentally friendly, thermally stable, non- volatile and reusable. ILs 
have been widely used as catalyst/solvent in many different reactions such as 
isomerization reaction, Claisen rearrangement (Han et al.2005), Friedel-Crafts reaction 
(Surette et al. 1996), alkylation reaction (Koch et al.1976), Diels-Alder reaction (Lee et 
al.1999), asymmetric hydrogenation (Monteiro et al.1997) and Heck coupling (Vallin et 
al.2002, Deshmukh et al. 2001). In some cases, the special properties of ILs have 
influenced the rate of chemical reactions such as in elimination reactions where, the rate 
of the reaction in ILs was observed to be faster than those carried out in conventional 
organic solvents (D'Anna et al.2006). 
 
 Multifunctional ILs, especially dicationic ILs have been reported to have a greater 
range of physical properties than most traditional, singly charged ILs. They are often 
more stable thermally, with lower volatility and are more flexible in tuning their 
physicochemical attributes (Anderson et al.2005; Payagala et al.2007).  
 
 The syntheses of 1,5-benzodiazepines based on the reaction of acyclic and cyclic 
ketones with o-PDA in ILs are well documented (Attri et al.2010; Jain et al. 2010; Xie 
et al.2009; Jadidi et al. 2009; Du et al.2006; Xu et al. 2005). However, the synthesis of 
1,5-benzothiazepine in ILs has never been reported. Hence, in this project, we examined 
the effect of ILs for the synthesis of 1,5- benzothiazepines based on the reaction of 
various chalcones with o-ATP. The efficiency of different groups of ILs, i.e. mono and 
dicationic imidazolium ionic liquids for the synthesis of 1,5-benzothiazepine was 
explored. 
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Ionic liquids (ILs) contain four monocationic ILs (IL-A to IL-D), and three 
dicationic ILs (IL-E to IL-G). The structures of ILs used in this work are shown in 
Table 8.1. Amongst these ILs, IL-B, C and D are commercially available. IL-A, E, F 
and G have been synthesized using reported methods (Mehdi et al.2007; Ganesan et 
al.2008). To investigate the effect of acidity of the media on these syntheses, the 
influence of various counter ions on the catalytic properties of ILs were tested. Among 
monocationic ILs, IL-C with acetate as counter ion, expected to has the least acidity 
while IL-B, and IL-D expected to be more acidic and among dicationic ILs, IL-F with 
two bromides as counter ions expected to be less acidic than IL-E and IL-G with  
triflamide and triflate respectively. 
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Table 8.1   Mono and dicationic imidazolium Ionic Liquids (ILs) 
                                      
  
 
               
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Entry Ionic 
liquid Structure 
 
1 
  
 
 
2 
 
 
 
3 
 
   
 
4 
 
 
 
 
 
5 
 
 
 
 
 
 
 
 
6 
 
 
 
 
 
 
 
 
7 
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The main aim of this investigation was to explore the efficiency of ILs as 
promoter / media for the synthesis of 1,5-benzothiazepines. However, with the purpose 
of generalizing the method, the reaction of chalcone with o-PDA was also carried out. 
Amongst all the ILs listed in Table 8.1, IL-A is relatively cheap and easy to prepare.  In 
addition, it can dissolve the starting materials easily. To begin with, 2′-hydroxychalcone 
was chosen as a model substrate to react with o-ATP in IL-A. To examine the capability 
of this media, the synthesis of 1,5-benzodiazepines also have been carried out via the 
reaction of o-PDA with 2′-hydroxychalcone. IL-A found to work best in equimolar 
quantity with respect to   o-PDA and the chalcone whereas, in the case of o-ATP, excess 
amount of the reagent was needed for the reaction to occur (Micheli et al, 2001). Other 
parameters such as temperatures and reaction time were also studied to determine its 
optimum condition (Table 8.2).The best condition leading to the highest yield was 
obtained when the reaction mixture stirred for 120 minute at 800C.  
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Table 8.2 Screening of the reaction conditions in IL-A 
 
 
Subsequently, 2′-hydroxychalcone was selected for further investigations to 
react with o-ATP and o-PDA in IL-A to IL-G (Table 8.3).  
 
 
 
 
 
Ratio 
Time (Yield) 
    30 oC      70 oC       80 oC      90 oC 
 
1:1:1 
IL-A:Chalcone:o-
PDA 
30 min (-) 
60 min (-) 
90 min (-) 
120 min (-) 
30 min (-) 
60 min (10%)   
90 min (27%) 
120min(30%) 
30 min (-) 
60 min (16%) 
90 min (32%) 
120min(35%) 
30 min (-) 
60min (16%) 
90min (30%) 
120min 
(35%) 
 
1:1:1.2 
IL-A:Chalcone:o-
ATP 
30 min (-) 
60 min (-) 
90 min (8%) 
120min(12%) 
30 min (2%) 
60 min (30%) 
90 min (62%) 
120min(72%) 
30 min (5%) 
60 min (45%) 
90 min (70%) 
120min(75%) 
30 min (5%) 
60min (45%) 
90min (72%) 
120min(75%) 
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Table 8.3  The reaction between 2′-hydroxychalcone and o-ATP /o-PDA in IL-A to 
 IL-G 
              
 
Entry Ionic liquids Reaction 
time(min) 
Yield of 
benzothiazepinea,b 
(%) 
Yield of 
benzodiazepinea,b 
1 IL-Ac 120 75% 35% 
2 IL-B 120 78% 35% 
3 IL-C 120 70% 30% 
4 IL-D 100 78% 30% 
5 IL-E 100 87% 35% 
6 IL-F 100 82% 30% 
7 IL-G 80 92% 40% 
 
a Yield of isolated product 
b The product was characterized by 1H NMR and mass spectral data was identical with the literature 
c
 
Our  collaborators reported the same reaction in 95% yield / 60 min for 1,5- benzothiazepine 
 
 
All ILs seemed to promote the synthesis of 1,5- benzothiazepine selectively, where the 
yield of reaction between o-ATP and, 2′-hydroxychalcone was observed to be good to 
excellent in all cases (75-90%). However, reaction between the same chalcone with o-
PDA gave lower yields (30-35%). Presumably, this low yield is due to the lower 
reactivity of o-PDA compare to o-ATP. 
 
The counter ion was observed to influence the reaction time as well as yield of the 
reaction. This observation could be explained by effect of the counter ion on the acidity 
of ILs (Du et al. 2006).Among the monocationic ILs (IL-A to IL-D), the lowest yield 
of 1,5-benzothiazepine formed was obtained  when the reaction was carried out in 
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 IL-C. However, when IL-B was used as the media for the reaction, the yield obtained 
was better at 78%.The difference between IL-C and IL-B lies in their counter ion. 
Acetate was the counter ion for IL-C while iodide was the counter ion for IL-B. 
Reaction in IL-D, with triflamide as the counter ion performed better than both 
reactions in IL-B and IL-C giving the same yield as product as IL-B (78%) but in 
shorter reaction time. Amongst the geminal dicationic ILs (IL-E to IL-G), triflamide, 
bromide and triflate counter ions were found also to affect on the reaction time and 
yield differently. In this case, IL-G was observed to be the most efficient media for the 
reaction of o-ATP with 2′-hydroxychalcone wherein a shorter reaction time and higher 
yield of desired product was observed. Based on this observation, the IL-G was used to 
further explore the efficiency of the media for the synthesis of various 1,5-
benzothiazapines using different chalcones (Yeaghoobi et al., 2012; unpublished result). 
Variety of 1,5-benzothizepines were successfully synthesized using this geminal 
dicationic IL (Scheme 8.3). 
  
 
 
Scheme 8.3 Synthesis of 1,5-benzothiazepines in IL-G 
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  In all the reactions carried out, the ionic liquid seemed to act not only as the 
medium but also a promoter for the reaction in relatively shorter reaction times were 
achieved to those reported when using the conventional medium (80-120 min). For 
example, the synthesis of 1,5-benzothiazepines in Ga(OTf)3 / acetonitrile  was reported 
to take in more than 8 hrs to complete (Pan et al. 2008). However, in all reaction 
conditions the amount of products obtained was also observed to be good, in most cases 
ranging between 75% to 90% yields with an easy work up.  
 
The reusability of a catalyst is important from the environmental and economic point of 
view. The reusability of these ionic liquids was therefore examined using sequential 
reactions. The results indicated that ILs could be recovered and reused successfully for 
several times without remarkable decrease in its activity.  As shown in Table 8.4, the 
recovered IL did not show appreciable loss in its activity since more than 83% yield of 
the 1,5-benzothiazepine was obtained even when the IL was reused for the third time 
(Table 8.4).         
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Table 8.4 The reaction between o-ATP and 2′-hydroxychalcone in IL-G media and the 
ionic liquid recycling  
 
 
Substrate 
 
Product 
 
Condition 
 
aYield  
 
 
1 equimolarIL, 800C 
80min  
 
97% 
1st recycle, 800C 
80min 
 
89% 
2ndrecycle, 800C 
80min 
83% 
 
                  aIsolated yield calculated from 2′-hydroxychalcone 
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 As expected, the reaction between chalcone, 1, with o-ATP in IL produced 1,5-
benzothiazepne, 2. Formation of compound 2 was observed in 1HNMR data (crude 
mixture of the reaction). In order to obtain pure 1,5-benzothiazepne, 2, the crude 
mixture was passed through a basified silica column. Surprisingly, a six membered ring 
thiazine, 3, was obtained as the product (Scheme 8.4). The six membered ring thiazine, 
3, resultes from ring contraction of the seven membered ring thiazepine, 2, shown in 
Scheme 8.4. The 1HNMR profile of three aliphatic protons for compounds 2, and 3, is 
shown in Figure 8.3 (Loghmani & Yaeghoobi, et al., 2012; unpublished result). 
 
 
Scheme 8.4 Transformation of thiazepine to thiazine 
 
 
112 
 
                                                  
 
 
 
Figure 8.1 Comparison   1H NMR of spin-spin coupling between CH and CH2 of the 
compounds 2 (right) and 3 (left) 
 
This ring rearrangement caused an up field shift in all signals belonging to aliphatic 
protons of the thiazepine ring. In addition, due to this ring contraction, the splitting 
profile of these protons was also affected. In compound 2, a triplet at δ 3.17 ppm, a dd 
at δ 3.34 ppm,  and a dd at δ  5.12 ppm was observed while in compound 3, three sets of 
dd at δ  2.82 ppm, δ  3.05 ppm and at δ  4.25 ppm was observed (Figure 8.1).  
Interestingly, in the 13C NMR spectrum, the aliphatic carbon of compound 2 appeared at 
δ  60.66 ppm while aliphatic carbon of compound 3 was observed at δ  35.78 ppm. This 
significant up field shift is may be attributed to the distance of this carbon from imine 
Compound 3 Compound 2 
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group in six membered ring.Finally, compounds 2 and 3 were recrystalized from ethyl 
acetate.  The crystal structure of compounds 2 and 3 are shown in Figures 8.2 and 8.3. 
 
Figure 8.2 X-ray crystal structure of 4-(4-methoxyphenyl0-2-(naphthalene-2-yl)-2, 3-
dihydrobenzo [b][1,4]thiazepne with thermal ellipsoids at 50% probability.  Atoms are 
labeled anonymously. Crystallographic data can be referred from appendix C.  
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Figure 8.3 X-ray crystal structure of 3-(4-methoxyphenyl0-2-(naphthalene-2-ylmethyl)-
2hydrobenzo [b][1,4]thiazine with thermal ellipsoids at 50% probability.  Atoms are 
labeled anonymously. Crystallographic data can be referred from appendix C.  
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There are two possible mechanistic interpretations for this transformation. The 
first possibility is demonstrated in Scheme 8.5 in which the compound 2 is converted to 
compound 3 through a naphthyl shift.  
 
 
Scheme 8.5 Conversion of thiazepine, 2 to thiazine, 3 through naphthyl shift 
 
The second plausible mechanism for this transformation is shown in Scheme 8.6 
which contain hydrogen shift followed by a ring opening and finally a ring closing. 
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Scheme 8.6 Conversion of thiazepine, 2 to thiazine, 3 through hydrogen shift 
  
 For the formation of 1,5-benzothiazepines from chalcones and o-ATP, two 
possible mechanisms were considered. One involves the 1, 4-addition reaction followed 
by a cyclo-condensation reaction (Scheme 8.7, path A) while the second one is thought 
to go 1, 2-addition followed by cyclization reaction (Scheme 8.7, path B). 
 
To deduce the reaction mechanism, the intermediate of the reaction between trans-
chalcone and o-ATP was isolated and characterized by 1H and 13C NMR spectroscopy.  
The NMR data clearly indicated that amongst the two possible intermediates  ( Scheme 
8.5, (4), path A and (4), path B)  ;   the preferred path is A due to  the presence of three 
key aliphatic protons in the 1H NMR spectrum; i.e. at δ 3.56 (dd, J=6.95Hz,  
J=17.62Hz, 1H; CO-CH2- CH-S), δ  3.64 (dd, J=7.31Hz, J=17.54 Hz, 1H; CO-CH2- 
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CH-S),  δ 4.74 (t, J = 6.73Hz, 1H; CO-CH2- CH-S; ); (Appendix B, spectral data for 
Michael adduct) and a carbonyl group in 13C NMR spectrum at δ  197.15 which is in 
agreement with reported data for a Michael adduct (Katritzky et al.2000). IR spectra of 
this compound indicated the presence of NH2 at 3352cm-1.  This intermediate was 
recrystallized from ethanol and the structure was confirmed by X-ray crystallography 
(Yaeghoobi et al. 2011). The X-ray crystal structure of this intermediate is shown in 
Figure 8.4. addition at the carbonyl carbon was expected to be faster since complexation 
of the IL to oxygen makes the carbonyl more electrophilic. However, the bulkiness of 
IL could reduce this side to be more hindered. The softer fourth position which 
presumably more exposed  then is subjected to the attack by sulfur and reaction will 
proceed through a 1, 4 Michael addition reaction. 
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Path A: 
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Path B: 
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Scheme 8.7 Proposed mechanism for Synthesis of 1,5-benzothiazepines in IL-G 
 
 
 
 
 
120 
 
 
 
 
  
 
 
Figure 8.4 X-ray crystal structure of the intermediate (4), path A, 3-(2-
aminophenylthio)-1, 3-diphenylpropan 1-one with thermal ellipsoids at 50% 
probability.  Atoms are labeled anonymously. Crystallographic data can be referred 
from Appendix C.  
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CHAPTER 9 
  
1,5-BENZOTHIAZEPINES 
WITH POTENTIAL 
NEURAMINIDASE 
INHIBITION EFFECT  
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As mentioned in previous chapters, 1,5-benzothiazepines  have been reported to  
possess a wide range of biological activities such as antifeedants (Reddy et al. 1993), 
tranquilizers (Kugita et al. 1971), antidepressants (Geyer et al. 1970), CNS stimulants 
(Kawashima et al.1985), calcium channel blockers (Kugita et al. 1971), antimicrobial 
agent (Dandia et al. 1998), antibacterial and antifungal properties (Jadhav et al.1983; 
Barot et al. 2001; Cherkupally et al. 2008) and Platelet aggregation inhibitory (Bariwal 
et al. 2008). Nevertheless, previous reports on the antiviral property of 1,5-
benzothiazepines were mainly concerned with its potential bioactivity against Hepatitis 
B and HIV-1 (Nicol et al. 1992; Delpa et al.2000; Pauwels et al. 1990; Grandolini et 
al.1999; Di Santo et al. 2005). In our continue efforts to search for a potent ihibitor for 
H1N1 virus, we set out to investigate 1,5-benzothiazepines as neuraminidase inhibitors 
of the H1N1 virus.  
 
A library of 1,5-benzothiazepine derivatives was generated by incorporating various 
substituent like OH, OMe, methylenedioxy, Methyl, halogen, naphthalene, and NH2 in 
various parts of the molecule. Electron-donating and electron-withdrawing groups were 
introduced into the basic structure of 1,5-benzothiazepines backbone, in order to study 
the influence of these substituents on the neuraminidase inhibition activity. Preliminary 
computer modeling results suggested that hydroxyl-, methoxy- and methylenedioxy- 
groups in the molecule could form hydrogen bonds with neuraminidase. Benzene and 
naphthalene rings on the other hand, could engage in pi interaction with the enzyme, 
allowing better protein- ligand interaction. The general strategy to further explore this 
template is depicted in Figure 9.1.  To explore the effect of different functional groups 
on the activity of 1,5-benzothiazepines, MA1-MA15 (Table 9.1) have been synthesized 
from chalcones (listed in Table 4.2) All the synthesized heterocycles have been 
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evaluated for their potential bioactivity as neuraminidase inhibitors (Manuscript under 
preparation). 
 
 
    
Figure 9.1. General strategy to prepare 1,5-benzothiazepines with potential 
H1N1inhibition effect 
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Table 9.1 Yields and melting points of 1,5-benzothiazepine synthesized 
 
Entry             Structure Yielda(%) mp(0C) 
found   
mp(0C) 
reported 
MA1 
 
52 102 96-97 
MA 2 
 
92 151 154-155 
MA 3 
N SOH
OCH3
 
91 165 160-161 
MA 4 
 
83 161-162 - 
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Entry             Structure Yielda(%) mp(0C) 
found   
mp(0C) 
reported 
MA 5 
 
80 160-162 - 
MA 6 
 
75 138 142 
MA 7 
 
87 154 156 
MA8 
 
85 162 168  
MA9 
 
90 152 156 
MA10 
 
87 168-170 - 
‘Table 9.1, continued’ 
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Entry             Structure Yielda(%) mp(0C) 
found   
mp(0C) 
reported 
MA11 
 
78 156-157 - 
MA12 
 
82 128-130 - 
MA 13 
 
73 119-121 - 
MA14 
 
75 118-119 - 
MA15 
 
70 179-181 - 
                         
a
 
Products were characterized by  1H NMR  and mass spectral data 
                
bYields of isolated products 
 
 
                                                                      
‘Table 9.1, continued’ 
 Figure 9.2. X-ray crystal structure of 2
dihydrobenzo[b][1, 4] thiazepin
Atoms are labeled anonymously. Crystallographic data can be referred from appendix 
C.  
 
 
   
 
1,5-benzothiazepines
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-2, 3-
neuraminidase of A/ 
 ID = 3B7E, 
these compounds for 
neuraminidase. The 
docker energy is 
 
 neuraminidase. 
-
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lack of flexibility and solubility of these compounds. This observation might be also 
due to the binding of azepines as ligand to the allosteric site rather than the active sites 
(Ryu et al. 2008). 
 
 
 
Table 9.2 1,5-benzothiazepines activity against Neuraminidase 
Entry (-) Cdocker 
interaction energya,b 
(kcal/mol) 
Inhibition  in 250µm 
(%)c 
MA1 29.26 5.2 
MA2 27.82 5.8 
MA3 32.81 10.5 
MA4 40.52 7.7 
MA5 28.85 5.1 
MA6 28.75 12.3 
MA7 32.86 6.4 
MA8 35.34 8.5 
MA9 25.63 12.4 
MA10 34.31 25.5 
MA11 36.23 16.8 
MA12 39.08 12.7 
MA13 23.50 14.7 
MA14 29.75 15.6 
MA15 23.26 16.8 
a Calculation performed by Frimayanti et al.using  Cdocker (Discovery Studio 2.5, Accelrys) ; 
b Enzym: 3b7E (Neuraminidase of  A/ Breving Mission/ 1/1918 H1N1 strain in complex with zanamivir;. 
c bioassay erformed by Ikram et al. using DANA as standard with -46.11 kcal/molCdocker interaction energy                         
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CHAPTER 10 
  
CONCLUSION 
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In conclusion, up to almost one hundred flavonoids and 1,5- benzothiazepines 
have been synthesised from well-established routes as well as newly developed one-pot 
synthetic method.  
The environmentally benign one-pot method using PMA/SiO2 in ethanol has 
successfully been applied toward the preparation of flavanone analogues in reasonable 
yields. The synthesized flavonoids (chalcones and flavanones) were investigated for 
their potency as NA inhibitors. 
 
 The mono and dicationic ILs were employed as reusable catalyst to synthesize 1,5- 
benzothiazepines in reasonable quantities. The synthesized compounds were 
investigated for their possible NA inhibitory activity. 
 
Chalcones are shown to be fairly active as NA inhibitors while flavanones, even with 
the promising calclulation results of Cdocker energy (compared to DANA with Cdocker 
interaction energy equal to -46.11 kcal/mol), were observed to be not active against 
neuramidase. This observation was due to the flavanones binding at the allosteric sites 
rather than the active sites.  In addition, quantitative structure-activity relationships for 
the chalcone compounds with the aid of 2D and 3D-QSAR models have been also 
studied.  
 
1,5-benzothiazepines, with promising Cdocker energy (compared to DANA with 
Cdocker interaction energy equal to -46.11 kcal/mol), were expected to be active 
against neuraminidase. Unfortunately, the bioassay result did not corroborate the 
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modeling results. The poor activity of 1,5-benzothiazepines against H1N1 could be due 
to the larger size of the seven membered ring, lack of flexibility and solubility.  
 
Further studies are underway to synthesize other chalcone-based and non chalcone-
based heterocyclic compounds with potential bioactivities. Moreover, enantioselective 
synthesis of these flavanone, 1,5-benzothiazepines and other heterocyclic systems, 
could be carried out to enable investigation on the effect of enantio purity on the 
bioactivity of these compounds.  
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CHAPTER 11 
  
EXPERIMENTAL 
SECTION 
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Experimental procedure and spectroscopy data for chapter 4 and 5: 
General 
 
All melting points were determined using a Mel-Temp II melting point 
instrument. NMR spectra were obtained using a Jeol ECA 400 (400 MHz) and Lambda 
400 NMR spectrometers with TMS as the internal standard.  All chemical shifts are 
reported in ppm. The IR spectra were taken with a Perkin Elmer 400 ATR-FTIR 
spectrophotometer. The mass spectra were taken on an Agilent 1200 LC/MS,  analytical 
thin-layer chromatography (TLC) was carried out on Merck precoated aluminum silica 
gel sheets (Kieselgel 60 F-254) using UV light (254 and 366 nm) for detection. Column 
chromatography was carried out with silica gel 60 (230-400 mesh) from Merck. All 
target compounds were characterized by 1H, 13C and other spectroscopy analyses. All 
reactions were carried out under nitrogen atmosphere unless specified. All solvents and 
reagents were purchased from Aldrich, Merck or Fisher. 
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General procedure for preparation of Chalcone MC1- MC50: 
 
 
The substituted chalcones MC1-MC50 were prepared via standard Claisen-
Schmidt reaction. To a solution of various acetophenones (1 eq) in Ethanol (AR grade) 
(2.5mL/mmol), Sodium hydroxide (3 eq) was added. After10 min, appropriated 
benzaldehydes (1.2eq) were added and the solutions were stirred at room temperature 
overnight. After cooling the reaction mixtures with ice, the mixture was neutralized 
carefully using 1N hydrochloric acid. The crude mixture was extracted with ethyl 
acetate, washed with water and brine afforded chalcones MC1-MC50 which were 
purified by column chromatography using hexane: ethyl acetate as eluent to give pure 
chalcones (32%-92%); except MC46-MC50 which directly utilized for synthesis of 
flavanones.  
 
 
 
 
 
 
 
 
136 
 
1, 3-Diphenyl-2-propen-1-one (E-chalcone)    MC1 
 
Pale yellow solid; Mp = 55 °C.  1H NMR (400 MHz, CDCl3): δ 8.01-8.03 (m, 2H), 7.81 
(d, J= 15.98Hz, 1H), 763-7.65 (m, 2H), 7.55-7.60 (m, 2H), 7.48-7.52 (m,  2H), 7.39-
7.42 (m, 3H);13C NMR (400 MHz, CDCl3): δ 190.52, 144.81, 138.16, 134.83, 132.76, 
130.52, 128.93, 128.59, 128.47, 128.41, 122.02. 
 
(E)-3-(2-hydroxyphenyl)-1-phenylprop-2-en-1-one    MC2 
 
Light green solid; Mp = 149 °C.   1H NMR (400 MHz, CDCl3): δ 8.09 (d, J= 16.05 Hz, 
1H), 7.97 (d, J= 6.93Hz, 2H), 765 (d, J= 16.05Hz, 1H), 7.51 (t, J= 8.75Hz, 2H), 7.43 (t, 
J= 8.39Hz,  2H), 7.23 (d, J= 8.02Hz, 1H), 6.89 (t, J= 8.02Hz, 1H), 6.84 (d, J= 8.39Hz, 
1H), 6.31 ( bs, OH);13C NMR (400 MHz, CDCl3): δ 191.07, 155.62, 140.63, 138.36, 
132.48, 131.81, 129.68, 128.68, 123.00, 122.34, 121.11, 116.63. 
 
(E)-3-(3-hydroxyphenyl)-1-phenylprop-2-en-1-one    MC3 
 
Yellow solid; Mp = 152°C.  1H NMR (400 MHz, CDCl3): δ 8.01(d, J= 7.80Hz, 2H), 
7.76 (d, J= 15.61Hz, 1H), 7.58-7.61 (m, 1H), 7.51 (t, J= 7.80Hz, 3H), 7.30 (t, J= 
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7.80Hz,  1H), 7.22 (d, J= 8.30Hz, 1H), 7.14 (s, 1H), 6.90-6.92 (m, 1H), 5.27 (bs, 
OH);13C NMR (400 MHz, CDCl3): δ 190.86, 155.98, 144.71, 138.08, 136.53, 133.02, 
130.28, 128.76, 128.63, 122.49, 121.27, 117.82, 114.97. 
 
(E)-3-(4-hydroxyphenyl)-1-phenylprop-2-en-1-one    MC4 
 
Yellow solid; Mp = 159 °C.  1H NMR (400 MHz, CDCl3): δ 8.00(d, J= 7.08Hz, 2H), 
7.78 (d, J= 15.45Hz, 1H), 7.55-7.59 (m, 3H), 7.50 (t, J= 7.72Hz, 2H), 7.41 (d, J= 
15.45Hz, 1H), 6.89 (d, J= 8.36HZ, 2H), 5.62 (bs, OH);13C NMR (400 MHz, CDCl3): δ 
191.06, 158.20, 145.04, 138.99, 132.78, 130.66, 128.70, 128.55, 127,74, 119.83, 
116.10. 
 
(E)-1-(2-hydroxyphenyl)-3-phenylprop-2-en-1-one    MC5 
 
Yellow solid; Mp = 89 °C.  1H NMR (400 MHz, CDCl3): δ 12.86 (s, OH), 7.81-7.90(m, 
2H), 7.61-7.64 (m, 3H), 7.35-7.49 (m, 4H), 7.02 (d, J= 8.80HZ, 1H), 6.92 (t, J= 
8.21HZ,1H); 13C NMR (400 MHz, CDCl3): δ 193.83, 163.69, 145.57, 136.52, 134.68, 
131.04, 129.75, 129.14, 128.76, 120.20, 120.10, 118.95, 118.73. 
 
(E)-1, 3-bis (2-hydroxyphenyl) prop-2-en-1-one   MC6 
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Yellow Crystals (recrystalized from Ethanol); Mp = 158 °C.  1H NMR (400 MHz, 
CDCl3):  δ 12.90 (s, OH), 8.18(d, J= 15.29HZ, 1H), 7.93 (dd, J= 1.56HZ, J= 8.23HZ, 
1H), 7.85 (d, J= 15.29HZ,  1H), 7.61 (dd, J= 1.56HZ, J= 7.84HZ, 1H), 7.50 (t, J= 
7.84HZ, 1H), 7.29 (t, J= 8.23HZ, 1H), 7.02 (t, J= 8.23HZ, 1H), 6.94 (t, J= 7.44HZ, 
1H), 6.84 (d, J= 8.23HZ, 1H), 5.53 (bs, OH); 13C NMR (400 MHz, CDCl3): δ 194.45, 
163.60, 155.45, 141.00, 136.37, 132.10, 130.35, 129.90, 121.37, 118.92, 118.65, 
116.58. 
 
(E)-1-(2-hydroxyphenyl)-3-(3-hydroxyphenyl) prop-2-en-1-one    MC7 
 
Orange Crystals (recrystalized from Ethanol); Mp = 148 °C. 1H NMR (400 MHz, 
CDCl3):  δ 12.79 (s, OH), 7.93(d, J=7.36 HZ, 1H), 7.86 (d, J= 15.94HZ, 1H), 7.63 (d, 
J= 15.94HZ,  1H), 7.51 (t,  J= 7.76HZ, 1H), 7.31 (t, J= 8.58HZ, 2H), 7.14 (s, 1H), 7.05 
(d, J= 8.17HZ, 1H), 6.91-6.97 (m, 2H), 5.10 (bs, OH); 13C NMR (400 MHz, CDCl3): δ 
193.74, 163.64, 155.98, 144.99, 136.50, 130.29, 129.66, 121.62,120.59, 118.67, 118.02, 
114.84. 
 
(E)-1-(2-hydroxyphenyl)-3-(4-hydroxyphenyl) prop-2-en-1-one    MC8 
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Yellow solid; Mp = 135 °C.  1H NMR (400 MHz, CDCl3):  δ 12.96 (s, OH), 7.82(d, 
J=15.57 HZ, 1H), 7.82 (d, J= 8.38HZ, 2H), 7.58 (t, J= 8.68HZ,  1H), 7.49 (t,  J= 
9.27HZ, 1H), 7.03 (d, J= 8.08HZ, 1H), 6.97 (d, J= 8.98HZ, 3H), 6.91 (d, J=8.86HZ,  
1H), 6.04 (bs, OH); 13C NMR (400 MHz, CDCl3): δ 191.32, 161.65, 158.45, 145.53, 
136.34, 132.61, 130.91, 129.93,129.67, 120.17, 118.93, 117.53, 116.14. 
 
(E)-1-(2-hydroxyphenyl)-3-(4-methoxyphenyl) prop-2-en-1-one    MC9 
 
Yellow solid; Mp = 91°C. 1H NMR (400 MHz, CDCl3): δ 12.94 (s, OH), 7.88-7.94(m, 
2H), 7.63 (d, J= 8.04HZ, 2H), 7.54 (d, J= 16.11HZ,  1H), 7.48 (t,  J= 8.05HZ, 1H), 7.02 
(d, J= 8.05HZ, 1H), 6.95 (d, J= 8.63HZ, 3H), 3.86 (s, 3H, OCH3); 13C NMR (400 MHz, 
CDCl3): δ 193.76, 163.64, 162.11, 145.45, 136.25, 130.66, 129.64, 127.40, 120.20, 
118.86, 118.67, 117.63, 114.61, 55.54. 
 
(E)-3-(3, 4-dimethoxyphenyl)-1-(2-hydroxyphenyl) prop-2-en-1-one    MC10 
 
Yellowsolid; Mp = 115 °C. 1H NMR (400 MHz, CDCl3):  δ 12.99 (s, OH), 7.91(d, J= 
8.71 HZ, 1H), 7.84 (d, J= 15.75HZ, 1H), 7.42-7.52 (m, 2H), 7.22 (d, J= 7.71HZ, 1H), 
7.15 (s, 1H), 7.00 (d, J= 8.38HZ, 1H), 6.85-6.93 (m, 2H), 3.92 (s, 3H, OCH3), 3.91 (s, 
3H, OCH3); 13C NMR (400 MHz, CDCl3): δ 193.65, 163.64, 151.89, 149.38, 145.75, 
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136.27, 129.63, 127.66, 123.71, 120.17, 118.83, 118.68, 117.83, 111.23, 110.33, 56.12, 
56.09. 
 
(E)-1-(2-hydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one   MC11 
 
Yellow solid; Mp = 158 °C.  1H NMR (400 MHz, CDCl3): δ 12.86 (s, OH), 7.92 (dd, J= 
1.52HZ, J= 8.21HZ, 1H), 7.84 (d, J= 15.21HZ, 1H), 7.53 (d, J= 15.21HZ, 1H), 7.48 (d, 
J= 8.21HZ, 1H), 7.03 (d, J= 8.82HZ, 1H), 6.94 (t, J= 8.21HZ, 1H), 6.88 (s, 2H), 3.93 (s, 
6H, 2OCH3), 3.91 (s, 3H, OCH3); 13C NMR (400 MHz, CDCl3): δ 193.59, 163.67, 
153.61, 145.72, 140.91, 136.45, 130.13, 129.69, 120.09, 119.33, 118.89, 118.72, 
108.02, 61.12, 56.35. 
 
(E)-3-(benzo[d][1,3]dioxol-5-yl)-1-(2-hydroxyphenyl)prop-2-en-1-one    MC12 
 
Yellow solid; Mp = 135°C.  1H NMR (400 MHz, CDCl3): δ 12.81 (s, OH), 7.83 (d, J= 
8.45HZ, 1H), 7.78 (d, J= 15.37HZ, 1H), 7.39-7.43 (m, 2H), 7.10 (s, 1H), 7.07 (d, J= 
8.45HZ, 1H), 6.94 (d, J= 8.84HZ, 1H), 6.86 (t, J= 7.68HZ, 1H), 6.78 (d, J= 8.07HZ, 
1H), 5.96 (s, 2H, O-CH2-O); 13C NMR (400 MHz, CDCl3): δ 193.62, 163.65, 150.39, 
148.60, 145.41, 136.30, 129.60, 129.17, 125.82, 120.15, 118.87, 118.83, 108.84, 
106.83, 101.84. 
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(E)-1-(2-hydroxyphenyl)-3-p-tolylprop-2-en-1-one    MC13 
 
Yellow solid; Mp = 115°C. 1H NMR (400 MHz, CDCl3): δ 12.89 (s, OH), 7.88-7.94(m, 
2H), 7.59 (d, J= 15.82HZ, 1H), 7.54 (d, J= 8.20HZ, 2H), 7.47 (t,  J= 7.03HZ, 1H), 7.22 
(d, J= 7.62HZ, 2H), 7.01 (d, J= 8.20HZ, 1H), 6.92 (t, J=7.62 HZ, 1H), 2.37 (s, 3H, 
CH3); 13C NMR (400 MHz, CDCl3): δ 193.87, 163.67, 145.68, 141.71, 136.37, 131.96, 
129.71, 128.82, 120.16, 118.90, 118.70,21.69. 
 
(E)-3-(4-chlorophenyl)-1-(2-hydroxyphenyl) prop-2-en-1-one    MC14 
 
Golden yellow solid; Mp = 149°C. 1H NMR (400 MHz, CDCl3):  δ 12.75 (s, OH), 
7.89(d, J=7.69, 1H), 7.84 (d, J= 15.11HZ, 1H), 7.55-7.63 (m, 3H), 7.49 (t,  J= 7.41HZ, 
1H), 7.39 (d, J= 8.26HZ, 2H), 7.02 (d, J= 8.26HZ, 1H), 6.94 (t, J=7.69 HZ, 1H); 13C 
NMR (400 MHz, CDCl3): δ 193.54, 163.71, 144.01, 136.96, 136.65, 131.16, 129.88, 
129.44, 120.65, 120.01, 118.99, 118.78. 
 
(E)-1-(2-hydroxyphenyl)-3-(naphthalen-2-yl) prop-2-en-1-one   MC15 
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Yellow crystals (recrystalized from Ethanol); Mp = 135°C. 1H NMR (400 MHz, 
CDCl3):  δ 12.86 (s, OH), 8.09(d, J=15.83, 2H), 7.99 (d, J= 7.70HZ, 1H), 7.76-7.92 (m, 
6H), 7.50-7.56 (m, 2H), 7.05 (d, J= 8.55HZ, 1H),  6.97 (t, J=7.70 HZ, 1H); 13C NMR 
(400 MHz, CDCl3): δ 193.76, 163.72, 145.65, 136.51, 134.64, 133.42, 132.18, 131.25, 
129.77, 128.94, 128.84, 127.93, 127.73, 126.98, 123.74, 120.26, 120.17, 118.96, 
118.75. 
 
(E)-3-(4-(dimethylamino) phenyl)-1-(2-hydroxy-4, 6-dimethoxyphenyl) prop-2-en-
1-one      MC16 
 
 
Dark orange solid; Mp = 138°C. 1H NMR (400 MHz, CDCl3):  δ 14.03 (s, OH), 7.78(d, 
J=14.02, 1H), 7.70 (d, J= 9.18HZ, 2H), 7.50 (d, J=14.41, 1H), 6.67 (d, J= 9.18HZ, 2H), 
6.04 (d, J= 2.44HZ, 1H), 5.91 (d, J=2.44 HZ, 1H), 3.82 (s, 3H, OCH3), 3.79 (s, 3H, 
OCH3), 3.06 (s, 6H, 2xCH3); 13C NMR (400 MHz, CDCl3): δ 192.64, 168.27, 166.18, 
162.30, 161.17, 142.77, 129.86, 127.92, 125.18, 114.37, 106.30, 93.38, 91.45, 55.78, 
40.61, 40.28. 
 
(E)-1-(2-hydroxy-4, 6-dimethoxyphenyl)-3-(4-methoxyphenyl) prop-2-en-1-one  
MC17 
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Yellow solid; Mp = 110°C. 1H NMR (400 MHz, CDCl3):  δ 14.41 (s, OH), 7.79(s,  2H), 
7.57 (d, J= 8.77HZ, 2H), 6.93 (d, J=8.29, 1H), 6.10 (d, J= 2.92HZ, 1H), 5.90 (d, J= 
2.92HZ, 1H), 3.91 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.83 (s, 3H, OCH3); 13C NMR 
(400 MHz, CDCl3): δ 192.68, 168.45, 166.09, 162.53, 161.42, 142.57, 130.20, 128.37, 
125.18, 114.43, 106.41, 93.86, 91.32, 55.93, 55.67, 55.48. 
 
(E)-3-(4-bromophenyl)-1-(2-hydroxy-3, 4-dimethoxyphenyl) prop-2-en-1-one   
MC18 
 
Yellow solid; Mp = 152°C. 1H NMR (400 MHz, CDCl3):  δ 13.12 (s, OH), 7.82 (d, J= 
15.49HZ, 1H), 7.67 (d, J=8.85, 1H), 7.49-7.59 (m, 5H), 6.54 (d, J= 8.85HZ, 1H), 3.96 
(s, 3H, OCH3), 3.91 (s, 3H, OCH3); 13C NMR (400 MHz, CDCl3): δ 192.23, 158.83, 
158.43, 143.35, 136.85, 133.85, 132.36, 129.99, 126.15, 125.15, 120.86, 115.61, 
103.03, 60.79, 56.27; IR (ATR): 2936, 1634, 1557, 1277, 1243, 1127, 1000, 790, 703 
cm-1;  HRMS (ESI):   calculated for C17H15BrO4H  [M+H] +  362.0154  , found  
362.0237.   
 
(E)-3-phenyl-1-(2, 4, 6-trimethoxyphenyl) prop-2-en-1-one   MC19 
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Golden- brown liquid. 1H NMR (400 MHz, CDCl3):  δ 7.28-7.52(m, 6H), 6.96 (d, J= 
15.26HZ, 1H), 6.15 (s, 2H), 3.79 (s, 3H, OCH3), 3.71 (s, 6H, 2x OCH3); 13C NMR (400 
MHz, CDCl3): δ 194.48, 162.54, 158.43, 144.53, 135.02, 130.18, 129.53, 128.89, 
128.08, 90.84, 55.92, 55.50. 
 
(E)-3-(2-nitrophenyl)-1-(2, 4, 6-trimethoxyphenyl) prop-2-en-1-one MC20 
 
Yellow solid; Mp = 152°C. 1H NMR (400 MHz, CDCl3):  δ 8.00(d, J=8.07HZ, 1H), 
7.62-7.72 (m, 3H), 7.51(t, J= 8.69HZ, 1H), 6.81(d, J= 15.53HZ, 1H),  6.15 (s, 2H), 3.84 
(s, 3H, OCH3), 3.77 (s, 6H, 2x OCH3); 13C NMR (400 MHz, CDCl3): δ  194.41, 162.84, 
159.04, 139.87, 133.59, 131.39, 130.15, 129.35, 124.95, 110.53, 90.69, 55.93, 55.52 
 
(E)-3-(4-nitrophenyl)-1-(2, 4, 6-trimethoxyphenyl) prop-2-en-1-one   MC21 
 
Yellow solid; Mp = 158°C. 1H NMR (400 MHz, CDCl3):  δ 8.24(d, J=8.35HZ, 2H), 
7.67(d, J=8.84HZ, 2H), 7.44(d, J=15.72HZ, 1H), 7.08(d, J= 15.72HZ, 1H),  6.17 (s, 
2H), 3.87 (s, 3H, OCH3), 3.80 (s, 6H, 2x OCH3); 13C NMR (400 MHz, CDCl3): δ  
192.86, 163.07, 159.33, 148.37, 141.37, 139.88, 132.50, 128.89, 124.14, 123.69, 
111.45, 90.84, 56.05, 55.58. 
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(E)-1-(2, 4-dimethoxyphenyl)-3-(4-nitrophenyl) prop-2-en-1-one      MC22 
 
Yellow solid; Mp = 172°C. 1H NMR (400 MHz, CDCl3):  δ 8.25(d, J=8.49Hz, 2H), 
7.82(d, J=8.49Hz, 1H), 7.73(d, J=7.92Hz, 2H), 7.67(s, 2H), 6.59 (dd, J=2.26Hz, 
J=8.82Hz,  1H), 6.51(d, J=2.83Hz, 1H), 3.94 (s, 3H, OCH3), 3.89 (s, 3H, OCH3); 13C 
NMR (400 MHz, CDCl3): δ  189.29, 164.84, 160.76, 148.33, 141.93, 138.34, 133.45, 
130.98, 128.71, 123.43, 105.56, 98.44, 55.83, 55.64. 
 
(E)-3-(4-chlorophenyl)-1-(2, 4-dimethoxyphenyl)prop-2-en-1-one   MC23 
 
Pale yellow solid; Mp = 125°C. 1H NMR (400 MHz, CDCl3):  δ 7.74-7.77(m, 1H), 
7.62(d, J=15.79Hz, 1H), 7.49-7.53(m, 2H), 7.35(d, J=8.88Hz, 1H), 7.10(d, J=8.24Hz, 
1H), 6.92(d, J=8.92Hz, 1H), 6.56(d, J=8.58Hz, 1H), 6.46-6.49(m, 1H), 3.90 (s, 3H, 
OCH3), 3.86(s, 3H, OCH3); 13C NMR (400 MHz, CDCl3): δ  190.07, 164.38, 160.50, 
140.36, 139.34, 132.68, 129.88, 129.44, 129.29, 127.63, 121.96, 105.31, 98.44, 55.58, 
55.51. 
 
(E)-3-(4-bromophenyl)-1-(2, 4-dimethoxyphenyl) prop-2-en-1-one  MC24 
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Yellow solid; Mp = 122°C. 1H NMR (400 MHz, CDCl3):  δ 7.74-7.77(m, 1H), 7.60(d, 
J=16.02HZ, 1H), 7.48-7.54(m, 2H), 7.44(d, J=8.20Hz, 1H), 7.26(d, J=2.34Hz, 1H), 
6.86(d, J=8.20Hz, 1H), 6.56(dd, J=2.34Hz, J=9.37, 1H), 6.49(d, J=2.34, 1H), 3.90 (s, 
3H, OCH3), 3.86(s, 3H, OCH3); 13C NMR (400 MHz, CDCl3): δ  190.06, 164.79, 
164.33, 140.39, 137.72, 135.78,  133.37, 133.13, 129.65, 127.69, 121.94, 105.26, 98.43, 
55.76, 55.64. 
 
(E)-3-(benzo[d] [1, 3] dioxol-5-yl)-1-(2, 4-dimethoxyphenyl) prop-2-en-1-one   
MC25 
 
Yellow solid; Mp = 119°C. 1H NMR (400 MHz, CDCl3):  δ 7.74(dd, J=2.59Hz, 
J=8.63Hz, 1H), 7.60(d, J=16.83Hz, 1H), 7.34(d, J=15.97Hz, 1H), 7.11(s, 1H), 7.04-
7.06(m, 1H), 6.80(dd, J=3.88Hz, J=8.63Hz, 1H), 6.55(d, J=8.63Hz, 1H), 6.48(s, 1H), 
5.99 (s, 2H),  3.89 (s, 3H, OCH3), 3.85(s, 3H, OCH3); 13C NMR (400 MHz, CDCl3): δ  
190.44, 164.23, 160.36, 149.54, 147.77, 141.80, 132.76, 129.86, 125.18, 124.86, 
122.27, 108.71, 106.45, 104.68, 101.61, 98.55, 55.83, 55.62. 
 
(E)-3-(benzo[d] [1, 3] dioxol-5-yl)-1-(2, 5-dimethoxyphenyl) prop-2-en-1-one  
MC26 
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Yellow solid; Mp = 112°C. 1H NMR (400 MHz, CDCl3):  δ 7.55(d, J=15.06Hz, 1H), 
7.24(d, J=15.54Hz, 1H), 7.17(d, J=2.91Hz, 1H), 7.10(s, 1H), 7.05(d, J=8.26Hz, 1H), 
7.00(dd, J=3.41Hz, J=9.23Hz, 1H), 6.92(d, J=9.23Hz, 1H), 6.80(d, J=8.26Hz, 1H), 5.98 
(s, 2H),  3.83 (s, 3H, OCH3), 3.78(s, 3H, OCH3); 13C NMR (400 MHz, CDCl3): δ 
192.36, 153.68, 152.55, 149.77, 148.40, 143.30, 129.92, 125.14, 119.02, 114.50, 
113.46, 108.67, 106.74, 101.64, 56.59, 56.11.  
 
(E)-1-(2, 5-dimethoxyphenyl)-3-(3, 4, 5-trimethoxyphenyl) prop-2-en-1-one  MC27 
 
Yellow solid; Mp = 123°C. 1H NMR (400 MHz, CDCl3):  δ 7.51(d, J=15.83Hz, 1H), 
7.27(d, J=15.83Hz, 1H), 7.15(d, J=3.34Hz, 1H), 7.03(dd, J=3.12Hz, J=8.92Hz, 
1H),6.94(d, J=8.47Hz, 1H), 6.81(s, 2H), 3.88(d, J=s, 9H, 3xOCH3), 3.83 (s, 3H, OCH3), 
3.81(s, 3H, OCH3); 13C NMR (400 MHz, CDCl3): δ 192.68, 153.69, 153.49, 152.46, 
143.80, 140.26, 130.68, 129.84, 126.43, 118.93, 114.46, 113.50, 105.64, 61.09, 56.62, 
55.96. 
 
(E)-3-(4-chlorophenyl)-1-(3, 4-dimethoxyphenyl) prop-2-en-1-one   MC28 
 
Yellow solid; Mp = 101°C. 1H NMR (400 MHz, CDCl3):  δ 7.68(d, J=15.82Hz, 1H), 
7.53-7.55(m, 3H), 7.36-7.41 (m, 3H), 7.20 (s, 1H), 7.03(d, J=16.22Hz, 1H), 3.97(s, 6H, 
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2x OCH3); 13C NMR (400 MHz, CDCl3): δ 188.33, 157.58, 142.07, 136.51, 133.18, 
130.99, 129.51, 129.17, 125.52, 110.17, 108.95, 52.42, 51.90. 
(E)-1-(3, 4-dimethoxyphenyl)-3-(4-(methylthio) phenyl) prop-2-en-1-one  MC29 
 
Yellow solid; Mp = 92°C. 1H NMR (400 MHz, CDCl3):  δ 7.77(d, J=15.26Hz, 1H), 
7.68(d, J=7.63Hz, 1H),  7.62 (s, 1H), 7.55 (t, J=8.39Hz, 2H), 7.23(d, J=7.63Hz, 3H), 
6.93(d, J=8.39Hz, 1H),  3.96 (s, 6H, 2x OCH3), 2.52(s, 3H, S-CH3 ); 13C NMR (400 
MHz, CDCl3): δ 188.57, 153.28, 149.30, 143.54, 142.17, 131.63, 131.48, 128.83, 
126.03, 123.03, 120.64, 110.82, 110.03, 56.18, 56.14, 15.23. 
 
(E)-3-(4-fluorophenyl)-1-(2-methoxyphenyl) prop-2-en-1-one  MC30 
 
Pale yellow solid; Mp = 107°C. 1H NMR (400 MHz, CDCl3):  δ 7.57-7.60 (m, 1H), 
7.51-7.54 (m, 2H), 7.32-7.47 (m, 4H), 7.23 (d, J=15.80Hz, 1H), 6.95-7.04 (m, 2H), 3.88 
(s, 3H, OCH3); 13C NMR (400 MHz, CDCl3): δ 193.29, 160.70, 158.02, 143.43, 132.66, 
130.18, 128.73, 128.40, 127.43, 125.66, 120.66, 115.30, 111.66, 55.85. 
 
(E)-3-(2-methoxyphenyl)-1-(4-methoxyphenyl) prop-2-en-1-one   MC31 
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Yellow solid; Mp = 51°C. 1H NMR (400 MHz, CDCl3):  δ 8.03(d, J=8.58Hz, 2H), 
7.76(d, J=15.37Hz, 1H), 7.52(d, J=15.72Hz, 1H), 7.33(t, J=7.86Hz, 1H),  7.24-7.25 (m, 
1H), 7.15-7.17 (m, 1H), 6.94-6.98 (m, 3H), 3.89 (s, 3H, OCH3), 3.86(s, 3H, OCH3 ); 13C 
NMR (400 MHz, CDCl3): δ 188.82, 163.53, 160.01, 143.98, 136.55, 131.14, 130.93, 
130.00, 122.28, 121.09, 116.14, 113.94, 113.47, 55.60, 55.45. 
 
(E)-3-(4-chlorophenyl)-1-(4-methoxyphenyl) prop-2-en-1-one  MC32 
 
Yellow solid; Mp = 135°C. 1H NMR (400 MHz, CDCl3):  δ 8.03(d, J=8.16Hz, 2H), 
7.75(d, J=16.33Hz, 1H), 7.57(d, J=8.16Hz, 2H), 7.51(d, J=16.33Hz, 1H),7.38(d, 
J=9.07Hz, 2H),  6.99 (d, J=9.28Hz, 2H), 3.90 (s, 3H, OCH3); 13C NMR (400 MHz, 
CDCl3): δ 188.49, 163.63, 142.55, 136.27, 133.66, 130.93, 129.59, 129.29, 122.36, 
113.98, 55.61. 
 
(E)-1-(4-methoxyphenyl)-3-(naphthalen-2-yl) prop-2-en-1-one   MC33 
 
Golden yellow solid; Mp = 155°C. 1H NMR (400 MHz, CDCl3):  δ 8.08(d, J=8.09Hz, 
2H), 8.02 (s, 1H), 7.96(d, J=15.32Hz, 1H), 7.79-7.89 (m, 4H), 7.66(d, J=15.36Hz, 1H), 
7.48-7.54 (m, 2H), 6.99 (d, J=8.94Hz, 2H), 3.88 (s, 3H, OCH3); 13C NMR (400 MHz, 
CDCl3): δ 188.76, 163.53, 144.14, 130.94, 130.54, 128.76, 128.71, 127.88, 127.36, 
126.82, 123.80, 122.07, 113.95, 55.60. 
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(E)-3-(4-(dimethylamino) phenyl)-1-p-tolylprop-2-en-1-one   MC34 
 
Yellow solid; Mp = 132°C. 1H NMR (400 MHz, CDCl3):  δ 7.92(d, J=8.21Hz, 2H), 
7.78(d, J=15.45Hz, 1H), 7.54(d, J=8.69Hz, 2H), 7.34(d, J=15.40Hz, 1H),7.27(d, 
J=7.24Hz, 2H),  6.68 (d, J=8.69Hz, 2H), 3.39 (s, 6H, 2xCH3), 2.42 (s, 3H, CH3); 13C 
NMR (400 MHz, CDCl3): δ 190.28, 152.04, 145.49, 142.95, 136.51, 130.43, 129.25, 
128.54, 122.82, 116.99, 111.90, 40.23, 21.73. 
 
(E)-3-(4-fluorophenyl)-1-p-tolylprop-2-en-1-one   MC35 
 
Golden yellow  solid; Mp = 145°C. 1H NMR (400 MHz, CDCl3):  δ 7.93(d, J=8.16Hz, 
2H), 7.76(d, J=15.86Hz, 1H), 7.62( dd, J=8.69Hz, J=5.89, 2H), 7.46(d, J=15.86Hz, 
1H),7.30(d, J=8.62Hz, 2H),  7.10 (t, J=8.16Hz, 2H),  2.42 (s, 3H, CH3); 13C NMR (400 
MHz, CDCl3): δ 189.86, 165.33, 162.81, 143.83, 143.15, 135.61, 131.31, 130.34, 
129.44, 128.65, 121.85, 116.29, 21.78. 
 
(E)-3-(4-chlorophenyl)-1-p-tolylprop-2-en-1-one MC36 
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Yellow  solid; Mp = 144°C. 1H NMR (400 MHz, CDCl3):  δ 7.92(d, J=8.10Hz, 2H), 
7.75(d, J=15.82Hz, 1H), 7.62(dd, J=8.65Hz, J=6.02, 2H), 7.45(d, J=15.86Hz, 
1H),7.29(d, J=8.65Hz, 2H),  7.10 (t, J=8.36Hz, 2H),  2.42 (s, 3H, CH3); 13C NMR (400 
MHz, CDCl3): δ 189.73, 165.28, 162.74, 143.77, 143. 06, 135.64, 131.34, 130.39, 
129.40, 128.57, 121.86, 116.20, 21.78.  
 
(E)-3-(4-(methylthio) phenyl)-1-p-tolylprop-2-en-1-one MC37 
 
Pale yellow solid; Mp = 142°C. 1H NMR (400 MHz, CDCl3):  δ 7.96(d, J=8.75Hz, 2H), 
7.77(d, J=16.41Hz, 1H), 7.65(d, J=8.05Hz, 2H), 7.21-7.29(m,  3H),6.73(d, J=8.75Hz, 
2H),    2.52 (s, 3H, CH3), 2.32 (s, 3H, S- CH3); 13C NMR (400 MHz, CDCl3): δ 189.20, 
144.89, 142.82, 133.13, 131.23, 129.58, 128.13, 126.98, 126.33, 126.00, 120.43, 21.25, 
15.61. 
 
(E)-1-(2-aminophenyl)-3-phenylprop-2-en-1-one   MC38 
 
Golden yellow solid; Mp = 66 °C.  1H NMR (400 MHz, CDCl3): δ 7.85 (d, J=8.51Hz, 
1H), 7.73 (d, J=15.14Hz, 1H), 7.58-7.64(m,  3H), 7.36-7.42 (m, 3H), 7.24-7.29 (m, 1H), 
6.97-6.71(m, 2H), 6.33 (bs, 2H, NH2); 13C NMR (400 MHz, CDCl3): δ 191.84, 151.21, 
143.08, 135.35, 134.57, 131.34, 130.18, 129.02, 128.51, 123.35, 119.09, 117.55, 
115.87. 
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(E)-1-(2-aminophenyl)-3-(4-nitrophenyl) prop-2-en-1-one   MC39 
 
Orange solid; Mp = 156 °C.  1H NMR (400 MHz, CDCl3): δ 7.85 (d, J=8.41Hz, 3H), 
7.67-7.90 (m, 6H), 7.32(t, J=7.65Hz, 1H), 6.69 (bs, 2H, NH2); 13C NMR (400 MHz, 
CDCl3): δ 190.70, 169.90, 151.49, 148.26, 141.45, 139.71, 135.18, 131.15, 128.76, 
127.05, 124.53, 117.59, 115.98. 
 
(E)-1-(2-aminophenyl)-3-(4-chlorophenyl) prop-2-en-1-one   MC40 
 
Pale yellow solid; Mp = 143 °C.  1H NMR (400 MHz, CDCl3): δ 7.84 (d, J=8.09Hz, 
1H), 7.67 (d, J=15.21Hz, 1H), 7.54 (d, J=8.79Hz, 2H), 7.37 (d, J=8.79Hz, 2H), 7.24-
7.33 (m, 2H), 6.63-6.67 (m, 2H), 6.37 (bs, 2H, NH2); 13C NMR (400 MHz, CDCl3): δ 
191.40, 171.27, 151.25, 141.55, 136.06, 134.53, 133.90, 131.09, 129.56, 129.04, 
123.69, 117.44, 115.91. 
 
(E)-1-(2-aminophenyl)-3-(4-methoxyphenyl) prop-2-en-1-one   MC41 
 
Yellow solid; Mp = 152 °C.  1H NMR (400 MHz, CDCl3): δ 7.79 (d, J=8.46Hz, 1H), 
7.66 (d, J=15.23Hz, 1H), 7.52 (d, J=8.80Hz, 2H), 7.44 (d, J=15.23Hz, 1H), 7.21-7.24 
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(m, 1H), 6.87 (d, J=8.12Hz, 2H), 6.60-6.65 (m, 2H), 6.22 (bs, 2H, NH2), 3.78 (s, 3H, 
OCH3); 13C NMR (400 MHz, CDCl3): δ 191.83, 161.40, 151.08, 142.90, 134.21, 
131.04, 130.11, 128.06, 120.82, 119.35, 117.43, 115.89, 114.41, 55.47. 
 
(E)-1-(2-aminophenyl)-3-(naphthalen-2-yl) prop-2-en-1-one   MC42 
 
 Golden yellow crystals (recrystalized from ethanole); Mp = 148°C. 1H NMR (400 
MHz, CDCl3): δ  8.21(s, 1H), 7.78-7.94 (m, 5H), 7.79 (d, J=8.91Hz, 1H), 7.73(d, 
J=15.37Hz, 1H), 7.49-7.54 (m, 2H), 7.30 (t, J=8.80Hz, 1H), 6.70-6.74 (m, 2H), 6.35 
(bs, 2H, NH2); 13C NMR (400 MHz, CDCl3): δ 191.73, 151.15, 143.12, 134.44, 134.39, 
133.51, 132.45, 131.16, 130.25, 128.73, 128.69, 127.24, 126.92, 126.78, 123.89, 
123.35, 119.92, 117.44, 115.99; IR (ATR): 3378, 1609, 1568, 1540, 1359, 1247, 1153, 
1008, 810, 737cm-1;  HRMS (ESI):   calculated for C19H15NOH  [M+H] +  274.1232  , 
found  274.1486 and C19H15NOH2  [M+2H] +  275.1310, found 275.1120. 
 
(E)-1-(4-aminophenyl)-3-phenylprop-2-en-1-one   MC43 
 
Dark yellow  solid; Mp = 172 °C.  1H NMR (400 MHz, CDCl3): δ 7.92 (d, J=8.61Hz, 
2H),  7.82 (d, J=14.64Hz, 1H),  7.55-7.64(m, 2H), 7.34-7.41 (m, 3H), 6.68 (d, 
J=8.30Hz, 2H), 6.57 (t, J=8.63Hz, 1H), 4.07 (s, 2H, NH2); 13C NMR (400 MHz, 
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CDCl3): δ 188.28, 151.36, 143.12, 135.38, 133.66, 131.26, 130.18, 128.95, 126.23, 
122.16, 114.03. 
(E)-1-(4-aminophenyl)-3-(2-chlorophenyl) prop-2-en-1-one   MC44 
 
Dark yellow solid; Mp = 104 °C.  1H NMR (400 MHz, CDCl3): δ 8.13 (d, J=15.63Hz, 
1H),  7.92 (d, J=8.52Hz, 2H), 7.47 (d, J=15.63Hz, 1H), 7.41-7.46(m, 2H), 7.28-7.34 (m, 
2H), 6.69 (d, J=7.81Hz, 2H), 4.09 (s, 2H, NH2); 13C NMR (400 MHz, CDCl3): δ 
188.06, 151.46, 139.02, 135.35, 133.75, 131.46, 130.82, 130.42, 128.22, 127.79, 
127.05, 124.96, 114.02. 
(E)-1-(4-aminophenyl)-3-(4-chlorophenyl) prop-2-en-1-one MC45 
 
Dark yellow solid; Mp = 162 °C.  1H NMR (400 MHz, CDCl3): δ 7.92 (d, J=8.25Hz, 
2H),  7.72 (d, J= 15.22Hz, 1H), 7.49-7.57(m, 3H), 7.36 (d, J=8.32Hz, 2H), 6.69 (d, 
J=8.32Hz, 2H), 4.09 (s, 2H, NH2); 13C NMR (400 MHz, CDCl3): δ 187.88, 151.40, 
141.75, 135.97, 133.88, 131.21, 129.37, 129.11, 128.32, 122.52, 114.03. 
 
(E)-1-(4-aminophenyl)-3-(2, 4-dichlorophenyl)prop-2-en-1-one  MC46 
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Orange crystals (recrystalized from Ethanole); Mp = 184 °C.  1H NMR (400 MHz, 
CDCl3): δ 8.06 (d, J=14.81Hz, 1H), 7.91 (d, J= 8.31Hz, 2H), 7.66 (d, J= 7.73Hz, 
1H),7.48 (d, J=14.81Hz, 2H), 7.27-7.30 (m, 2H), 6.70(d, J=7.08Hz, 2H), 4.17 (s, 2H, 
NH2); 13C NMR (400 MHz, CDCl3): δ 187.92, 151.49, 137.79, 135.85, 132.51, 131.32, 
130.13, 128.52, 127.52, 125.24, 114.03. 
 
Procedure for preparation of PMA / SiO2 (1 mol %): 
PMA/SiO2 was prepared by adding 0.1 equivalent of phosphoMolibdic acid 
(H3PMo12O40) and 0.9 equivalents silica gel (100-200 mesh) in Methanol and stirring at 
room temperature for around six hours. Methanol was removed under reduced pressure 
and PMA/SiO2 was yielded as a yellow solid (Kumar et al. 2004).  
 
General procedure for preparation of Flavanones MF1- MCF17: 
 
 A mixture of PMA-SiO2 (1 mol %), 2′-hydroxychalcones, 2′-aminochalcones and 2′-
mercaptochalcones in ethanol (5 ml / mmol of chalcone) under N2 atmosphere was 
stirred under reflux for the appropriate time (8-18 hrs). The reaction monitored by TLC, 
after completion of the reaction, the solvent was removed under reduced pressure and 
the residue was dissolved in diethylether (10 ml) and filtered. The filtrate was 
concentrated under reduced pressure and purified by column chromatography (silica gel 
100-200 mesh) using n-hexane/ ethyl acetate as eluent to afford pure flavanone MF1-
MF17. The filtered catalyst was reused after drying. 
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2-phenylchroman-4-one   MF1 
 
Light yellow solid; Mp = 95 °C. 1H NMR (400MHz, CDCl3): δ 7.86 (m, 1H), 7.29-7.46 
(m, 6H), 6.96-7.01(m, 2H), 5.41 (dd, J=2.86Hz, J=13.37Hz , 1H), 3.01 (dd, J=13.44Hz, 
J=16.78Hz, 1H), 2.82 (dd, J=2.86Hz, J=16.88Hz, 1H);13C NMR (100MHz, CDCl3): δ 
191.99, 161.57, 138.75, 136.22, 129.05, 128.87, 128.79, 128.68, 127.06, 126.16, 
121.63, 120.94, 118.15, 79.62, 44.69. 
 
2- (4-methoxyphenyl) chroman-4-one   MF2 
 
Yellow solid; Mp = 153 °C. 1H NMR (400MHz, CDCl3): δ 7.84 (d, J= 7.86 Hz, 1H), 
7.39-7.43 (m, 1H), 7.32(d, J= 8.94 Hz, 2H), 6.97 (t, J=7.84 Hz, 2H), 6.87 (d, J=8.94Hz, 
2H), 5.34 (dd, J=3.30Hz, J=13.65Hz , 1H), 3.74 (s, 3H), 3.02 (dd, J=13.90Hz, 
J=16.62Hz, 1H), 2.78 (dd, J=3.39Hz, J=16.96Hz, 1H);13C NMR (100MHz, CDCl3): δ 
192.35, 161.73,160.05, 136.26, 130.84, 127.84, 127.12,121.62, 121.00, 118.23, 114.61, 
114.29, 77.47, 55.45, 44.54. 
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2- (3, 4- dimethoxyphenyl) chroman-4-one   MF3 
 
Yellow solid; Mp = 152 °C. 1H NMR (400MHz, CDCl3): δ 7.93 (dd, J= 7.93Hz, J= 
1.93 Hz, 1H), 7.48-7.53 (m, 1H), 7.02-7.07 (m, 4H), 6.91 (d, J=7.97 Hz, 1H), 5.43 (dd, 
J=2.5Hz, J=13.38Hz , 1H), 3.92 (s, 3H), 3.90 (s, 3H),  3.13 (dd, J=13.39Hz, J=16.72Hz, 
1H), 2.87 (dd, J=3.30Hz, J=16.73Hz, 1H);13C NMR (100MHz, CDCl3): δ  192.24, 
161.63, 149.52, 149.34, 136.28, 127.14, 121.68, 121.00, 118.92, 118.23,  111.21, 
109.48, 79.66, 56.07, 44.68; IR (ATR): 3004, 2944, 1689, 1603, 1462, 1259, 1141, 
1065, 1023, 758 cm -1. HRMS (ESI): calculated for C17H16O4H [M+H]+  285.1049,  
found  285.1352. 
 
2- (3, 4, 5- trimethoxyphenyl) chroman-4-one   MF4 
 
Yellow solid; Mp = 136 °C. 1H NMR (400MHz, CDCl3): δ 7.94 (dd, J= 8.22Hz, J= 
1.91Hz, 1H), 7.50-7.54 (m, 1H), 7.05-7.09 (m, 2H), 6.91 (s, 2H), 5.42 (dd, J=3.37 Hz, 
J=13.49Hz , 1H), 3.89 (s, 6H), 3.87 (s, 3H),  3.10 (dd, J=13.49Hz, J=16.86Hz, 1H), 
2.88 (dd, J=3.38Hz, J=16.71Hz, 1H);13C NMR (100MHz, CDCl3): δ =192.04, 161.51, 
153.64, 138.28, 136.36, 134.38, 127.16, 121.84, 120.98, 118.23, 103.30, 79.96,60.96, 
56.29, 44.95. 
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2- (benzo [d][1, 3] dioxol-5-yl) chroman-4-one    MF5 
 
Yellow solid; Mp = 127 °C. 1H NMR (400MHz, CDCl3): δ 7.93 (d, J= 8.54Hz,1H), 
7.49-7.53 (m, 1H), 7.00-7.09 (m, 3H), 6.91 (d, J= 8.03Hz,1H), 6.84 (d, J= 7.58Hz,1H), 
6.00 (s,2H), 5.39 (dd, J=3.40 Hz, J=13.60Hz , 1H), 3.06 (dd, J=13.60Hz, J=16.15Hz, 
1H), 2.85(dd, J=3.42Hz, J=16.45Hz, 1H);13C NMR (100MHz, CDCl3): δ =192.15, 
161.57, 148.17,148.09, 136.32, 132.60, 127.14, 121.72, 120.95, 120.16, 118.21, 108.51, 
106.89, 79.59,  44.74. 
 
2- p- tolylchroman-4-one   MF6 
 
Light yellow solid; Mp = 86 °C. 1H NMR (400MHz, CDCl3): δ 7.86 (dd, J= 1.68 Hz, J= 
8.08 Hz 1H), 7.41-7.45 (m, 1H), 7.29(d, J= 8.08 Hz, 2H),  7.18(d, J= 8.75 Hz, 2H), 
6.96-6.99 (m, 2H), 5.39 (dd, J=2.49Hz, J=13.45Hz , 1H), 3.03 (dd, J=13.82Hz, 
J=17.01Hz, 1H), 2.80 (dd, J=2.71Hz, J=17.05Hz, 1H), 2.31(s, 3H);13C NMR (100MHz, 
CDCl3): δ 192.33, 161.72,138.83, 136.28, 135.81, 129.60, 127.13,126.29, 
121.64,121.00, 118.25,77.47, 44.65, 21.31. 
 
2- (4- clorophenyl) chroman-4-one   MF7 
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Yellow solid; Mp = 185 °C. 1H NMR (400MHz, CDCl3): δ 7.85 (dd, J= 2.17 Hz, J= 
7.98 Hz 1H), 7.42-7.46 (m, 1H), 7.30-7.38(m, 4H),  6.95-7.01(m, 2H), 5.39 (dd, 
J=3.40Hz, J=13.62Hz , 1H), 2.97 (dd, J=13.65Hz, J=17.03Hz, 1H), 2.80 (dd, 
J=3.45Hz, J=17.25Hz, 1H); 13C NMR (100MHz, CDCl3): δ 191.49, 161.30,137.27, 
136.29, 134.57, 129.34, 128.79,  127.08, 121.80, 120.89, 118.08,78.81, 44.58. 
 
2- (naphtalen-2-yl) chroman-4-one   MF8 
 
Orange solid; Mp = 188 °C. 1H NMR (400MHz, CDCl3): δ 7.84-7.96 (m, 5H), 7.45-
7.59 (m, 4H), 7.04-7.09(m, 2H),  5.62 (dd, J=2.93Hz, J=13.36Hz , 1H), 3.17 (dd, 
J=13.52Hz, J=16.98Hz, 1H), 2.96 (dd, J=2.71Hz, J=16.98Hz, 1H); 13C NMR 
(100MHz, CDCl3): δ 192.02, 161.64, 136.35, 133.47, 133.26,  128.84, 128.28, 127.91, 
127.84, 127.19, 126.98, 126.65, 125.50, 123.74, 121.75, 121.08, 118.27, 79.80, 44.75. 
 
2- phenyl-2, 3-dihydroquinolin-4-(1H)-one   MF9 
 
Yellow solid; Mp = 145°C. 1H NMR (400MHz, CDCl3): δ 7.89 (d, J= 8.15Hz, 1H), 
7.32-7.50 (m, 6H), 6.80 (t, J=7.95 Hz, 1H),  6.72 (d, J=8.16 Hz, 1H), 4.76 (dd, 
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J=3.21Hz, J=13.67Hz , 1H), 4.50 (bs, NH), 2.90 (dd, J=13.67Hz, J=17.70Hz, 1H), 2.80 
(dd, J=3.21Hz, J=17.23Hz, 1H);13C NMR (100MHz, CDCl3): δ  193.41, 151.64, 
141.09,  135.51, 129.09, 128.57, 127.71, 126.72, 119.11, 118.55, 116.00, 58.61, 46.55; 
IR (ATR): 3328, 1651, 1602, 1331, 1153, 761, 698 cm-1;  HRMS (ESI):   calculated for 
C15H13NOH  [M+H] +  224.0997, found  224.1079.   
 
2- (4-nitrophenyl)-2, 3-dihydroquinolin-4-(1H)-one   MF10 
 
Dark orange solid; Mp = 193 °C. 1H NMR (400MHz, CDCl3): δ 8.20 (d, J= 8.93Hz, 
2H), 7.81 (dd, J= 8.03Hz, J= 1.70 Hz, 1H), 7.59 (d,  J= 8.95 Hz, 2H), 7.47(d,  J= 8.93 
Hz, 1H), 6.78 (dt, J=7.82 Hz, J= 1.68 Hz, 1H),6.70(d, J= 8.19 Hz, 1H ),  4.83 (dd, 
J=6.71Hz, J=10.06Hz , 1H), 4.46 (bs, NH), 2.76- 2.79 (m, 2H);13C NMR (100MHz, 
CDCl3): δ  192.52, 151.09, 148.49, 135.71,127.69, 127.51,  126.99, 124.33, 123.75, 
119.22, 116.04, 57.91, 46.11. 
 
2- (4-clorophenyl)-2, 3-dihydroquinolin-4-(1H)-one   MF11 
 
Yellow solid; Mp = 171 °C. 1H NMR (400MHz, CDCl3): δ 7.87 (d, J= 8.12 Hz, 1H), 
7.33-7.41 (m, 5H), 6.81 (t, J=7.71 Hz 1H), 6.72 (d, J=7.57 Hz, 1H), 4.74 (dd, 
J=3.45Hz, J=13.41Hz , 1H), 4.41 (bs, NH), 2.83 (dd, J=13.41Hz, J=16.60Hz, 1H), 2.74 
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(dd, J=3.41Hz, J=15.95Hz, 1H);13C NMR (100MHz, CDCl3): δ  193.00, 151.44, 
139.61, 135.61, 134.25, 129.49, 128.09, 127.70, 119.14, 118.80, 116.06, 57.99, 46.51. 
2- (4-methoxyphenyl)-2, 3-dihydroquinolin-4-(1H)-one   MF12 
 
Yellow solid; Mp = 149 °C. 1H NMR (400MHz, CDCl3): δ 7.80 (d, J= 8.62 Hz, 1H), 
7.23-7.32 (m, 3H), 6.85 (d, J= 8.56 Hz, 2H), 6.71 (t, J=8.01 Hz, 1H),6.61 (d, J= 8.05 
Hz, 1H), 4.62 (dd, J=3.53Hz, J=13.21Hz , 1H), 4.39 (bs, NH), 3.74 (s, 3H),  2.79 (dd, 
J=13.58Hz, J=15.73Hz, 1H), 2.66 (dd, J=3.55Hz, J=16.05Hz, 1H);13C NMR (100MHz, 
CDCl3): δ  193.81, 160.91, 151.15, 135.45, 132.55, 127.92, 127.71, 118.48, 115.96, 
114.38, 58.02, 55.45, 46.63. 
 
2- (naphthalen2-yl)-2, 3-dihydroquinolin-4-(1H)-one   MF13 
 
Yellow solid; Mp = 243 °C. 1H NMR (400MHz, CDCl3): δ 7.76- 7.83 (m, 5H), 7.50 
(dd, J=1.77Hz, J=8.61Hz , 1H), 7.43-7.46 (m, 2H), 7.26 (td, J=1.51Hz, J=8.86Hz, 1H), 
6.74 (t, J=7.59Hz, 1H), 6.68 (d, J=7.85Hz, 1H), 4.85 (dd, J=3.89Hz, J=13.62Hz , 1H), 
4.51 (bs, NH), 2.91(dd, J=13.63Hz, J=16.87Hz, 1H), 2.77 (dd, J=3.85Hz, J=16.85Hz, 
1H);13C NMR (100MHz, CDCl3): δ  193.21, 151.55, 138.36, 135.46, 133.37, 133.32, 
128.92, 127.94, 127.79, 127.68, 126.57, 126.38, 125.64, 124.29, 119.12, 118.56, 
115.98, 58.66, 46.42; IR (ATR) 3315, 1654, 1606, 1478, 1115, 747,  cm-1; HRMS (ESI) 
calculated for C19H15NOH [M+H]+  274.1154,  found  274.1862. 
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2-phenylthiochroman-4-one   MF14 
 
Golden yellow solid; Mp = 52 °C. 1H NMR (400MHz, CDCl3): δ 8.15 (d,  J= 8.78 Hz, 
1H), 7.28-7.49 (m, 7H), 7.21 (t, J=8.20 Hz, 1H), 4.73 (dd, J=3.65Hz, J=12.78Hz , 1H), 
3.32 (dd, J=13.39Hz, J=15.92Hz, 1H), 3.20 (dd, J=3.04Hz, J=16.43Hz, 1H);13C NMR 
(100MHz, CDCl3): δ  194.47, 142.18, 138.51, 133.77, 130.48, 129.30, 129.10, 128.57, 
127.53, 127.32, 125.33, 46.75, 45.56; IR (ATR) 3059, 3030, 2949, 1673, 1585, 1435, 
1284, 1084, 753,  695cm-1; HRMS (ESI) calculated for C15H12OSH [M+H]+ 241.0609,  
found  241.0687. 
 
2-(4-clorophenyl) thiochroman-4-one   MF15 
 
Light yellow solid; Mp = 122 °C. 1H NMR (400MHz, CDCl3): δ 8.14 (dd, J= 1.26Hz, 
J= 8.79 Hz, 1H), 7.26-7.46 (m, 7H), 4.69 (dd, J=2.99Hz, J=12.15Hz , 1H), 3.27 (dd, 
J=13.19Hz, J=16.74Hz, 1H), 3.19 (dd, J=3.15Hz, J=16.35Hz, 1H);13C NMR (100MHz, 
CDCl3): δ  194.25, 145.95, 141.67, 135.63, 133.92, 132.13, 129.31, 127.31, 125.84, 
125.40, 129.05, 46.96, 44.73. 
 
2-(4-methoxyphenyl) thiochroman-4-one   MF16 
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Yellow solid; Mp = 97 °C. 1H NMR (400MHz, CDCl3): δ 8.14 (d, J= 7.82Hz,  1H), 
7.41(t, J= 6.98Hz, 1H), 7.32 (d, J= 8.70Hz, 2H), 7.28 (d, J= 8.70Hz,  1H), 7.20 (t, J= 
7.10Hz,  1H), 6.90 (d, J=7.97 Hz, 2H), 4.68 (dd, J=3.30Hz, J=13.20Hz , 1H), 3.81 (s, 
3H), 3.30 (dd, J=13.20Hz, J=16.50Hz, 1H), 3.18 (dd, J=3.30Hz, J=16.23Hz, 1H);13C 
NMR (100MHz, CDCl3): δ  194.73, 159.66, 142.38, 133.72, 130.51, 129.28, 128.67, 
127.27, 125.25, 114.39, 55.43, 47.00, 45.02. 
 
2-(3-nitrophenyl) thiochroman-4-one   MF17 
 
Yellow solid; Mp = 112 °C. 1H NMR (400MHz, CDCl3): δ 8.26 (s, 1H), 8.14 (d, J=8.24 
Hz  1H), 8.08 (d, J=8.49 Hz  1H), 7.70 (d, J=8.95 Hz, 1H), 7.51 (t, J=7.92 Hz, 1H), 
7.38 (t, J=7.92 Hz, 1H), 7.16-7.24 (m, 2H),  4.75 (dd, J=3.66Hz, J=12.56Hz , 1H), 3.29 
(dd, J=12.56Hz, J=16.22Hz, 1H), 3.19 (dd, J=3.66Hz, J=16.74Hz, 1H);13C NMR 
(100MHz, CDCl3): δ  193.19, 148.54, 140.77, 140.55, 133.97, 133.48, 130.07, 129.94, 
129.33, 127.27, 125.73, 123.46, 122.64, 46.14, 44.58. 
 
(E)-1-(2-(3-(2-aminophenyl)-3-oxo-1-phenylpropylamino) phenyl)-3-phenylprop-2-
en-1-one  MF.s 
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Golden yellow solid; Mp = 118 °C. 1H NMR (400MHz, CDCl3): δ 9.73 (d,  J= 6.17 Hz, 
1H, NH), 7.89 (d,  J= 6.25 Hz, 1H), 7.62-7.77 (m, 5H), 7.39-7.49 (m, 5H), 7.31 (t, 
J=8.61 Hz, 2H), 7.20-7.25 (m, 4H), 6.69 (d,  J= 8.81 Hz, 1H), 6.60-6.63(m, 2H), 6.25 
(bs, NH2), 5.30 (dd, J=7.19Hz, J=13.87Hz, 1H), 3.59 (dd, J=7.19Hz, J=15.92Hz, 1H), 
3.48 (dd, J=6.26Hz, J=15.91Hz, 1H);13C NMR (100MHz, CDCl3): δ  198.83, 191.85, 
150.83, 150.63, 143.00, 142.76, 134.57, 131.12, 130.09, 128.96, 128.88, 128.30, 
127.36, 126.57, 115.91, 114.73, 53.43, 47.71; IR (ATR) 3470, 3344, 1638, 1569, 1513, 
1198, 1159, 735, 696cm-1; HRMS (ESI) calculated for C30H26N2O2H [M+H]+ 447.1994,  
found  447.2104. 
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Experimental procedure and spectroscopic data for chapter 8 and 9 
General 
All melting points were determined using a Mel-Temp II melting point instrument. 
Elemental analyses (C, H, N) were conducted using a PerkinElmer 2400 elemental 
analyzer, their results were found to be in good agreement (±0.3%) with the calculated 
values.NMR spectra were obtained using a Jeol ECA 400 (400 MHz) and Lambda 400. 
EX 270 (270MHz) NMR spectrometers with TMS as the internal standard.  All 
chemical shifts are reported in ppm. The IR spectra were taken with a Perkin Elmer 400 
ATR-FTIR spectrophotometer. The mass spectra were taken on an Agilent 1200 
LC/MS.  Analytical thin-layer chromatography (TLC) was carried out on Merck 
precoated aluminum silica gel sheets (Kieselgel 60 F-254) using UV light (254 and 366 
nm) for detection. Column chromatography was carried out with silica gel 60 (230-400 
mesh) from Merck. All target compounds were characterized by 1H, 13C and other 
spectroscopy analyses. All reactions were carried out under nitrogen atmosphere unless 
specified. All solvents, reagents and ionic liquids were purchased from Aldrich, Merck 
or Fisher except for IL-A, IL-E, IL-F and IL-G which were synthesized in our labratory.   
 
Synthesis of IL-A: 
A dilute nitric acid solution (5.059 g of nitric acid (65 wt %) in 20 mL water) was added 
to a solution of 1.05 equiv of N-methylimidazol (4.089 g , 49.79 mmol) at 0 ˚C. The 
reaction mixture was allowed to warm to room temperature. Water was removed by 
passing compressed air above the solution at 80 ˚C. The mixture was cold to room 
temperature and white solid was separated. The resulting solid material was washed 
with diethyl ether and dried in vacuum at 40 ºC. IL-A was decolorized by refluxing the 
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aqueous solution in the presence of charcoal for 24 h. The mixture was filtered and 
water of filtrate was removed in vacuum for 12 h. 
 
Synthesis of IL-F: 
α,α-Dibromo-p-xylene and 1-butylimidazole (1:2.1) were refluxed in acetonitrile (50 
ml) for 4 h. The solvent was removed under reduced pressure and the ionic liquid was 
dissolved in water and extracted with ethyl acetate several times. The water was 
removed under reduced pressure and the product was dried under vacuum at 80 °C. 
85% yield, colorless solid. M.p. 165-166 oC.  
 
 
Synthesis of IL-E: 
An aqueous solution of LiN(CF3SO2)2 was added to IL-F in water (2.1:1) and stirred for 
24 h. Dichloromethane was added to the solution and the ionic liquid was washed 
several times with aliquots of water until no longer bromide residues were detected by 
the AgNO3 test. The product was dried with MgSO4, filtered and the solvent was 
removed under reduced pressure. Crystals of IL-E were formed at room temperature 
before they were dried under vacuum for a few hours. 85% yield, colorless solid. M.p. 
49-50 oC 
 
 
Synthesis of IL-G: 
An aqueous solution of NaCF3SO3 was added to IL-F in water (2.1:1) and stirred for 24 
h. The solvent was removed under reduced pressure and crystals of IL-G were formed 
at 4 °C and were dried under vacuum. 70% yield, colorless crystals. M.p. 92-94 oC 
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General procedure for preparation of 1, 5- benzodiazepine and 1, 5-
benzothiazepines MA1- MA15: 
 
A mixture of o-aminothiophenol (1.2 mmol) / o-phenylendiamine (1mmol), chalcone 
(1.0 mmol), and ILG (0.2 mmol, 0.1 gr per mmol of chalcone) was stirred at 80 0C for 
an appropriate time. The completion of reaction was followed by TLC using EtOAc in 
hexane as eluent. After completion, the reaction mixture was diluted with water and 
extracted with diethyl ether. The combined organic layer was separated, dried over 
anhydrous magnesium sulphate and the solvent evaporated under reduced pressure to 
afford the 1, 5-benzothiazepines and purified by chromatography through a column of 
silica-gel ethyl acetate in n-hexane as eluent and fully characterized. The aqueous layer 
consisting of the IL was subjected to distillation to remove water, leaving behind the IL, 
which could be recycled. 
 
 
 
2-(2-phenyl-2, 3-dihydro-1H-benzo[b][1,4]diazepin-4-yl)phenol   MAZ 
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Light yellow solid; Mp = 115°C. 1H NMR (400MHz, CDCl3): δ 15.28 (s, OH), 7.42-
7.43 (m, 2H), 7.27-7.37 (m, 6H), 7.12(td, J=1.53Hz, J=8.26Hz,  1H), 6.99-7.05 (m, 
2H), 6.85(dd, J=1.34Hz, J=7.79Hz,  1H), 6.72-6.79 (m, 1H),  5.21 (dd, J=3.08Hz, 
J=8.02Hz , 1H), 3.84 (bs, NH), 3.33 (dd, J=3.70Hz, J=13.58Hz, 1H), 3.06 (dd, 
J=8.64Hz, J=13.58Hz, 1H);13C NMR (100MHz, CDCl3): δ 171.32, 162.59, 144.26, 
139.04, 135.23, 132.84, 128.99, 128.34, 128.29, 128.05, 127.42, 125.88, 121.48, 
120.72, 119.07, 118.30, 118.00, 69.99, 36.52. 
 
2, 4-diphenyl-2, 3-dihydrobenzo[b][1,4]thiazepine     MA1 
 
 
 Yellow solid; Mp = 102 °C. 1H NMR (400MHz, CDCl3): δ 8.01-8.06 (m, 3H), 7.30-
7.52 (m, 11H), 4.98 (dd, J=4.76Hz, J=12.70Hz , 1H), 3.31 (dd, J=4.69Hz, J=12.90Hz, 
1H), 3.07 (t, J=12.61Hz, 1H);13C NMR (100MHz, CDCl3): δ 168.67, 152.42, 144.84, 
137.65, 135.04, 128.81, 128.74, 128.60, 128.48, 128.42, 128.32, 127.82, 127.29, 
126.00, 121.84, 60.47, 37.63. 
 
2-(2-phenyl-2, 3-dihydrobenzo[b][1,4] thiazepin-4-yl)phenol       MA2 
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Yellow  Crystal (recrystalized from  ethanol); Mp = 151 °C. 1H NMR (400MHz, 
CDCl3): δ 14.49 (bs, OH), 7.65 (dd, J=1.68Hz, J=7.98Hz , 1H), 7.50 (dd, J=1.68Hz, 
J=8.51Hz , 1H), 7.49 (dt, J=1.05Hz, J=7.98Hz , 1H), 7.39-7.43 (m, 1H), 7.31-7.34 (m, 
6H), 7.22 (dt, J=1.26Hz, J=8.40Hz , 1H), 7.07 (d, J= 8.40, 1H), 6.68-6.92(m, 1H), 5.06 
(dd, J=4.67Hz, J=12.64Hz , 1H), 3.41 (dd, J=4.74Hz, J=13.27Hz, 1H), 3.09 (t, 
J=13.27Hz, 1H);13C NMR (100MHz, CDCl3): δ 173.13, 162.78, 148.83, 143.68, 
135.21, 133.65, 129.95, 128.89, 128.36, 128.07, 126.41, 126.04, 125.66, 124.44, 
118.68, 118.59, 118.29, 60.05, 36.89; IR ( ATR): 3055, 1596, 1445, 1194, 725, 737  
cm-1  
 
2-(2-(4-methoxyphenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol     MA3 
 
Yellow solid; Mp = 165 °C.1H NMR (400MHz, CDCl3): δ 14.52 (bs, OH), 7.58 (dd, 
J=1.62Hz, J=7.67Hz , 1H), 7.58 (dd, J=1.39Hz, J=7.91Hz , 1H), 7.48 (dt, J=1.62Hz, 
J=8.37Hz , 1H), 7.38-7.43 (m, 1H), 7.19-7.32 (m, 4H), 7.07 (dd, J=1.16Hz, J=8.61Hz , 
1H), 6.84-6.92(m, 3H), 5.04 (dd, J=4.95Hz, J=12.11Hz , 1H), 3.80 (s, 3H), 3.38 (dd, 
J=4.95Hz, J=12.66Hz, 1H), 3.05 (t, J=12.66Hz, 1H);13C NMR (100MHz, CDCl3): δ 
173.12, 162.31, 159.31, 135.19, 133.59, 131.14, 129.86, 128.41, 127.20, 126.65,  
126.34, 125.62, 125.48, 124.42, 118.65, 118.55, 114.15, 59.67, 55.35, 37.07. 
 
2-(2-(3, 4-dimethoxyphenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol   MA4 
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Yellow solid; Mp = 161-162 °C. 1H NMR (400MHz, CDCl3): δ 14.52 ( bs, OH), 7.65 ( 
d, J = 7.76 Hz, 1H ),  7.52 ( d,  J
 
= 8.11  Hz,1H ), 7.47 ( d,  J
 
= 8.11  Hz, 1H ), 7.40 ( t, J 
=  8.46 Hz, 1H ), 7.32 (d, J
 
= 8.11 Hz, 1H ), 7.21 (dt, J = 1.28  Hz, J = 7.76  Hz, 2H ), 
7.07 ( d,  J
 
= 7.76 Hz, 1H ), 6.78 - 6.90 ( m,  , 3H ), 5.05 ( dd,  J
 
= 4.90 Hz, J
 
=11.72 Hz, 
1H ),  3.87 ( s, 3H ),  3.77 ( s, 3H ),  3.38 ( dd,  J
 
= 4.96Hz, J
 
=12.94 Hz, 1H ), 3.08 (t, J
 
= 12.41 Hz, 1H ); 13C NMR (100MHz,CDCl3): δ 173.20, 162.74, 149.04, 148.82, 
136.81, 135.05, 133.62, 131.59, 130.87, 129.97, 128.58, 126.28, 125.58, 124.68, 
118.61, 118.13, 115.20, 110.97, 109.45, 60.17, 55.94, 55.77, 36.99;  IR (ATR): 2920, 
1565, 1419, 1266, 651 cm -1; HRMS (ESI): calculated for C23H21 NO3SH [M+H]+  
392.1276,  found  392.1295; CHN analysis: calculated for C23H21NO3S: C: 70.56; H: 
5.41; N: 3.58; O: 12.26; S: 8.19. Found: C: 70.42; H: 5.22; N: 3.44. 
 
2-(2-(3, 4, 5-trimethoxyphenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol   
MA5 
 
 
Yellow crystal (recrystalized from 30%  ethyl acetate in n-hezane); Mp = 160-162 °C. 
1H NMR (400MHz, CDCl3): δ 14.51 ( bs, OH), 7.66( d, J = 8.18 Hz, 1H ), 7.47- 7.52 ( 
m,  2H ), 7.38-7.42 (m, 1H ), 7.31( d,  J =  8.57  Hz, 1H ), 7.21(dt, J
 
= 1.38 Hz,  J
 
= 8.36 
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Hz,1H ), 7.07 (d,  J = 8.46  Hz, 1H ), 6.87 ( t,  J
 
= 8.18  Hz, 1H ), 6.54 ( s,  2H ), 5.02 ( 
dd,  J
 
= 4.67 Hz,  J
 
= 11.30 Hz, 1H ),   3.83( s, 3H ), 3.77( s, 6H ), 3.38 ( dd,  J
 
= 4.67 
Hz, , J
 
=12.86 Hz, 1H ), 3.08 (t,  J
 
= 12.47  Hz, 1H ); 13C NMR (100MHz, CDCl3): δ 
173.21,162.72, 153.27, 148.89, 138.80, 134.99, 133.67, 130.11, 128.62, 126.29, 125.63, 
124.67, 118.63, 118.61, 118.47, 103.30, 103.28, 60.84,60.66, 56.02, 36.90; IR ( ATR): 
3001, 2926, 1589, 1455, 1243, 760 cm-1; HRMS (ESI): calculated for C24H23NO4SH 
[M+H]+  422.1381, found  422.1391; CHN analysis: calculated for C24H23NO4S: C: 
68.39; H: 5.50; N: 3.32;  O: 15.18; S: 7.61. Found: C: 68.50; H: 5.64; N: 3.18. 
 
2-(2-(benzo[d][1,3]dioxol-5-yl)-2,3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol  
MA6 
 
 
Light yellow solid; Mp = 138 °C. 1H NMR (400MHz, CDCl3): δ 14.47 ( bs, OH), 7.65( 
dd, J = 1.25 Hz,  J = 7.65 Hz, 1H ), 7.58( dd, J = 1.29 Hz,  J = 7.98 Hz, 1H ), 7.48( dt, J 
= 1.33 Hz,  J = 8.36 Hz, 1H ), 7.38-7.41 (m, 1H), 7.31( dd, J = 1.17 Hz,  J = 7.94 Hz, 
1H ),  7.22 (dt, J
 
= 1.42 Hz,  J
 
= 8.36 Hz,1H ), 7.07 (dd, J = 1.00 Hz,  J = 8.27  Hz, 1H 
),6.82-6.91 (m, 1H),  6.82 ( d,  J
 
= 1.33  Hz, 1H ), 6.72-6.78 (m, 2H), 5.96 (s, 2H, O-
CH2-O),  5.00 ( dd,  J = 4.70 Hz,  J = 12.18 Hz, 1H ),  3.37 ( dd,  J = 4.98 Hz,  J =13.28 
Hz, 1H ), 3.02 (t,  J
 
= 13.28  Hz, 1H );13C NMR (100MHz, CDCl3): δ 172.95, 162.85, 
148.66, 147.99, 147.31, 137.85, 135.15, 133.63, 129.93, 128.30, 126.44, 125.66, 
124.31, 119.23, 118.67, 118.58, 118.23, 108.21, 106.48, 101.23, 59.95, 37.09. 
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2-(2-p-tolyl-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol     MA7 
 
 
Yellow solid; Mp = 154 °C. 1H NMR (400MHz, CDCl3): δ 14.44 ( bs, OH), 7.51-758 
(m, 2H), 7.42 ( dt, J = 1.55 Hz, J = 9.21 Hz, 1H ), 7.34 ( dt, J = 1.82 Hz, J = 9.48 Hz, 
1H ),7.22-7.25 (m, 1H ), 7.09-7.14 (m, 2H ), 7.07 ( d,  J =  7.85  Hz, 2H ), 7.00 (d,  J
 
= 
7.85 Hz,1H ), 6.81-6.86 (m, 1H ),  4.95 ( dd,  J
 
= 4.58 Hz,  J
 
= 12.43 Hz, 1H ), 3.29 ( dd,  
J
 
= 4.58 Hz,  J
 
=12.43 Hz, 1H ), 3.00 (t,  J
 
= 12.43  Hz, 1H ),2.27 (s, 3H) ;13C NMR 
(100MHz, CDCl3): δ 173.20, 162.73, 148.86, 141.00, 137.95, 135.30, 133.71, 130.11, 
129.60, 128.39, 126.22, 125.97, 124.53, 123.14, 121.72, 118.73, 118.59, 59.95, 36.96, 
21.16. 
 
2-(2-(4-chlorophenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol     MA8 
 
Yellow solid; Mp = 162 °C. 1H NMR (400MHz, CDCl3):  δ 14.42 ( bs, OH), 7.63 (dd, J 
= 1.94 Hz, J = 8.05 Hz, 1H ), 7.55 (dd, J = 1.66 Hz, J = 8.60 Hz, 1H ), 7.50 ( dt, J = 
1.66 Hz, J = 8.87 Hz, 1H ), 7.40-7.44 (m, 1H ), 7.29-7.33 (m, 4H ), 7.20-7.24 (m, 2H ), 
7.08 ( d,  J =  7.60  Hz, 1H ), 6.89-6.3 (m, 1H ),  5.02 ( dd,  J
 
= 4.94 Hz,  J
 
= 12.20 Hz, 
1H ), 3.38 ( dd,  J
 
= 4.71 Hz,  J
 
=13.04Hz, 1H ), 3.04 (t,  J
 
= 12.76  Hz, 1H );13C NMR 
(100MHz, CDCl3): δ 172.93, 162.95, 148.85, 142.18, 135.09, 133.83, 130.16, 129.11, 
128.42, 127.53, 126.69, 126.25, 125.72, 123.44, 121.14, 118.75, 118.63, 59.29, 36.89. 
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2-(2-(4-fluorophenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol  MA9 
 
 
Yellow solid; Mp = 152 °C. 1H NMR (400MHz, CDCl3): δ 14.45 ( bs, OH), 7.66 (d, J = 
7.77 Hz, 1H ), 7.57 (d, J = 7.77 Hz, 1H ), 7.51 ( dt, J = 1.29 Hz, J = 7.77 Hz, 1H ), 7.42 
(dt, J = 1.29 Hz, J = 8.03 Hz, 1H ), 7.29-7.38 (m, 4H ), 7.09 ( d,  J =  7.78  Hz, 1H ), 
7.02 (t, J= 8.29, 2H ), 6.92 (t, J= 7.51, 1H ), 5.05 ( dd,  J
 
= 4.41 Hz,  J
 
= 11.92 Hz, 1H ), 
3.41 ( dd,  J
 
= 4.66 Hz, J
 
=12.95Hz, 1H ), 3.05 (t,  J
 
= 12.44  Hz, 1H );13C NMR 
(100MHz, CDCl3): δ 172.94, 163.13, 149.00, 134.72, 133.71,133.14,  130.14, 128.36, 
127.98, 127.45, 126.70, 126.06, 124.42, 124.32, 118.81, 118.45, 115.75, 59.33, 36.91. 
 
3, 5-dimethoxy-2-(2-(4-methoxyphenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-
yl)phenol   MA10 
 
 
Yellow solid; Mp = 168-170 °C. 1H NMR (400MHz, CDCl3): δ 16.82 ( bs, OH), 7.64 
(d, J = 8.19 Hz, 1H ), 7.45 (d, J = 7.56 Hz, 1H ), 7.45 ( t, J = 7.56 Hz, 1H ), 7.16-7.31 
(m, 4H ), 6.85 (d,  J = 8.83 Hz, 2H ), 6.17 (d,  J = 1.89 Hz, 1H ), 5.96 ( d,  J =  1.89  Hz, 
1H ), 5.20 ( dd,  J
 
= 4.41 Hz,  J
 
= 12.93 Hz, 1H ), 3.89 ( s, 3H), 3.87 ( s, 3H), 3.79 ( s, 
3H),  3.62 ( dd,  J
 
= 4.73 Hz, J
 
=12.29Hz, 1H ), 2.89 (t,  J
 
= 12.29  Hz, 1H );13C NMR 
(100MHz, CDCl3): δ 172.14, 168.42, 164.23, 161.65, 158.90, 147.28, 137.25, 135.29, 
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129.79, 127.12, 126.14, 126.02, 125.63, 114.15, 103.71, 94.72, 90.55, 59.13, 55.66, 
55.54, 55.39, 41.90; HRMS (ESI): calculated for C24H23NO4SH [M+H]+  422.1381, 
found  422.1973. 
 
6-(2-(4-bromophenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)-2,3-
dimethoxyphenol    MA11 
 
Yellow solid; Mp =156-157 °C. 1H NMR (270MHz, CDCl3): δ 14.40 ( bs, OH), 7.60 
(dd, J = 1.05 Hz,  J = 7.62 Hz, 1H ), 7.48 (dd, J = 1.27 Hz, J = 7.62 Hz, 1H ), 7.46 ( d, J 
= 8.47 Hz, 2H ), 7.18-7.30 (m, 5H ), 6.50 (d,  J = 8.89 Hz, 1H ), 4.97 ( dd,  J
 
= 4.87 Hz,  
J
 
= 12.49 Hz, 1H ), 3.95 ( s, 3H), 3.94 ( s, 3H), 3.31 ( dd,  J
 
= 4.66 Hz, J
 
=13.13Hz, 1H 
), 3.02 (t,  J
 
= 12.71  Hz, 1H );13C NMR (67.5MHz, CDCl3): δ172.34, 157.60, 156.62, 
148.70, 142.56, 137.19, 135.08, 131.98, 130.17,127.78, 126.29, 125.67, 124.09, 123.97, 
121.78, 113.44, 102.52, 60.60, 59.16, 56.04, 36.64 ; IR ( ATR): 2927, 1605, 1556,1449, 
1289, 1076, 783, 702 cm-1;  HRMS (ESI): calculated for C23H20BrNO3S H [M+H]+  
470.0350, found  470.0454; CHN analysis: calculated for C23H20BrNO3S: C: 58.73; H: 
4.29; Br: 16.99;  N: 2.98; S: 6.82. Found: C: 58.81; H: 4.35; N: 2.84. 
 
4-(4-methoxyphenyl)-2-(naphthalen-2-yl)-2,3-dihydrobenzo[b][1,4]thiazepine  
MA12 
175 
 
 
Yellow crystal (recrystalized from 20%  ethyl acetate in n-hezane);  Mp = 128-130 °C. 
1H NMR (400MHz, CDCl3): δ 8.06 (d,  J=8.79 Hz , 2H),7.76-7.89 (m, 3H), 7.67 (s, 
1H), 7.63 (d, J=7.88 Hz, 1H), 7.42-7.51 (m, 4H), 7.32 (d, J=8.19 Hz , 1H), 7.14 (t, 
J=8.19 Hz , 1H), 7.01 (d, J=8.79 Hz, 2H), 5.13 (dd, J=4.85 Hz , J=12.43 Hz , 1H), 3.88 
(s, 3H), 3.34 (dd, J=4.85Hz, J=12.74Hz, 1H), 3.18 (t, J=12.43Hz, 1H);13C NMR 
(100MHz, CDCl3): δ 168.24, 162.21, 152.77, 141.23, 135.18, 132.85, 132.19, 131.18,  
129.88, 129.29, 128.94, 128.04, 127.78, 127.15, 126.49, 126.17, 125.49, 125.13, 
124.54, 124.29, 114.19, 60.66, 55.57, 37.23; IR (ATR): 3051, 2929, 1592, 1235,  751 
cm -1; HRMS (ESI): calculated for C26H21NOSH [M+H]+  396.1377,  found  396.1473. 
 
2-(4-chlorophenyl)-4-p-tolyl-2, 3-dihydrobenzo[b][1,4]thiazepine  MA13 
 
Light yellow solid; Mp = 119-121 °C. 1H NMR (400MHz, CDCl3): δ 7.93 (d, 
J=8.05Hz, 2H), 7.58 (d, J=7.24Hz, 1H), 7.46 (t, J=7.65Hz, 1H), 7.22-7.30(m, 7H), 7.13 
(t, J=8.05Hz, 1H), 4.93 (dd, J=4.00Hz, J=12.50Hz , 1H), 3.27 (dd, J=4.00Hz, 
J=13.15Hz, 1H), 3.00 (t, J=12.58Hz, 1H), 2.43 (s, 3H, CH3);13C NMR (100MHz, 
CDCl3): δ 168.53, 152.55, 142.63, 141.60, 135.00, 134.98, 133.43, 129.89, 129.53, 
128.90, 127.45, 127.39,125.42,  125.37, 122.39, 59.65, 37.36, 21.47;  IR (ATR): 2919, 
1600, 1565, 1452, 1246, 749 cm -1;  HRMS (ESI): calculated for C22H18ClNS H 
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[M+H]+  364.0921, found 364.0914; CHN analysis: calculated for C22H18ClNS: C: 
72.61; H: 4.99; Cl: 9.74;  N: 3.85; S : 8.81. Found: C: 72.73; H: 4.86: N, 3.97. 
 
2-(4-fluorophenyl)-4-p-tolyl-2, 3-dihydrobenzo[b][1,4]thiazepine MA14 
 
Light yellow solid; Mp = 118-119 °C. 1H NMR (400MHz, CDCl3): δ 7.93 (d, 
J=7.81Hz, 2H), 7.59 (d, J=7.48Hz, 1H), 7.46 (t, J=7.81Hz, 1H), 7.24-7.34(m, 5H), 7.13 
(t, J=7.81Hz, 1H),6.98 (t, J=8.46Hz, 2H), 4.95 (dd, J=4.49Hz, J=12.34Hz ,1H), 3.26 
(dd, J=3.92Hz, J=12.34Hz, 1H), 3.00 (t, J=12.90Hz, 1H), 2.43 (s, 3H, CH3) ;13C NMR 
(100MHz, CDCl3): δ 168.60, 163.36, 160.95, 152.55, 141.60, 140.16, 134.97, 129.82, 
129.50, 127.75, 127.38, 125.16, 122.53, 115.66, 115.45, 59.68, 37.67, 21.48; IR (ATR): 
2891, 1600, 1580, 1505, 1450, 1212,744  cm -1; HRMS (ESI): calculated for 
C22H18FNSH [M+H]+  348.1217,  found  348.1232; CHN analysis: calculated for 
C22H18FNS: C: 76.05; H: 5.22; F: 5.47;  N: 4.03; S: 9.23. Found: C: 76.17; H: 5.13; N: 
4.14. 
 
 
 
4-(2-(2, 4-dichlorophenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)aniline    MA15 
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Pale yellow solid; Mp = 179-181 °C. 1H NMR (400MHz, CDCl3): δ 7.97 (d, J=8.51Hz, 
2H), 7.59-7.67 (m, 2H), 7.45 (dt, J=1.85Hz, J=8.88Hz, 1H), 7.38 (d, J=1.85Hz,  1H), 
7.28 (s, 1H), 7.20 (dd, J=1.48Hz,  J=8.51Hz, 1H),7.10 (dt, J=1.48Hz,  J=8.14Hz, 1H), 
6.74 (d, J=8.81Hz, 2H), 5.43 (dd, J=4.40Hz, J=12.58Hz ,1H), 4.02 (bs, NH2), 3.27 (dd, 
J=4.81Hz, J=12.95Hz, 1H), 2.78 (t, J=12.95Hz, 1H);13C NMR (100MHz, CDCl3): δ  
167.61, 153.09, 149.51, 140.15, 134.94,131.83, 129.96, 129.27, 129.05, 128.97, 128.12, 
127.71, 127.41, 125.50, 124.78, 122.20, 114.59, 55.32, 35.72; IR (ATR): 3315, 3060, 
1626, 1550, 1450, 1240, 735 cm-1 ;  HRMS (ESI): calculated for C 21H16Cl2N2S H 
[M+H]+  399.0484,  found  399.0524; CHN analysis: calculated for C 21H16Cl2N2S: C: 
63.16; H: 4.04; Cl: 17.76;  N: 7.01; S: 8.03. Found: C: 63.23; H: 4.25; N: 7.28. 
 
3-(4-methoxyphenyl)-2-(naphthalen-2-ylmethyl)-2H-benzo[b][1,4]thiazine  (6MR) 
 
Golden yellow crystal (recrystalized from 5%  ethyl acetate in n-hexane);  Mp = 157-
158 °C. 1H NMR (400MHz, CDCl3): δ 7.95 (d,  J=8.34 Hz , 2H), 7.74-7.83 (m, 3H), 
7.57 (t,  J=8.34 Hz, 2H), 7.39-7.47 (m, 3H), 7.28-7.33 (m, 2H), 7.17-7.21 (m,  1H), 6.93 
(d, J=8.34 Hz , 2H), 4.26 (dd, J=4.94 Hz , J=9.27 Hz, 1H), 3.83 (s, 3H, OCH3), 3.60 
(dd, J=4.63Hz, J=13.60Hz, 1H), 2.83 (dd, J=9.89Hz, J=13.91Hz, 1H);13C NMR 
(100MHz, CDCl3): δ13C NMR (100MHz, CDCl3): δ 161.80, 158.33, 143.07, 134.87, 
133.36, 132.37,129.85,  129.73, 129.24, 128.92, 128.45, 128.28, 127.99, 127.68, 
127.32, 126.61, 126.52, 126.06, 125.61, 119.84, 114.04, 55.42, 37.21, 35.79; IR (ATR): 
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3053, 2935, 1561, 1507, 1249, 751 cm -1; HRMS (ESI): calculated for C26H21NOSH 
[M+H]+  396.1377,  found  396.1982. 
 
3-(2-aminophenylthio)-1,3-diphenylpropan-1-one;   Michael adduct 
 
Colorless crystal (recrystalized from ethanol);  Mp = 107-108 °C. 1H NMR (400MHz, 
CDCl3): δ 7.88 (d, J=8.29Hz, 2H), 7.51-7.55 (m, 1H), 7.42 (t, J=8.78 Hz, 1H), 7.12-
7.26 (m, 5H), 7.06 (d, J=8.78Hz, 2H), 6.66 (d, J=8.29Hz, 1H), 6.52 (t, J=7.80Hz, 1H), 
4.74 (t, J=6.73Hz , 1H), 4.43 (bs, NH2), 3.64 (dd, J=7.31Hz, J=17.54Hz, 1H), 3.56 (dd, 
J=6.95Hz,  J=17.62Hz, 1H);13C NMR (100MHz, CDCl3): δ 197.15, 149.47, 141.61, 
137.66, 136.73, 133.23, 130.63, 129.29, 128.36, 128.06, 127.61, 127.26, 117.98, 
115.69, 114.81, 47.07, 44.03; IR (ATR):3449, 3352, 1679, 1600, 1477, 744 cm -1; 
HRMS (ESI): calculated for C21H19NOSH [M+H]+  334.1221,  found  334.1356. 
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196 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of 1, 3-Diphenyl-2-propen-1-one (E-chalcone)    MC1 
 
197 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-3-(2-hydroxyphenyl)-1-phenylprop-2-en-1-one    MC2 
 
198 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-3-(3-hydroxyphenyl)-1-phenylprop-2-en-1-one    MC3 
 
199 
 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-3-(4-hydroxyphenyl)-1-phenylprop-2-en-1-one    MC4 
200 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1-(2-hydroxyphenyl)-3-phenylprop-2-en-1-one    MC5 
201 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1, 3-bis (2-hydroxyphenyl) prop-2-en-1-one   MC6 
 
202 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1-(2-hydroxyphenyl)-3-(3-hydroxyphenyl) prop-2-en-1-one    MC7 
 
203 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1-(2-hydroxyphenyl)-3-(4-hydroxyphenyl) prop-2-en-1-one    MC8 
 
204 
 
 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1-(2-hydroxyphenyl)-3-(4-methoxyphenyl) prop-2-en-1-one    MC9 
205 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-3-(3, 4-dimethoxyphenyl)-1-(2-hydroxyphenyl) prop-2-en-1-one    MC10 
 
206 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1-(2-hydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one   MC11 
 
207 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-3-(benzo[d][1,3]dioxol-5-yl)-1-(2-hydroxyphenyl)prop-2-en-1-one    MC12 
 
208 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1-(2-hydroxyphenyl)-3-p-tolylprop-2-en-1-one    MC13 
 
209 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-3-(4-chlorophenyl)-1-(2-hydroxyphenyl) prop-2-en-1-one    MC14 
 
210 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1-(2-hydroxyphenyl)-3-(naphthalen-2-yl) prop-2-en-1-one   MC15 
 
211 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-3-(4-(dimethylamino) phenyl)-1-(2-hydroxy-4, 6-dimethoxyphenyl) prop-2-en-1-one MC16 
 
212 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1-(2-hydroxy-4, 6-dimethoxyphenyl)-3-(4-methoxyphenyl) prop-2-en-1-one  MC17 
213 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-3-(4-bromophenyl)-1-(2-hydroxy-3, 4-dimethoxyphenyl) prop-2-en-1-one   MC18 
214 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR of (E)-3-(4-bromophenyl)-1-(2-hydroxy-3, 4-dimethoxyphenyl) prop-2-en-1-one   MC18 
 
215 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-3-phenyl-1-(2, 4, 6-trimethoxyphenyl) prop-2-en-1-one   MC19 
 
216 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-3-(2-nitrophenyl)-1-(2, 4, 6-trimethoxyphenyl) prop-2-en-1-one  MC20 
 
217 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-3-(4-nitrophenyl)-1-(2, 4, 6-trimethoxyphenyl) prop-2-en-1-one   MC21 
 
218 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1-(2, 4-dimethoxyphenyl)-3-(4-nitrophenyl) prop-2-en-1-one      MC22 
 
219 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-3-(4-chlorophenyl)-1-(2, 4-dimethoxyphenyl) prop-2-en-1-one   MC23 
 
220 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-3-(4-bromophenyl)-1-(2, 4-dimethoxyphenyl) prop-2-en-1-one   MC24 
 
221 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-3-(benzo[d] [1, 3] dioxol-5-yl)-1-(2, 4-dimethoxyphenyl) prop-2-en-1-one   MC25 
222 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-3-(benzo[d] [1, 3] dioxol-5-yl)-1-(2, 5-dimethoxyphenyl) prop-2-en-1-one   MC26 
 
223 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1-(2, 5-dimethoxyphenyl)-3-(3, 4, 5-trimethoxyphenyl) prop-2-en-1-one   MC27 
 
224 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-3-(4-chlorophenyl)-1-(3, 4-dimethoxyphenyl) prop-2-en-1-one   MC28 
 
225 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1-(3, 4-dimethoxyphenyl)-3-(4-(methylthio) phenyl) prop-2-en-1-one   MC29 
226 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-3-(4-fluorophenyl)-1-(2-methoxyphenyl) prop-2-en-1-one   MC30 
227 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR   of (E)-3-(2-methoxyphenyl)-1-(4-methoxyphenyl) prop-2-en-1-one   MC31 
 
228 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-3-(4-chlorophenyl)-1-(4-methoxyphenyl) prop-2-en-1-one   MC32 
 
229 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1-(4-methoxyphenyl)-3-(naphthalen-2-yl) prop-2-en-1-one   MC33 
 
230 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-3-(4-(dimethylamino) phenyl)-1-p-tolylprop-2-en-1-one   MC34 
 
231 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-3-(4-fluorophenyl)-1-p-tolylprop-2-en-1-one   MC35 
 
232 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-3-(4-chlorophenyl)-1-p-tolylprop-2-en-1-one   MC36 
 
233 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-3-(4-(methylthio) phenyl)-1-p-tolylprop-2-en-1-one MC37 
 
234 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1-(2-aminophenyl)-3-phenylprop-2-en-1-one   MC38 
 
235 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1-(2-aminophenyl)-3-(4-nitrophenyl) prop-2-en-1-one   MC39 
 
236 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1-(2-aminophenyl)-3-(4-chlorophenyl) prop-2-en-1-one   MC40 
 
237 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1-(2-aminophenyl)-3-(4-methoxyphenyl) prop-2-en-1-one   MC41 
238 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1-(2-aminophenyl)-3-(naphthalen-2-yl) prop-2-en-1-one   MC42 
 
239 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR of (E)-1-(2-aminophenyl)-3-(naphthalen-2-yl) prop-2-en-1-one   MC42 
 
240 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1-(4-aminophenyl)-3-phenylprop-2-en-1-one   MC43 
 
241 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1-(4-aminophenyl)-3-(2-chlorophenyl) prop-2-en-1-one   MC44 
 
242 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1-(4-aminophenyl)-3-(4-chlorophenyl) prop-2-en-1-one MC45 
 
243 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1-(4-aminophenyl)-3-(2, 4-dichlorophenyl)prop-2-en-1-one  MC46 
244 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of 2-phenylchroman-4-one   MF1 
245 
 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of 2- (4-methoxyphenyl) chroman-4-one   MF2 
 
246 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of 2- (3, 4- dimethoxyphenyl) chroman-4-one   MF3 
247 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR of 2- (3, 4- dimethoxyphenyl) chroman-4-one   MF3 
 
248 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of 2- (3, 4, 5- trimethoxyphenyl) chroman-4-one   MF4 
 
249 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of 2- (benzo [d][1, 3] dioxol-5-yl) chroman-4-one    MF5 
 
250 
 
  
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of 2- p- tolylchroman-4-one   MF6 
 
251 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of 2- (4- clorophenyl) chroman-4-one   MF7 
 
252 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of 2- (naphtalen-2-yl) chroman-4-one   MF8 
253 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of 2- phenyl-2, 3-dihydroquinolin-4-(1H)-one   MF9 
 
254 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR of 2- phenyl-2, 3-dihydroquinolin-4-(1H)-one   MF9 
 
255 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of 2- (4-nitrophenyl)-2, 3-dihydroquinolin-4-(1H)-one   MF10 
 
256 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of 2- (4-clorophenyl)-2, 3-dihydroquinolin-4-(1H)-one   MF11 
 
257 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of 2- (4-methoxyphenyl)-2, 3-dihydroquinolin-4-(1H)-one   MF12 
258 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of 2- (naphthalen2-yl)-2, 3-dihydroquinolin-4-(1H)-one   MF13 
259 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR of 2- (naphthalen2-yl)-2, 3-dihydroquinolin-4-(1H)-one   MF13 
 
260 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of 2-phenylthiochroman-4-one   MF14 
 
261 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR of 2-phenylthiochroman-4-one   MF14 
 
262 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of 2-(4-clorophenyl) thiochroman-4-one   MF15 
263 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of 2-(4-methoxyphenyl) thiochroman-4-one   MF16 
 
264 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of 2-(3-nitrophenyl) thiochroman-4-one   MF17 
 
265 
 
 
 
 
 
 
 
 
 
 
1HNMR and 13CNMR of (E)-1-(2-(3-(2-aminophenyl)-3-oxo-1-phenylpropylamino) phenyl)-3- 
phenylprop-2-en-1-one    MFs 
 
266 
 
 
 
 
 
 
 
 
 
 
 
 
IR of (E)-1-(2-(3-(2-aminophenyl)-3-oxo-1-phenylpropylamino) phenyl)-3 
-phenylprop-2-en-1-one; MFs 
 
 
267 
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DATA OF CHAPTER 8 
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 268 
 
 
 
 
1HNMR of 2-(2-phenyl-2, 3-dihydro-1H-benzo[b][1,4]diazepin-4-yl)phenol   MAZ 
 
 269 
 
 
13CNMR of 2-(2-phenyl-2, 3-dihydro-1H-benzo[b][1,4]diazepin-4-yl)phenol   MAZ 
 
 270 
 
 
 
1HNMR of 2, 4-diphenyl-2, 3-dihydrobenzo[b][1,4]thiazepine     MA1 
 
 271 
 
 
 
 
13CNMR of 2, 4-diphenyl-2, 3-dihydrobenzo[b][1,4]thiazepine     MA1 
 
 272 
 
 
 
1HNMR of 2-(2-phenyl-2, 3-dihydrobenzo[b][1,4] thiazepin-4-yl)phenol       MA2 
 
 273 
 
 
 
13CNMR of 2-(2-phenyl-2, 3-dihydrobenzo[b][1,4] thiazepin-4-yl)phenol       MA2 
 
 274 
 
 
 
IR of 2-(2-phenyl-2, 3-dihydrobenzo[b][1,4] thiazepin-4-yl)phenol       MA2 
 
 275 
 
 
1HNMR of 2-(2-(4-methoxyphenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol     MA3 
 
 276 
 
 
13CNMR of 2-(2-(4-methoxyphenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol     MA3 
 
 277 
 
 
 
 
1HNMR of 2-(2-(3, 4-dimethoxyphenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol   MA4 
 
 278 
 
 
13CNMR of 2-(2-(3, 4-dimethoxyphenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol   MA4 
 
 279 
 
 
 
 
IR of 2-(2-(3, 4-dimethoxyphenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol   MA4 
 
 280 
 
 
 
 
 
1HNMR of 2-(2-(3, 4, 5-trimethoxyphenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol   MA5 
 
 281 
 
 
 
 
13CNMR of 2-(2-(3, 4, 5-trimethoxyphenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol   MA5 
 
 282 
 
 
 
 
IR of 2-(2-(3, 4, 5-trimethoxyphenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol   MA5 
 
 283 
 
 
 
1HNMR of 2-(2-(benzo[d][1,3]dioxol-5-yl)-2,3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol  MA6 
 
 284 
 
 
 
13CNMR of 2-(2-(benzo[d][1,3]dioxol-5-yl)-2,3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol  MA6 
 
 285 
 
 
 
1HNMR of 2-(2-p-tolyl-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol     MA7 
 
 286 
 
 
 
 
13CNMR of 2-(2-p-tolyl-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol     MA7 
 
 287 
 
 
1HNMR of 2-(2-(4-chlorophenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol     MA8 
 
 288 
 
 
 
 
13CNMR of 2-(2-(4-chlorophenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol     MA8 
 
 289 
 
 
 
1HNMR of 2-(2-(4-fluorophenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol  MA9 
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13CNMR of 2-(2-(4-fluorophenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol  MA9 
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1HNMR of 3, 5-dimethoxy-2-(2-(4-methoxyphenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol   MA10 
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13CNMR of 3, 5-dimethoxy-2-(2-(4-methoxyphenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol   MA10 
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1HNMR of 6-(2-(4-bromophenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)-2,3-dimethoxyphenol    MA11 
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13CNMR of 6-(2-(4-bromophenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)-2,3-dimethoxyphenol    MA11 
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IR of 6-(2-(4-bromophenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)-2,3-dimethoxyphenol    MA11 
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1HNMR of 4-(4-methoxyphenyl)-2-(naphthalen-2-yl)-2, 3-dihydrobenzo[b][1,4]thiazepine  MA12 
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13CNMR of 4-(4-methoxyphenyl)-2-(naphthalen-2-yl)-2, 3-dihydrobenzo[b][1,4]thiazepine  MA12 
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IR of 4-(4-methoxyphenyl)-2-(naphthalen-2-yl)-2, 3-dihydrobenzo[b][1,4]thiazepine  MA12 
 
 299 
 
 
 
1HNMR of 2-(4-chlorophenyl)-4-p-tolyl-2, 3-dihydrobenzo[b][1,4]thiazepine  MA13 
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13CNMR of 2-(4-chlorophenyl)-4-p-tolyl-2, 3-dihydrobenzo[b][1,4]thiazepine  MA13 
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IR of 2-(4-chlorophenyl)-4-p-tolyl-2, 3-dihydrobenzo[b][1,4]thiazepine  MA13 
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1HNMR of 2-(4-fluorophenyl)-4-p-tolyl-2, 3-dihydrobenzo[b][1,4]thiazepine MA14 
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13CNMR of 2-(4-fluorophenyl)-4-p-tolyl-2, 3-dihydrobenzo[b][1,4]thiazepine MA14 
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IR of 2-(4-fluorophenyl)-4-p-tolyl-2, 3-dihydrobenzo[b][1,4]thiazepine MA14 
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1HNMR of 4-(2-(2, 4-dichlorophenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)aniline    MA15 
SN
H2N
Cl
Cl
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13CNMR of 4-(2-(2, 4-dichlorophenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)aniline    MA15 
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IR of 4-(2-(2, 4-dichlorophenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)aniline    MA15 
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1HNMR of 3-(4-methoxyphenyl)-2-(naphthalen-2-ylmethyl)-2H-benzo[b][1,4]thiazine  (6MR) 
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13CNMR of 3-(4-methoxyphenyl)-2-(naphthalen-2-ylmethyl)-2H-benzo[b][1,4]thiazine  (6MR) 
S
N
H3CO
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IR of 3-(4-methoxyphenyl)-2-(naphthalen-2-ylmethyl)-2H-benzo[b][1,4]thiazine  (6MR) 
S
N
H3CO
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1HNMR of 3-(2-aminophenylthio)-1,3-diphenylpropan-1-one;   Michael adduct 
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13CNMR of 3-(2-aminophenylthio)-1,3-diphenylpropan-1-one;   Michael adduct 
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IR of 3-(2-aminophenylthio)-1,3-diphenylpropan-1-one;   Michael adduct 
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APPENDIX C 
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REFINEMENT 
DETAILS 
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X-ray diffraction data were collected on a Bruker APEX II CCD diffractometer 
using MoKa radiation. The structures were solved by direct methods and refined by a 
full-matrix least-squares procedure based on F 2 
(E)-1-(2-aminophenyl)-3-(naphthalen-2-yl) prop-2-en-1-one   MC42 
 
 
  
Empirical formula 
 
C19 H15 N O 
Formula weight 
 
273.32 
Crystal system 
 
Monoclinic 
Space group 
 
P2(1)/n 
 
a (Å)  13.595(3)  
b (Å) 5.0500(10)  
c (Å) 19.905(4) 
α (°) 90 
β (°) 98.593(2) 
γ (°) 90 
  
Volume (Å3) 
 
1351.2(5)  
Z value 
 
4 
Calculated density, Dcalc (Mg/m3) 
 
1.344 
Crystal size (mm) 
Crystal color and habit 
0.22 x 0.20 x 0.11 
yellow Blade 
Reflections collected  7030 
Independent reflections 2927 [R(int) = 0.0213] 
Observed reflections (I > 2sigma(I)) 2347 
Completeness to theta = 26.99° 98.6 %  
 
Final R indices [I>2σ(I)] 
 
R1 = 0.0387, wR2 = 0.0942 
 
R indices (all data) 
 
R1 = 0.0387, wR2 = 0.0942 
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3-(2-aminophenylthio)-1,3-diphenylpropan-1-one           Michael adduct 
            
 
 
 
 
  
Empirical formula 
 
C21 H19 N O S 
 
Formula weight 
 
333.43 
Crystal system 
 
Monoclinic 
Space group 
 
P2(1)/n 
 
a (Å) 11.1741(16) 
b (Å)  5.6788(8)  
c (Å) 27.308(4) 
α (°) 90 
β (°)                                                                                                95.266(2) 
γ (°) 90 
  
Volume (Å3) 
 
1725.5(4)   
Z value 
 
4 
Calculated density, Dcalc (Mg/m3) 
 
1.344 
Crystal size (mm) 
Crystal color and habit 
0.22 x 0.20 x 0.11 
Colorless, blade 
Reflections collected  7303 
 
Independent reflections 3195 [R(int) = 0.0648] 
 
Observed reflections (I > 2sigma(I)) 1784 
Completeness to theta = 25.50° 99.7 %  
Final R indices [I>2σ(I)] 
 
R1 = 0.0568, wR2 = 0.0844 
 
R indices (all data) R1 = 0.1233, wR2 = 0.1008 
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3-(4-methoxyphenyl)-2-(naphthalen-2-ylmethyl)-2H-benzo[b][1,4]thiazine  6MR 
                          
 
 
  
Empirical formula 
 
C26H21NOS  
Formula weight 
 
395.50 
Crystal system 
 
Orthorhombic 
Space group 
 
P2(1)2(1)2(1) 
 
a (Å) 8.9621(7) 
b (Å)  12.2332(9) 
c (Å) 18.2916(14) 
α (°) 90 
β (°) 90                                                                                                                                    
γ (°) 90  
  
Volume (Å3) 
 
2005.4(3) 
Z value 
 
4 
Calculated density, Dcalc (Mg/m3) 
 
1.310 
Crystal size (mm) 
Crystal color and habit 
0.30 x 0.20 x 0.10 
 
Yellow block 
Reflections collected  24615 
 
Independent reflections 4385 [R(int) = 0.0375] 
 
Observed reflections (I > 2sigma(I)) 4144 
 
Completeness to theta = 27.00° 99.9 % 
Final R indices [I>2σ(I)] 
 
R1 = 0.0285, wR2 = 0.0691 
 
R indices (all data) 
 
R1 = 0.0314, wR2 = 0.0716 
 
F(000) 832.00 
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4-(4-methoxyphenyl)-2-(naphthalen-2-yl)-2, 3-dihydrobenzo[b][1,4]thiazepine         
MA12 
        
 
 
  
Empirical formula C26H21NOS  
Formula weight 395.51 
Crystal system Monoclinic 
Space group P b c a  
a (Å) 18.821(2) 
b (Å) 5.1632(6) 
c (Å) 20.450(3) 
α (°) 90 
β (°) 94     
γ (°) 90 
  
Volume (Å3) 1981.2(4) 
Z value 4 
Calculated density, Dcalc (Mg/m3) 1.323 
Crystal size (mm) 
Crystal color and habit 
0.30 x 0.08 x 0.06 
 
   Pale  yellow, columnar 
Reflections collected  24615 
 
Independent reflections 4385 [R(int) = 0.0375] 
 
Observed reflections (I > 2sigma(I)) 4144 
 
Completeness to theta = 27.00° 99.9 % 
Final R indices [I>2σ(I)] R1 = 0.0285, wR2 = 0.0691 
R indices (all data) 
 
R1 = 0.0314, wR2 = 0.0716 
 
F(000) 828.00 
  
2-(2-(3, 4, 5-trimethoxyphenyl)
MA5 
SNOH
OCH3
OCH
H3CO
 
 
 
Calculated density, D
Observed reflections (I > 2sigma(I))
Completeness to theta = 27.00°
Final R indices [I>2
-2, 3-dihydrobenzo[b][1,4]thiazepin
3
     
 
 
Empirical formula C24 H23 N O4 S 
Formula weight 421.49 
Crystal system Orthorhombic 
Space group P b c a  
a (Å) 10.6438(5) 
b (Å) 13.6221(6) 
c (Å) 27.4699(13) 
α (°) 90 
β (°) 90     
γ (°) 90 
Volume (Å3) 3982.9(3) 
Z value 
 
8 
calc (Mg/m3) 
 
1.406 
Crystal size (mm) 
Crystal color and habit 
0.30 x 0.08 x 0.06 
Yellow,  bladed 
                                                              
Reflections collected  24294 
 
Independent reflections 4352 [R(int) = 0.0732]
 
 3150 
 
 99.9 % 
σ(I)] 
 
R1 = 0.0419, wR2 = 0.0892
R indices (all data) 
 
R1 = 0.0679, wR2 = 0.1006
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-4-yl)phenol        
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